{
  "drug": "Prednisone",
  "fetched_at": "2026-01-16T12:31:04.998023+00:00",
  "drug_class_search": {
    "fetched_at": "2026-01-16T12:31:04.998023+00:00",
    "results": [
      {
        "title": "Prednisone | C21H26O5 | CID 5865 - PubChem - NIH",
        "url": "https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone",
        "content": "FDA Pharmacology Summary\n\nPrednisone is a Corticosteroid. The mechanism of action of prednisone is as a Corticosteroid Hormone Receptor Agonist.\n\nFDA Pharm Classes\n\n3 of 5 items\n\nNon-Proprietary Name\n\nPREDNISONE \n\nPharmacological Classes\n\nCorticosteroid Hormone Receptor Agonists [MoA]; Corticosteroid [EPC] \n\nNational Drug Code (NDC) Directory\n\n4 of 5 items\n\nNon-Proprietary Name\n\nPREDNISONE INTENSOL \n\nPharmacological Classes\n\nCorticosteroid Hormone Receptor Agonists [MoA]; Corticosteroid [EPC] \n\nNational Drug Code (NDC) Directory\n\n5 of 5 items\n\nNon-Proprietary Name\n\nDR ADAM AU \n\nPharmacological Classes\n\nCorticosteroid [EPC]; Corticosteroid Hormone Receptor Agonists [MoA] \n\nNational Drug Code (NDC) Directory\n\n### 8.4 ATC Code\n\nA - Alimentary tract and metabolism [...] Prednisone is a synthetic, anti-inflammatory glucocorticoid that derives from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone is an FDA-approved, delayed-release corticosteroid indicated as an anti-inflammatory or immunosuppressive agent to treat a broad range of diseases, including immunosuppressive/endocrine, rheumatic, collagen, dermatologic, allergic states, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal (GI, acute exacerbations of multiple sclerosis, and as an anti-inflammatory and an antineoplastic agent. Prednisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions. This medication is available only by [...] 3EN3HG4WSW \n\nActive Moiety\n\nPREDNISONE ANHYDROUS \n\nPharmacological Classes\n\nEstablished Pharmacologic Class [EPC] - Corticosteroid \n\nPharmacological Classes\n\nMechanisms of Action [MoA] - Corticosteroid Hormone Receptor Agonists \n\nFDA Pharmacology Summary\n\nPrednisone anhydrous is a Corticosteroid. The mechanism of action of prednisone anhydrous is as a Corticosteroid Hormone Receptor Agonist.\n\nFDA Pharm Classes\n\n2 of 5 items\n\nFDA UNII\n\nVB0R961HZT \n\nActive Moiety\n\nPREDNISONE \n\nPharmacological Classes\n\nEstablished Pharmacologic Class [EPC] - Corticosteroid \n\nPharmacological Classes\n\nMechanisms of Action [MoA] - Corticosteroid Hormone Receptor Agonists \n\nFDA Pharmacology Summary",
        "raw_content": "Prednisone | C21H26O5 | CID 5865 - PubChem\n===============\n\nAn official website of the United States government\n\nHere is how you know\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.\n\n**The site is secure.**\nThe **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n[NIH National Library of Medicine NCBI](https://www.ncbi.nlm.nih.gov/)\n\n[PubChem](https://pubchem.ncbi.nlm.nih.gov/)\n*   [About](https://pubchem.ncbi.nlm.nih.gov/docs/about)\n*   [Docs](https://pubchem.ncbi.nlm.nih.gov/docs)\n*   [Submit](https://pubchem.ncbi.nlm.nih.gov/submit/)\n*   [Contact](https://pubchem.ncbi.nlm.nih.gov/docs/contact)\n*   Theme Settings \n\nSearch PubChem \n\nDraw\n\nID File\n\nSubmit search\n\nAdvanced Search\n\n[Search History](https://pubchem.ncbi.nlm.nih.gov/history)\n\n[Help](https://pubchem.ncbi.nlm.nih.gov/docs/quick-search)\n\n[compound](https://pubchem.ncbi.nlm.nih.gov/compound/)\nPrednisone\n==========\n\nPubChem CID\n\n5865\n\nStructure\n\n[![Image 2: Prednisone_small.png](https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?cid=5865&t=s)](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=2D-Structure \"Go to 2D Structure section\")\n\n[![Image 3: Prednisone_3D_Structure.png](https://pubchem.ncbi.nlm.nih.gov/image/img3d.cgi?&cid=5865&t=s)](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=3D-Conformer \"Go to 3D Conformer section\")\n\n[![Image 4: Crystal Structure Depiction](https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/3357641_1)](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Crystal-Structures \"Go to Crystal Structures section\")\n\nPrimary Hazards\n\n[![Image 5: Health Hazard](https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS08.svg)](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=GHS-Classification)\n\n[Laboratory Chemical Safety Summary (LCSS) Datasheet](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#datasheet=LCSS)\n\nMolecular Formula\n\n*   [C 21 H 26 O 5](https://pubchem.ncbi.nlm.nih.gov/#query=C21H26O5 \"Find all compounds that have this formula\")\n\nSynonyms\n\n*   prednisone \n*   53-03-2 \n*   Dehydrocortisone \n*   Deltasone \n*   Decortin \n\nView More...\n\nMolecular Weight\n\n358.4 g/mol\n\nComputed by PubChem 2.2 (PubChem release 2025.04.14)\n\nDates\n\n*   Create: 2005-03-26 \n*   Modify: 2025-12-27 \n\nDescription\n\nPrednisone is an odorless white crystalline powder. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\nCAMEO Chemicals\n\nPrednisone is a synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid. It has a role as a prodrug, an anti-inflammatory drug, an antineoplastic agent, an immunosuppressive agent and an adrenergic agent. It is a 20-oxo steroid, an 11-oxo steroid, a 21-hydroxy steroid, a 17alpha-hydroxy steroid, a glucocorticoid, a 3-oxo-Delta(1),Delta(4)-steroid, a primary alpha-hydroxy ketone, a tertiary alpha-hydroxy ketone and a C21-steroid.\n\nChEBI\n\nA synthetic anti-inflammatory glucocorticoid derived from [[cortisone](https://pubchem.ncbi.nlm.nih.gov/compound/cortisone)]. It is biologically inert and converted to [[prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone)] in the liver. Prednisone was granted FDA approval on 21 February 1955.\n\nDrugBank\n\nView More...\n\n[See also](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Other-Relationships): [![Image 6](https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=s&cid=5755)Prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/5755) (has active moiety); [![Image 7](https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=s&cid=9878)Fluorometholone](https://pubchem.ncbi.nlm.nih.gov/compound/9878) (related); [![Image 8](https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=s&cid=5311067)Desoximetasone](https://pubchem.ncbi.nlm.nih.gov/compound/5311067) (related) ... [View More](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Other-Relationships) ...\n\n1 Structures[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Structures&fullscreen=true \"Open this section in a new browser window\")\n---------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 1.1 2D Structure[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=2D-Structure&fullscreen=true \"Open this section in a new browser window\")\n\nStructure Search\n\nGet Image\n\nDownload Coordinates\n\nChemical Structure Depiction\n\n![Image 9: Prednisone.png](https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?cid=5865&t=l)\n\nFull screen Zoom in Zoom out\n\nPubChem\n\n### 1.2 3D Conformer[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=3D-Conformer&fullscreen=true \"Open this section in a new browser window\")\n\nStructure Search\n\nGet Image\n\nDownload Coordinates\n\nInteractive Chemical Structure Model\n\nBall and Stick\n\nSticks\n\nWire-Frame\n\nSpace-Filling\n\nShow Hydrogens\n\nAnimate\n\nFull screen Zoom in Zoom out\n\nFirst Previous\n\nConformer of 3\n\nNext Last\n\nPubChem\n\n### 1.3 Crystal Structures[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Crystal-Structures&fullscreen=true \"Open this section in a new browser window\")\n\nCCDC Number\n\n[681818](http://doi.org/10.5517/ccqwh46)\n\nCrystal Structure Data\n\n[DOI:10.5517/ccqwh46](http://doi.org/10.5517/ccqwh46)\n\nCrystal Structure Depiction\n\n[![Image 10: Crystal Structure Depiction](https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/3357641_1)](http://doi.org/10.5517/ccqwh46)\n\nThe Cambridge Structural Database\n\n2 Names and Identifiers[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Names-and-Identifiers&fullscreen=true \"Open this section in a new browser window\")\n-------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 2.1 Computed Descriptors[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Computed-Descriptors&fullscreen=true \"Open this section in a new browser window\")\n\n#### 2.1.1 IUPAC Name[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=IUPAC-Name&fullscreen=true \"Open this section in a new browser window\")\n\n(8 _S_,9 _S_,10 _R_,13 _S_,14 _S_,17 _R_)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione\n\nComputed by Lexichem TK 2.7.0 (PubChem release 2025.04.14)\n\nPubChem\n\n#### 2.1.2 InChI[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=InChI&fullscreen=true \"Open this section in a new browser window\")\n\nInChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1 \n\nComputed by InChI 1.07.2 (PubChem release 2025.04.14)\n\nPubChem\n\n#### 2.1.3 InChIKey[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=InChIKey&fullscreen=true \"Open this section in a new browser window\")\n\nXOFYZVNMUHMLCC-ZPOLXVRWSA-N \n\nComputed by InChI 1.07.2 (PubChem release 2025.04.14)\n\nPubChem\n\n#### 2.1.4 SMILES[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=SMILES&fullscreen=true \"Open this section in a new browser window\")\n\nC[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C \n\nComputed by OEChem 2.3.0 (PubChem release 2025.04.14)\n\nPubChem\n\n### 2.2 Molecular Formula[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Molecular-Formula&fullscreen=true \"Open this section in a new browser window\")\n\nC 21 H 26 O 5\n\nComputed by PubChem 2.2 (PubChem release 2025.04.14)\n\nCAMEO Chemicals; PubChem\n\n### 2.3 Other Identifiers[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Other-Identifiers&fullscreen=true \"Open this section in a new browser window\")\n\n#### 2.3.1 CAS[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=CAS&fullscreen=true \"Open this section in a new browser window\")\n\n53-03-2 \n\nAustralian Industrial Chemicals Introduction Scheme (AICIS); CAMEO Chemicals; CAS Common Chemistry; ChemIDplus; DrugBank; EPA Chemicals under the TSCA; EPA DSSTox; European Chemicals Agency (ECHA); FDA Global Substance Registration System (GSRS); Hazardous Substances Data Bank (HSDB); Human Metabolome Database (HMDB); New Zealand Environmental Protection Authority (EPA)\n\n53032 \n\nDTP/NCI\n\n#### 2.3.2 Deprecated CAS[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Deprecated-CAS&fullscreen=true \"Open this section in a new browser window\")\n\n68-59-7 \n\nChemIDplus; EPA Chemicals under the TSCA\n\n#### 2.3.3 European Community (EC) Number[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=European-Community-EC-Number&fullscreen=true \"Open this section in a new browser window\")\n\n[200-160-3](https://chem.echa.europa.eu/100.000.147)\n\nEuropean Chemicals Agency (ECHA)\n\n#### 2.3.4 UNII[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=UNII&fullscreen=true \"Open this section in a new browser window\")\n\n[VB0R961HZT](https://gsrs.ncats.nih.gov/ginas/app/beta/substances/VB0R961HZT)\n\nFDA Global Substance Registration System (GSRS)\n\n#### 2.3.5 AIDS Number[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=AIDS-Number&fullscreen=true \"Open this section in a new browser window\")\n\n[184445](https://pubchem.ncbi.nlm.nih.gov/substance/?source=niaid&sourceid=184445)\n\nNIAID ChemDB\n\n#### 2.3.6 ChEBI ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=ChEBI-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[CHEBI:8382](https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8382)\n\nChEBI\n\n#### 2.3.7 ChEMBL ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=ChEMBL-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[CHEMBL635](https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL635)\n\nChEMBL\n\n#### 2.3.8 DrugBank ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=DrugBank-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[DB00635](https://www.drugbank.ca/drugs/DB00635)\n\nDrugBank\n\n#### 2.3.9 DSSTox Substance ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=DSSTox-Substance-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[DTXSID4021185](https://comptox.epa.gov/dashboard/DTXSID4021185)\n\nEPA DSSTox\n\n#### 2.3.10 HMDB ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=HMDB-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[HMDB0014773](https://hmdb.ca/metabolites/HMDB0014773)\n\nHuman Metabolome Database (HMDB)\n\n#### 2.3.11 HTS Number[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=HTS-Number&fullscreen=true \"Open this section in a new browser window\")\n\n[2937.21.00.30](https://hts.usitc.gov/search?query=2937.21.00.30)\n\nUSITC Harmonized Tariff Schedule\n\n#### 2.3.12 KEGG ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=KEGG-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[C07370](https://www.kegg.jp/entry/C07370)\n\nKEGG\n\n#### 2.3.13 Lipid Maps ID (LM_ID)[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Lipid-Maps-ID-LMID&fullscreen=true \"Open this section in a new browser window\")\n\n[LMST02030180](https://lipidmaps.org/databases/lmsd/LMST02030180)\n\nLIPID MAPS\n\n#### 2.3.14 Metabolomics Workbench ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Metabolomics-Workbench-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[35459](https://www.metabolomicsworkbench.org/data/StructureData.php?RegNo=35459)\n\nMetabolomics Workbench\n\n#### 2.3.15 NCI Thesaurus Code[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=NCI-Thesaurus-Code&fullscreen=true \"Open this section in a new browser window\")\n\n[C770](https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C770)\n\nNCI Thesaurus (NCIt)\n\n#### 2.3.16 Nikkaji Number[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Nikkaji-Number&fullscreen=true \"Open this section in a new browser window\")\n\n[J4.137H](http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J4.137H)\n\nJapan Chemical Substance Dictionary (Nikkaji)\n\n#### 2.3.17 NSC Number[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=NSC-Number&fullscreen=true \"Open this section in a new browser window\")\n\n[10023](https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=10023)\n\nDTP/NCI\n\n#### 2.3.18 PharmGKB ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=PharmGKB-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[PA451100](https://www.pharmgkb.org/chemical/PA451100)\n\nPharmGKB\n\n#### 2.3.19 Pharos Ligand ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Pharos-Ligand-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[62BR9C5ANC22](https://pharos.nih.gov/ligands/62BR9C5ANC22)\n\nPharos\n\n#### 2.3.20 RXCUI[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=RXCUI&fullscreen=true \"Open this section in a new browser window\")\n\n[8640](https://rxnav.nlm.nih.gov/id/rxnorm/8640)\n\nNLM RxNorm Terminology\n\n#### 2.3.21 Wikidata[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Wikidata&fullscreen=true \"Open this section in a new browser window\")\n\n[Q424972](https://www.wikidata.org/wiki/Q424972)\n\nWikidata\n\n#### 2.3.22 Wikipedia[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Wikipedia&fullscreen=true \"Open this section in a new browser window\")\n\n[Prednisone](https://en.wikipedia.org/wiki/Prednisone)\n\nWikipedia\n\n### 2.4 Synonyms[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Synonyms&fullscreen=true \"Open this section in a new browser window\")\n\n#### 2.4.1 MeSH Entry Terms[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=MeSH-Entry-Terms&fullscreen=true \"Open this section in a new browser window\")\n\nMeSH Entry Terms for Prednisone\n\n*   Prednisone \n*   Dehydrocortisone \n*   delta-Cortisone \n\nMedical Subject Headings (MeSH)\n\nMeSH Entry Terms for deltacortene\n\ndeltacortene \n\nMedical Subject Headings (MeSH)\n\nMeSH Entry Terms for Deltasone\n\nDeltasone \n\nMedical Subject Headings (MeSH)\n\nMeSH Entry Terms for Liquid Pred\n\nLiquid Pred \n\nMedical Subject Headings (MeSH)\n\nMeSH Entry Terms for Meticorten\n\nMeticorten \n\nMedical Subject Headings (MeSH)\n\nMeSH Entry Terms for Cortan\n\nCortan \n\nMedical Subject Headings (MeSH)\n\nMeSH Entry Terms for Decortin\n\n*   Decortin \n*   Dacortin \n\nMedical Subject Headings (MeSH)\n\nMeSH Entry Terms for Decortisyl\n\nDecortisyl \n\nMedical Subject Headings (MeSH)\n\nMeSH Entry Terms for Orasone\n\nOrasone \n\nMedical Subject Headings (MeSH)\n\nMeSH Entry Terms for Prednidib\n\nPrednidib \n\nMedical Subject Headings (MeSH)\n\nMeSH Entry Terms for Predniment\n\nPredniment \n\nMedical Subject Headings (MeSH)\n\nMeSH Entry Terms for Sterapred\n\nSterapred \n\nMedical Subject Headings (MeSH)\n\n#### 2.4.2 Depositor-Supplied Synonyms[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Depositor-Supplied-Synonyms&fullscreen=true \"Open this section in a new browser window\")\n\n*   [prednisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22prednisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [53-03-2](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%2253-03-2%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Dehydrocortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Dehydrocortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Deltasone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Deltasone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Decortin](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Decortin%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Meticorten](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Meticorten%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Metacortandracin](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Metacortandracin%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Supercortil](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Supercortil%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Orasone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Orasone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Paracort](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Paracort%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [1,2-Dehydrocortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%221%2C2-Dehydrocortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Deltacortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Deltacortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Colisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Colisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Decortisyl](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Decortisyl%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednison](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednison%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Di-Adreson](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Di-Adreson%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Ancortone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Ancortone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Bicortone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Bicortone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Decortancyl](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Decortancyl%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Deltacortone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Deltacortone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Hostacortin](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Hostacortin%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednilonga](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednilonga%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Servisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Servisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Sterapred](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Sterapred%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Dacortin](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Dacortin%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Deltison](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Deltison%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Encorton](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Encorton%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Lodotra](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Lodotra%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Cortan](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Cortan%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Delta-Cortelan](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Delta-Cortelan%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Liquid Pred](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Liquid%20Pred%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednicen-M](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednicen-M%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Delta-Dome](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Delta-Dome%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Ultracortene](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Ultracortene%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Cortidelt](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Cortidelt%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Dekortin](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Dekortin%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Delta E](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Delta%20E%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Enkorton](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Enkorton%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Lisacort](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Lisacort%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednizon](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednizon%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Pronison](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Pronison%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Adasone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Adasone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Deltra](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Deltra%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Juvason](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Juvason%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Nurison](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Nurison%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone Intensol](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%20Intensol%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Deltacortene](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Deltacortene%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Econosone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Econosone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Panafcort](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Panafcort%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Predeltin](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Predeltin%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednicort](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednicort%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednidib](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednidib%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisona](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisona%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisonum](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisonum%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednitone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednitone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [delta-Cortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22delta-Cortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [SK-Prednisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SK-Prednisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy-](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Pregna-1%2C4-diene-3%2C11%2C20-trione%2C%2017%2C21-dihydroxy-%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone tablets](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%20tablets%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [delta-1-Cortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22delta-1-Cortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [prednisone anhydrous](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22prednisone%20anhydrous%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Rayos](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Rayos%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%221%2C4-Pregnadiene-17alpha%2C21-diol-3%2C11%2C20-trione%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Fernisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Fernisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [3en3hg4wsw](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%223en3hg4wsw%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [delta(sup 1)-Cortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22delta(sup%201)-Cortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [delta-1-Dehydrocortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22delta-1-Dehydrocortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NSC-10023](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NSC-10023%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [delta(sup 1)-Dehydrocortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22delta(sup%201)-Dehydrocortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NCI-C04897](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCI-C04897%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NSC 10023](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NSC%2010023%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [VB0R961HZT](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22VB0R961HZT%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Deltadehydrocortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Deltadehydrocortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [CHEBI:8382](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22CHEBI%3A8382%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [DTXSID4021185](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22DTXSID4021185%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%221%2C4-Pregnadiene-17-alpha%2C21-diol-3%2C11%2C20-trione%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22(8S%2C9S%2C10R%2C13S%2C14S%2C17R)-17-hydroxy-17-(2-hydroxyacetyl)-10%2C13-dimethyl-6%2C7%2C8%2C9%2C12%2C14%2C15%2C16-octahydrocyclopenta%5Ba%5Dphenanthrene-3%2C11-dione%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [DTXCID701185](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22DTXCID701185%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NSC10023](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NSC10023%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Pregna-1,4-diene-3,11,20-trione monohydrate, 17,21-dihydroxy-](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Pregna-1%2C4-diene-3%2C11%2C20-trione%20monohydrate%2C%2017%2C21-dihydroxy-%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [delta1-Cortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22delta1-Cortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Predicorten](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Predicorten%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Predniment](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Predniment%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Ofisolona](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Ofisolona%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Predicor](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Predicor%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Promifen](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Promifen%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Meprosona-F](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Meprosona-F%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Panasol-S](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Panasol-S%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Acsis, Prednison](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Acsis%2C%20Prednison%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Perrigo Prednisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Perrigo%20Prednisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Delta 1-Cortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Delta%201-Cortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Dr Adam Au](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Dr%20Adam%20Au%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta(a)phenanthrene-3,11-dione](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22(8S%2C9S%2C10R%2C13S%2C14S%2C17R)-17-hydroxy-17-(2-hydroxyacetyl)-10%2C13-dimethyl-6%2C7%2C8%2C9%2C12%2C14%2C15%2C16-octahydrocyclopenta(a)phenanthrene-3%2C11-dione%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [RefChem:6162](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22RefChem%3A6162%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [1, 2-Dehydrocortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%221%2C%202-Dehydrocortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [A07EA03](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22A07EA03%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [H02AB07](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22H02AB07%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PredniSONE Tablets, USP, 5 mg](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PredniSONE%20Tablets%2C%20USP%2C%205%20mg%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PredniSONE Tablets, USP, 10 mg](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PredniSONE%20Tablets%2C%20USP%2C%2010%20mg%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PredniSONE Tablets, USP, 20 mg](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PredniSONE%20Tablets%2C%20USP%2C%2020%20mg%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [P-PACK PREDNISONE 20MG, 7-DAY TAPERING DOSE PACK](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22P-PACK%20PREDNISONE%2020MG%2C%207-DAY%20TAPERING%20DOSE%20PACK%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo(8.7.0.02,7.011,15)heptadeca-3,6-diene-5,17-dione](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22(1S%2C2R%2C10S%2C11S%2C14R%2C15S)-14-hydroxy-14-(2-hydroxyacetyl)-2%2C15-dimethyltetracyclo(8.7.0.02%2C7.011%2C15)heptadeca-3%2C6-diene-5%2C17-dione%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [200-160-3](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22200-160-3%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Rectodelt](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Rectodelt%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Ultracorten](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Ultracorten%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Diadreson](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Diadreson%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Encortone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Encortone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Zenadrid](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Zenadrid%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Cotone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Cotone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Wojtab](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Wojtab%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [In-Sone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22In-Sone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Cartancyl](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Cartancyl%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Deltisona](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Deltisona%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Winpred](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Winpred%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Deltisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Deltisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisonum [INN-Latin]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisonum%20%5BINN-Latin%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisona [INN-Spanish]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisona%20%5BINN-Spanish%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Zenadrid (veterinary)](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Zenadrid%20(veterinary)%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [1-Dehydrocortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%221-Dehydrocortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [MFCD00003608](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MFCD00003608%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone(Adasone)](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone(Adasone)%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [U 6020](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22U%206020%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Zenadrid [veterinary]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Zenadrid%20%5Bveterinary%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Novoprednisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Novoprednisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Dellacort](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Dellacort%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Incocortyl](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Incocortyl%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Parmenison](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Parmenison%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednicorm](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednicorm%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednicot](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednicot%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednovister](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednovister%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Retrocortine](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Retrocortine%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Dacorten](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Dacorten%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Fiasone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Fiasone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Panasol](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Panasol%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Pehacort](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Pehacort%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Presone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Presone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [delta cortelan](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22delta%20cortelan%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Nisona](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Nisona%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Nizon](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Nizon%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Sone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Sone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Apo-Prednisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Apo-Prednisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Dellacort A](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Dellacort%20A%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Me-Korti](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Me-Korti%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Origen Prednisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Origen%20Prednisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [(8S,9S,10R,13S,14S,17R)-17-Hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthrene-3,11(6H)-dione](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22(8S%2C9S%2C10R%2C13S%2C14S%2C17R)-17-Hydroxy-17-(2-hydroxyacetyl)-10%2C13-dimethyl-7%2C8%2C9%2C10%2C12%2C13%2C14%2C15%2C16%2C17-decahydro-3H-cyclopenta%5Ba%5Dphenanthrene-3%2C11(6H)-dione%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [.delta.-Cortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22.delta.-Cortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [.delta.1-Cortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22.delta.1-Cortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NCGC00090766-01](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCGC00090766-01%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Precort](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Precort%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [.delta.1-Dehydrocortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22.delta.1-Dehydrocortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [1-Cortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%221-Cortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Meticorten (Veterinary)](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Meticorten%20(Veterinary)%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Lodtra](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Lodtra%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [SMR000718760](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SMR000718760%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [SMR001227202](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SMR001227202%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Delta E.](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Delta%20E.%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [CCRIS 2646](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22CCRIS%202646%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [HSDB 3168](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HSDB%203168%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [MLS002638114](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MLS002638114%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [EINECS 200-160-3](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22EINECS%20200-160-3%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [UNII-VB0R961HZT](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22UNII-VB0R961HZT%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone [USP:INN:BAN]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%20%5BUSP%3AINN%3ABAN%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [AI3-52939](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AI3-52939%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [.delta.sone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22.delta.sone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone CRS](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%20CRS%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [.delta.-Cortone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22.delta.-Cortone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [.delta.-Cortelan](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22.delta.-Cortelan%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [CAS-53-03-2](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22CAS-53-03-2%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prestwick_405](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prestwick_405%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [.delta. E](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22.delta.%20E%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [.delta.-E](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22.delta.-E%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone (Adasone)](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%20(Adasone)%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone (Standard)](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%20(Standard)%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone, >=98%](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%2C%20%3E%3D98%25%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PREDNISONE [MI]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PREDNISONE%20%5BMI%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PREDNISONE [INN]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PREDNISONE%20%5BINN%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prestwick0_000077](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prestwick0_000077%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prestwick1_000077](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prestwick1_000077%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prestwick2_000077](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prestwick2_000077%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prestwick3_000077](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prestwick3_000077%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PREDNISONE [HSDB]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PREDNISONE%20%5BHSDB%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PREDNISONE [IARC]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PREDNISONE%20%5BIARC%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [.delta.(sup1)-Cortisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22.delta.(sup1)-Cortisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [P1276](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22P1276%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PREDNISONE [VANDF]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PREDNISONE%20%5BVANDF%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [CHEMBL635](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22CHEMBL635%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PREDNISONE [MART.]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PREDNISONE%20%5BMART.%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [SCHEMBL3288](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SCHEMBL3288%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PREDNISONE [USP-RS]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PREDNISONE%20%5BUSP-RS%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PREDNISONE [WHO-DD]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PREDNISONE%20%5BWHO-DD%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [BSPBio_000293](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BSPBio_000293%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [MLS001061265](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MLS001061265%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [MLS001304073](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MLS001304073%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [MLS001335907](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MLS001335907%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [MLS001335908](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MLS001335908%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [MLS002154191](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MLS002154191%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [MLS002207083](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MLS002207083%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [MLS002548880](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MLS002548880%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [SPBio_002214](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SPBio_002214%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [BPBio1_000323](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BPBio1_000323%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [GTPL7096](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22GTPL7096%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [MEGxm0_000443](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MEGxm0_000443%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [orb1710534](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22orb1710534%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PREDNISONE [GREEN BOOK]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PREDNISONE%20%5BGREEN%20BOOK%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [17alpha,21-dihydroxypregna-1,4-diene-3,11,20-trione](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%2217alpha%2C21-dihydroxypregna-1%2C4-diene-3%2C11%2C20-trione%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PREDNISONE [ORANGE BOOK]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PREDNISONE%20%5BORANGE%20BOOK%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [ACon0_000082](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22ACon0_000082%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [ACon1_000297](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22ACon1_000297%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [HY-B0214R](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HY-B0214R%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [MSK2227](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MSK2227%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PREDNISONE [EP MONOGRAPH]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PREDNISONE%20%5BEP%20MONOGRAPH%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [GLXC-07880](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22GLXC-07880%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [HMS1568O15](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS1568O15%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [HMS2090J13](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS2090J13%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [HMS2095O15](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS2095O15%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [HMS2231I24](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS2231I24%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [HMS3039K07](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS3039K07%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [HMS3259I09](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS3259I09%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [HMS3712O15](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS3712O15%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [HMS3884C04](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HMS3884C04%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PREDNISONE [USP MONOGRAPH]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PREDNISONE%20%5BUSP%20MONOGRAPH%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [1,21-diol-3,11,20-trione](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%221%2C21-diol-3%2C11%2C20-trione%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [BB_NC-00587](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BB_NC-00587%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [HY-B0214](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22HY-B0214%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PREDNISONE TABLETS [USP-RS]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PREDNISONE%20TABLETS%20%5BUSP-RS%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Tox21_111014](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Tox21_111014%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Tox21_201564](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Tox21_201564%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Tox21_300196](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Tox21_300196%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [BDBM50550126](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BDBM50550126%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [EBC-26720](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22EBC-26720%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [LMST02030180](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22LMST02030180%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [MSK2227-100A](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MSK2227-100A%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [s1622](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22s1622%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [AKOS005267096](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AKOS005267096%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [AKOS007930684](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AKOS007930684%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [MSK2227-1000A](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MSK2227-1000A%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [MSK2227-1000M](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22MSK2227-1000M%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Tox21_111014_1](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Tox21_111014_1%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [CCG-220077](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22CCG-220077%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [DB00635](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22DB00635%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [FP27134](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22FP27134%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NC00475](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NC00475%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NCGC00090766-02](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCGC00090766-02%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NCGC00090766-03](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCGC00090766-03%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NCGC00090766-04](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCGC00090766-04%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NCGC00090766-05](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCGC00090766-05%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NCGC00090766-07](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCGC00090766-07%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NCGC00254096-01](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCGC00254096-01%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NCGC00259113-01](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCGC00259113-01%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [(1R,3aS,3bS,9aR,9bS,11aS)-1-hydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-7,10-dione](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22(1R%2C3aS%2C3bS%2C9aR%2C9bS%2C11aS)-1-hydroxy-1-(2-hydroxyacetyl)-9a%2C11a-dimethyl-1H%2C2H%2C3H%2C3aH%2C3bH%2C4H%2C5H%2C7H%2C9aH%2C9bH%2C10H%2C11H%2C11aH-cyclopenta%5Ba%5Dphenanthrene-7%2C10-dione%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [AC-11112](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AC-11112%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [AS-11685](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22AS-11685%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NCI60_000008](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NCI60_000008%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [NS00007844](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22NS00007844%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [PREDNISOLONE IMPURITY B [EP IMPURITY]](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22PREDNISOLONE%20IMPURITY%20B%20%5BEP%20IMPURITY%5D%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone Solution in Methanol, 1000ug/mL](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%20Solution%20in%20Methanol%2C%201000ug%2FmL%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Pregna-1,11,20-trione, 17,21-hydroxy-](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Pregna-1%2C11%2C20-trione%2C%2017%2C21-hydroxy-%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [EN300-52605](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22EN300-52605%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Pregna-1,11,20-trione, 17,21-dihydroxy-](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Pregna-1%2C11%2C20-trione%2C%2017%2C21-dihydroxy-%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [C07370](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22C07370%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone Solution in Acetonitrile, 100ug/mL](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%20Solution%20in%20Acetonitrile%2C%20100ug%2FmL%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone Solution in Acetonitrile, 1000ug/mL](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%20Solution%20in%20Acetonitrile%2C%201000ug%2FmL%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [003P608](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22003P608%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [1,4-Pregnadiene-17a,21-diol-3,11,20-trione](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%221%2C4-Pregnadiene-17a%2C21-diol-3%2C11%2C20-trione%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Q424972](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Q424972%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [SR-01000837536](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SR-01000837536%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [SR-01000837536-3](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22SR-01000837536-3%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [BRD-K85883481-001-04-2](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BRD-K85883481-001-04-2%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [BRD-K85883481-001-08-3](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BRD-K85883481-001-08-3%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [BRD-K85883481-001-22-4](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BRD-K85883481-001-22-4%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [BRD-K85883481-001-25-7](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22BRD-K85883481-001-25-7%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22WLN%3A%20L%20E5%20B666%20CV%20OV%20AHTTT%26J%20A1%20E1%20FV1Q%20FQ%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Z756390288](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Z756390288%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone, British Pharmacopoeia (BP) Reference Standard](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%2C%20British%20Pharmacopoeia%20(BP)%20Reference%20Standard%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone, European Pharmacopoeia (EP) Reference Standard](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%2C%20European%20Pharmacopoeia%20(EP)%20Reference%20Standard%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [17,21-Dihydroxypregna-1,4-diene-3,11,20-trione;Prednisone](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%2217%2C21-Dihydroxypregna-1%2C4-diene-3%2C11%2C20-trione%3BPrednisone%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone, United States Pharmacopeia (USP) Reference Standard](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%2C%20United%20States%20Pharmacopeia%20(USP)%20Reference%20Standard%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone, Pharmaceutical Secondary Standard; Certified Reference Material](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%2C%20Pharmaceutical%20Secondary%20Standard%3B%20Certified%20Reference%20Material%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone for peak identification, European Pharmacopoeia (EP) Reference Standard](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%20for%20peak%20identification%2C%20European%20Pharmacopoeia%20(EP)%20Reference%20Standard%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [Prednisone, pharmaceutical secondary standard; traceable to USP, PhEur and BP](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Prednisone%2C%20pharmaceutical%20secondary%20standard%3B%20traceable%20to%20USP%2C%20PhEur%20and%20BP%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n*   [(8S,10R,13S,17R)-17-Hydroxy-17-(2-hydroxy-acetyl)-10,13-dimethyl-7,8,9,10,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,11-dione](https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22(8S%2C10R%2C13S%2C17R)-17-Hydroxy-17-(2-hydroxy-acetyl)-10%2C13-dimethyl-7%2C8%2C9%2C10%2C12%2C13%2C14%2C15%2C16%2C17-decahydro-6H-cyclopenta%5Ba%5Dphenanthrene-3%2C11-dione%22[CompleteSynonym]%20AND%205865[StandardizedCID])\n\nPubChem\n\n3 Chemical and Physical Properties[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Chemical-and-Physical-Properties&fullscreen=true \"Open this section in a new browser window\")\n-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 3.1 Computed Properties[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Computed-Properties&fullscreen=true \"Open this section in a new browser window\")\n\nProperty Name\n\nProperty Value\n\nReference\n\nProperty Name\n\nMolecular Weight\n\nProperty Value\n\n358.4 g/mol\n\nReference\n\nComputed by PubChem 2.2 (PubChem release 2025.04.14)\n\nProperty Name\n\nXLogP3\n\nProperty Value\n\n1.5 \n\nReference\n\nComputed by XLogP3 3.0 (PubChem release 2025.04.14)\n\nProperty Name\n\nHydrogen Bond Donor Count\n\nProperty Value\n\n2 \n\nReference\n\nComputed by Cactvs 3.4.8.18 (PubChem release 2025.04.14)\n\nProperty Name\n\nHydrogen Bond Acceptor Count\n\nProperty Value\n\n5 \n\nReference\n\nComputed by Cactvs 3.4.8.18 (PubChem release 2025.04.14)\n\nProperty Name\n\nRotatable Bond Count\n\nProperty Value\n\n2 \n\nReference\n\nComputed by Cactvs 3.4.8.18 (PubChem release 2025.04.14)\n\nProperty Name\n\nExact Mass\n\nProperty Value\n\n358.17802393 Da\n\nReference\n\nComputed by PubChem 2.2 (PubChem release 2025.04.14)\n\nProperty Name\n\nMonoisotopic Mass\n\nProperty Value\n\n358.17802393 Da\n\nReference\n\nComputed by PubChem 2.2 (PubChem release 2025.04.14)\n\nProperty Name\n\nTopological Polar Surface Area\n\nProperty Value\n\n91.7 Å²\n\nReference\n\nComputed by Cactvs 3.4.8.18 (PubChem release 2025.04.14)\n\nProperty Name\n\nHeavy Atom Count\n\nProperty Value\n\n26 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nFormal Charge\n\nProperty Value\n\n0 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nComplexity\n\nProperty Value\n\n764 \n\nReference\n\nComputed by Cactvs 3.4.8.18 (PubChem release 2025.04.14)\n\nProperty Name\n\nIsotope Atom Count\n\nProperty Value\n\n0 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nDefined Atom Stereocenter Count\n\nProperty Value\n\n6 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nUndefined Atom Stereocenter Count\n\nProperty Value\n\n0 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nDefined Bond Stereocenter Count\n\nProperty Value\n\n0 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nUndefined Bond Stereocenter Count\n\nProperty Value\n\n0 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nCovalently-Bonded Unit Count\n\nProperty Value\n\n1 \n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nCompound Is Canonicalized\n\nProperty Value\n\nYes \n\nReference\n\nComputed by PubChem (release 2025.04.14)\n\nPubChem\n\n### 3.2 Experimental Properties[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Experimental-Properties&fullscreen=true \"Open this section in a new browser window\")\n\n#### 3.2.1 Physical Description[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Physical-Description&fullscreen=true \"Open this section in a new browser window\")\n\nPrednisone is an odorless white crystalline powder. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\nCAMEO Chemicals\n\nSolid \n\nHuman Metabolome Database (HMDB)\n\n#### 3.2.2 Color / Form[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Color-Form&fullscreen=true \"Open this section in a new browser window\")\n\nCrystals \n\nO'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 1432\n\nHazardous Substances Data Bank (HSDB)\n\nWhite to practically white, crystalline powder \n\nOsol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 897\n\nHazardous Substances Data Bank (HSDB)\n\n#### 3.2.3 Odor[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Odor&fullscreen=true \"Open this section in a new browser window\")\n\nOdorless \n\nOsol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 897\n\nHazardous Substances Data Bank (HSDB)\n\n#### 3.2.4 Taste[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Taste&fullscreen=true \"Open this section in a new browser window\")\n\nPersistent bitter after-taste \n\nReynolds, J.E.F., Prasad, A.B. (eds.) Martindale-The Extra Pharmacopoeia. 28th ed. London: The Pharmaceutical Press, 1982., p. 483\n\nHazardous Substances Data Bank (HSDB)\n\n#### 3.2.5 Melting Point[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Melting-Point&fullscreen=true \"Open this section in a new browser window\")\n\n451 to 455 °F (DEC) (NTP, 1992) \n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\nCAMEO Chemicals\n\n230 - 235 °C (decomposes)\n\nMSDS\n\nDrugBank\n\n234 °C (decomposes) \n\nHaynes, W.M. (ed.). CRC Handbook of Chemistry and Physics. 95th Edition. CRC Press LLC, Boca Raton: FL 2014-2015, p. 3-192\n\nHazardous Substances Data Bank (HSDB)\n\n233 - 235 °C \n\nHuman Metabolome Database (HMDB)\n\n#### 3.2.6 Solubility[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Solubility&fullscreen=true \"Open this section in a new browser window\")\n\nVery slightly soluble (NTP, 1992) \n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\nCAMEO Chemicals\n\nVery slightly soluble \n\nMSDS\n\nDrugBank\n\nVery slightly soluble in [water](https://pubchem.ncbi.nlm.nih.gov/compound/water); 1 g soluble in 150 mL alcohol, in 200 mL [chloroform](https://pubchem.ncbi.nlm.nih.gov/compound/chloroform); slightly soluble in [methanol](https://pubchem.ncbi.nlm.nih.gov/compound/methanol)\n\nO'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 1432\n\nHazardous Substances Data Bank (HSDB)\n\n1.11e-01 g/L \n\nHuman Metabolome Database (HMDB)\n\n#### 3.2.7 LogP[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=LogP&fullscreen=true \"Open this section in a new browser window\")\n\n1.46 \n\nMSDS\n\nDrugBank\n\nlog Kow = 1.46 \n\nHansch, C., Leo, A., D. Hoekman. Exploring QSAR - Hydrophobic, Electronic, and Steric Constants. Washington, DC: American Chemical Society., 1995., p. 173\n\nHazardous Substances Data Bank (HSDB)\n\n0.6 \n\nHuman Metabolome Database (HMDB)\n\n#### 3.2.8 Stability / Shelf Life[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Stability-Shelf-Life&fullscreen=true \"Open this section in a new browser window\")\n\nStable under recommended storage conditions. \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\n#### 3.2.9 Optical Rotation[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Optical-Rotation&fullscreen=true \"Open this section in a new browser window\")\n\nSpecific optical rotation: +172 deg at 25 °C/D ([dioxane](https://pubchem.ncbi.nlm.nih.gov/compound/dioxane)); max absorption ([methanol](https://pubchem.ncbi.nlm.nih.gov/compound/methanol)): 238 nm (e = 15,500)\n\nO'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 1432\n\nHazardous Substances Data Bank (HSDB)\n\n#### 3.2.10 Decomposition[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Decomposition&fullscreen=true \"Open this section in a new browser window\")\n\nHazardous decomposition products formed under fire conditions - Carbon oxides. \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\nWhen heated to decomposition it emits acrid smoke and irritating fumes. \n\nLewis, R.J. Sr. (ed) Sax's Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley & Sons, Inc. Hoboken, NJ. 2004., p. 3049\n\nHazardous Substances Data Bank (HSDB)\n\n#### 3.2.11 pH[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=pH&fullscreen=true \"Open this section in a new browser window\")\n\nPrednisone-syrup has a pH of 3-4.5 and contains 2-5% alcohol. Prednisone oral solution has a pH of 2.6-3.6 and contains 4-6% alcohol, and the oral concentrate solution has a pH of 3-4 and contains about 30% alcohol.\n\nMcEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 834\n\nHazardous Substances Data Bank (HSDB)\n\n#### 3.2.12 Collision Cross Section[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Collision-Cross-Section&fullscreen=true \"Open this section in a new browser window\")\n\n253.9 Å² [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: TOXCAST; Source Identifier: DTXSID4021185]\n\n192.2 Å² [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID4021185]\n\n184.1 Å² [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID4021185]\n\n[https://tarheels.live/bakerlab/](https://tarheels.live/bakerlab/)\n\nBaker Lab, Chemistry Department, The University of North Carolina at Chapel Hill\n\n181.8 Å² [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]\n\n[https://pubs.acs.org/doi/abs/10.1021/acs.analchem.7b01709](https://pubs.acs.org/doi/abs/10.1021/acs.analchem.7b01709)\n\nCCSbase\n\n180.52 Å² [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]\n\n174.8 Å² [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]\n\nRoss et al. JASMS 2022; 33; 1061-1072. [DOI:10.1021/jasms.2c00111](https://doi.org/DOI:10.1021/jasms.2c00111)\n\nCCSbase\n\n180.1 Å² [M+H]+ [CCS Type: TW]\n\n[https://pubs.acs.org/doi/abs/10.1021/acs.analchem.7b00741](https://pubs.acs.org/doi/abs/10.1021/acs.analchem.7b00741)\n\nCCSbase\n\n#### 3.2.13 Other Experimental Properties[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Other-Experimental-Properties&fullscreen=true \"Open this section in a new browser window\")\n\nCrystals, decomposes 226-232 °C, specific optical rotation: +186 ([dioxane](https://pubchem.ncbi.nlm.nih.gov/compound/dioxane)), maximum UV adsorption: 238 nm (E 16,1000) /21-Acetate/\n\nO'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 1432\n\nHazardous Substances Data Bank (HSDB)\n\n### 3.3 SpringerMaterials Properties[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=SpringerMaterials-Properties&fullscreen=true \"Open this section in a new browser window\")\n\n*   [Chemical shift](https://materials.springer.com/search?searchTerm=%288S%2C10R%2C13S%2C17R%29-17-Hydroxy-17-%282-hydroxy-acetyl%29-10%2C13-dimethyl-7%2C8%2C9%2C10%2C12%2C13%2C14%2C15%2C16%2C17-decahydro-6H-cyclopenta%5Ba%5Dphenanthrene-3%2C11-dione&propertyFacet=chemical%20shift&substanceId=smsid_vmhadjufiuojiuof)\n*   [Lineshape](https://materials.springer.com/search?searchTerm=%288S%2C10R%2C13S%2C17R%29-17-Hydroxy-17-%282-hydroxy-acetyl%29-10%2C13-dimethyl-7%2C8%2C9%2C10%2C12%2C13%2C14%2C15%2C16%2C17-decahydro-6H-cyclopenta%5Ba%5Dphenanthrene-3%2C11-dione&propertyFacet=lineshape&substanceId=smsid_vmhadjufiuojiuof)\n\nSpringerMaterials\n\n### 3.4 Chemical Classes[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Chemical-Classes&fullscreen=true \"Open this section in a new browser window\")\n\nPharmaceutical \n\nUSGS Health-Based Screening Levels for Evaluating Water-Quality Data\n\n#### 3.4.1 Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Drugs&fullscreen=true \"Open this section in a new browser window\")\n\nPharmaceuticals -> Steroids \n\nS57 | GREEKPHARMA | Suspect Pharmaceuticals from the National Organization of Medicine, Greece | [DOI:10.5281/zenodo.3248883](https://doi.org/DOI:10.5281/zenodo.3248883)\n\nNORMAN Suspect List Exchange\n\nPharmaceuticals -> Listed in ZINC15 \n\nS55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | [DOI:10.5281/zenodo.3247749](https://doi.org/DOI:10.5281/zenodo.3247749)\n\nNORMAN Suspect List Exchange\n\nPharmaceuticals -> Metabolite of [Prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisolone)\n\nS113 | SWISSPHARMA24 | 2024 Swiss Pharmaceutical List with Metabolites | [DOI:10.5281/zenodo.10501043](https://doi.org/DOI:10.5281/zenodo.10501043)\n\nNORMAN Suspect List Exchange\n\n##### 3.4.1.1 Human Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Human-Drugs&fullscreen=true \"Open this section in a new browser window\")\n\nBreast Feeding; Lactation; Milk, Human; Corticosteroids, Systemic; Glucocorticoids; Anti-Inflammatory Agents \n\nDrugs and Lactation Database (LactMed)\n\nHuman drug -> Discontinued \n\nDrugs@FDA\n\nHuman drug -> Prescription \n\nDrugs@FDA\n\nHuman drug -> Prescription; Discontinued; Active ingredient (PREDNISONE)\n\nDrugs@FDA\n\nPharmaceuticals \n\nS72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | [DOI:10.5281/zenodo.3955664](https://doi.org/DOI:10.5281/zenodo.3955664)\n\nNORMAN Suspect List Exchange\n\nAntiallergics and medicines used in anaphylaxis\n\nHormones and antihormones\n\nWHO Model Lists of Essential Medicines\n\n##### 3.4.1.2 Animal Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Animal-Drugs&fullscreen=true \"Open this section in a new browser window\")\n\nActive Ingredients (Prednisone) -> FDA Greenbook\n\nFDA Approved Animal Drug Products (Green Book)\n\n#### 3.4.2 Endocrine Disruptors[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Endocrine-Disruptors&fullscreen=true \"Open this section in a new browser window\")\n\nPotential endocrine disrupting compound \n\nS109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | [DOI:10.5281/zenodo.10944198](https://doi.org/DOI:10.5281/zenodo.10944198)\n\nNORMAN Suspect List Exchange\n\n#### 3.4.3 Lipids[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Lipids&fullscreen=true \"Open this section in a new browser window\")\n\nLipids -> Sterol Lipids [ST] -> Steroids [ST02] -> C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives [ST0203] \n\nLIPID MAPS\n\n4 Spectral Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Spectral-Information&fullscreen=true \"Open this section in a new browser window\")\n-----------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 4.1 1D NMR Spectra[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=1D-NMR-Spectra&fullscreen=true \"Open this section in a new browser window\")\n\n#### 4.1.1 1H NMR Spectra[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=1H-NMR-Spectra&fullscreen=true \"Open this section in a new browser window\")\n\nInstrument Name\n\nVarian CFT-20 \n\nCopyright\n\nCopyright © 2009-2025 John Wiley & Sons, Inc. All Rights Reserved. \n\nThumbnail\n\n[![Image 11: Thumbnail](https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4880963_1)](https://spectrabase.com/spectrum/9siTYwh3f4L)\n\nSpectraBase\n\n#### 4.1.2 13C NMR Spectra[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=13C-NMR-Spectra&fullscreen=true \"Open this section in a new browser window\")\n\nSource of Sample\n\n[Fluka AG](https://pubchem.ncbi.nlm.nih.gov/compound/Fluka%20AG), Buchs, Switzerland\n\nCopyright\n\nCopyright © 1980, 1981-2025 John Wiley & Sons, Inc. All Rights Reserved. \n\nThumbnail\n\n[![Image 12: Thumbnail](https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4880962_1)](https://spectrabase.com/spectrum/JZ9JwLRAM85)\n\nSpectraBase\n\n### 4.2 Mass Spectrometry[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Mass-Spectrometry&fullscreen=true \"Open this section in a new browser window\")\n\n#### 4.2.1 GC-MS[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=GC-MS&fullscreen=true \"Open this section in a new browser window\")\n\nSource of Spectrum\n\nMass Spectrometry Committee of the Toxicology Section of the American Academy of Forensic Sciences \n\nCopyright\n\nCopyright © 2012-2025 John Wiley & Sons, Inc. Portions provided by AAFS, Toxicology Section. All Rights Reserved. \n\nThumbnail\n\n[![Image 13: Thumbnail](https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4880959_1)](https://spectrabase.com/spectrum/2yM3So9r0r7)\n\nSpectraBase\n\n#### 4.2.2 MS-MS[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=MS-MS&fullscreen=true \"Open this section in a new browser window\")\n\n1 of 6 items\n\n[View All](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=MS-MS&fullscreen=true \"Open this section in a new browser window\")\n\nSpectra ID\n\n[2226306](https://hmdb.ca/spectra/ms_ms/2226306)\n\nIonization Mode\n\nPositive \n\nSPLASH\n\n[splash10-00dj-0970000000-b61d7f78a4036739cb07](https://mona.fiehnlab.ucdavis.edu/spectra/browse?query==exists(splash.splash:%27splash10-00dj-0970000000-b61d7f78a4036739cb07%27))\n\nTop 5 Peaks\n\n147.0808 100\n\n171.0805 64.69\n\n159.0803 49.73\n\n222.104 32.55\n\n173.0965 30.81\n\nThumbnail\n\n[![Image 14: Thumbnail](https://pubchem.ncbi.nlm.nih.gov/image/ms.cgi?peaks=147.0808:100,171.0805:64.69,159.0803:49.73,222.104:32.55,173.0965:30.81)](https://pubchem.ncbi.nlm.nih.gov/image/ms.cgi?peaks=147.0808:100,171.0805:64.69,159.0803:49.73,222.104:32.55,173.0965:30.81)\n\nHuman Metabolome Database (HMDB)\n\n2 of 6 items\n\n[View All](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=MS-MS&fullscreen=true \"Open this section in a new browser window\")\n\nSpectra ID\n\n[2226385](https://hmdb.ca/spectra/ms_ms/2226385)\n\nIonization Mode\n\nPositive \n\nSPLASH\n\n[splash10-0a4l-0149000000-e36403a2dae0a4f97002](https://mona.fiehnlab.ucdavis.edu/spectra/browse?query==exists(splash.splash:%27splash10-0a4l-0149000000-e36403a2dae0a4f97002%27))\n\nTop 5 Peaks\n\n359.1855 100\n\n341.1749 92.39\n\n313.1799 38.74\n\n323.1643 37.94\n\n295.1694 29.13\n\nThumbnail\n\n[![Image 15: Thumbnail](https://pubchem.ncbi.nlm.nih.gov/image/ms.cgi?peaks=359.1855:100,341.1749:92.39,313.1799:38.74,323.1643:37.94,295.1694:29.13)](https://pubchem.ncbi.nlm.nih.gov/image/ms.cgi?peaks=359.1855:100,341.1749:92.39,313.1799:38.74,323.1643:37.94,295.1694:29.13)\n\nHuman Metabolome Database (HMDB)\n\n#### 4.2.3 LC-MS[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=LC-MS&fullscreen=true \"Open this section in a new browser window\")\n\n1 of 83 items\n\n[View All](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=LC-MS&fullscreen=true \"Open this section in a new browser window\")\n\nAccession ID\n\n[MSBNK-ACES_SU-AS000541](https://massbank.eu/MassBank/RecordDisplay?id=MSBNK-ACES_SU-AS000541)\n\nAuthors\n\nACESx, National Facility for Exposomics \n\nInstrument\n\nExploris 480 Orbitrap (Thermo Scientific) \n\nInstrument Type\n\nLC-ESI-QFT \n\nMS Level\n\nMS2 \n\nIonization Mode\n\nPOSITIVE \n\nIonization\n\nESI \n\nCollision Energy\n\nRamp 20%-70% (nominal) \n\nFragmentation Mode\n\nHCD \n\nColumn Name\n\nWaters; Acquity UPLC BEH C18, 3.0 x 100 mm, 1.7 um, Waters \n\nRetention Time\n\n9.98 \n\nPrecursor m/z\n\n359.1844 \n\nPrecursor Adduct\n\n[M+H]+ \n\nTop 5 Peaks\n\n341.17447 999\n\n359.18408 860\n\n147.0808 497\n\n313.17847 425\n\n323.16391 333\n\nSPLASH\n\n[splash10-0abd-1769000000-595df63c6b4ab75f5624](https://massbank.eu/MassBank/search?splash=splash10-0abd-1769000000-595df63c6b4ab75f5624)\n\nThumbnail\n\n[![Image 16: Thumbnail](https://pubchem.ncbi.nlm.nih.gov/image/ms.cgi?peaks=341.17447:999,359.18408:860,147.0808:497,313.17847:425,323.16391:333)](https://pubchem.ncbi.nlm.nih.gov/image/ms.cgi?peaks=341.17447:999,359.18408:860,147.0808:497,313.17847:425,323.16391:333)\n\nLicense\n\nCC BY \n\nMassBank Europe\n\n2 of 83 items\n\n[View All](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=LC-MS&fullscreen=true \"Open this section in a new browser window\")\n\nAccession ID\n\n[MSBNK-ACES_SU-AS001405](https://massbank.eu/MassBank/RecordDisplay?id=MSBNK-ACES_SU-AS001405)\n\nAuthors\n\nACESx, National Facility for Exposomics \n\nInstrument\n\nExploris 480 Orbitrap (Thermo Scientific) \n\nInstrument Type\n\nLC-ESI-QFT \n\nMS Level\n\nMS2 \n\nIonization Mode\n\nNEGATIVE \n\nIonization\n\nESI \n\nCollision Energy\n\nRamp 20%-70% (nominal) \n\nFragmentation Mode\n\nHCD \n\nColumn Name\n\nWaters; Acquity UPLC BEH C18, 3.0 x 100 mm, 1.7 um, Waters \n\nRetention Time\n\n9.98 \n\nPrecursor m/z\n\n357.1709 \n\nPrecursor Adduct\n\n[M-H]- \n\nTop 5 Peaks\n\n327.16074 999\n\n123.04518 220\n\n299.16684 202\n\n149.06041 143\n\n328.1647 112\n\nSPLASH\n\n[splash10-004i-0629000000-537555407e72bf038b8c](https://massbank.eu/MassBank/search?splash=splash10-004i-0629000000-537555407e72bf038b8c)\n\nThumbnail\n\n[![Image 17: Thumbnail](https://pubchem.ncbi.nlm.nih.gov/image/ms.cgi?peaks=327.16074:999,123.04518:220,299.16684:202,149.06041:143,328.1647:112)](https://pubchem.ncbi.nlm.nih.gov/image/ms.cgi?peaks=327.16074:999,123.04518:220,299.16684:202,149.06041:143,328.1647:112)\n\nLicense\n\nCC BY \n\nMassBank Europe\n\n#### 4.2.4 Other MS[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Other-MS&fullscreen=true \"Open this section in a new browser window\")\n\n1 of 3 items\n\n[View All](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Other-MS&fullscreen=true \"Open this section in a new browser window\")\n\nOther MS\n\nMASS: 42900 (NIST/EPA/[MSDC](https://pubchem.ncbi.nlm.nih.gov/compound/MSDC) Mass Spectral Database, 1990 version)\n\nHazardous Substances Data Bank (HSDB)\n\n2 of 3 items\n\n[View All](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Other-MS&fullscreen=true \"Open this section in a new browser window\")\n\nMoNA ID\n\n[MoNA041712](https://mona.fiehnlab.ucdavis.edu/spectra/display/MoNA041712)\n\nMS Category\n\nExperimental \n\nMS Type\n\nOther \n\nPrecursor Type\n\n[M+H]+ \n\nPrecursor m/z\n\n359.1853004 \n\nInstrument\n\nAgilent 6560 \n\nIonization Mode\n\npositive \n\nCollision Energy\n\n20 \n\nRetention Time\n\n7.339433 \n\nTop 5 Peaks\n\n147.08022 100\n\n237.12732 90.50\n\n265.1586 66.57\n\n267.13803 64.05\n\n295.16907 59.52\n\nSPLASH\n\n[splash10-00r2-0591000000-ca9902d04d23331a4706](https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=exists(splash.splash:%27splash10-00r2-0591000000-ca9902d04d23331a4706%27))\n\nThumbnail\n\n[![Image 18: Thumbnail](https://pubchem.ncbi.nlm.nih.gov/image/ms.cgi?peaks=147.08022:100,237.12732:90.50,265.1586:66.57,267.13803:64.05,295.16907:59.52)](https://pubchem.ncbi.nlm.nih.gov/image/ms.cgi?peaks=147.08022:100,237.12732:90.50,265.1586:66.57,267.13803:64.05,295.16907:59.52)\n\nMassBank of North America (MoNA)\n\n### 4.3 UV Spectra[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=UV-Spectra&fullscreen=true \"Open this section in a new browser window\")\n\nUV: 4-867 (Organic Electronic Spectral Data, Phillips et al, John Wiley & Sons, New York) \n\nLide, D.R., G.W.A. Milne (eds.). Handbook of Data on Organic Compounds. Volume I. 3rd ed. CRC Press, Inc. Boca Raton ,FL. 1994., p. V5: 4237\n\nHazardous Substances Data Bank (HSDB)\n\n#### 4.3.1 UV-VIS Spectra[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=UV-VIS-Spectra&fullscreen=true \"Open this section in a new browser window\")\n\nCopyright\n\nCopyright © 2008-2025 John Wiley & Sons, Inc. All Rights Reserved. \n\nThumbnail\n\n[![Image 19: Thumbnail](https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4880968_1)](https://spectrabase.com/spectrum/EfYuJ78PNr1)\n\nSpectraBase\n\n### 4.4 IR Spectra[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=IR-Spectra&fullscreen=true \"Open this section in a new browser window\")\n\nIR Spectra\n\nIR: 5124 (Coblentz Society Spectral Collection) \n\nHazardous Substances Data Bank (HSDB)\n\n#### 4.4.1 FTIR Spectra[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=FTIR-Spectra&fullscreen=true \"Open this section in a new browser window\")\n\nTechnique\n\nKBr WAFER \n\nSource of Sample\n\nThe Upjohn Company \n\nCopyright\n\nCopyright © 1980, 1981-2025 John Wiley & Sons, Inc. All Rights Reserved. \n\nThumbnail\n\n[![Image 20: Thumbnail](https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/8152282_1)](https://spectrabase.com/spectrum/AYFozxCHyD1)\n\nSpectraBase\n\n#### 4.4.2 ATR-IR Spectra[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=ATR-IR-Spectra&fullscreen=true \"Open this section in a new browser window\")\n\nInstrument Name\n\nBio-Rad FTS \n\nTechnique\n\nATR-Neat (DuraSamplIR II) \n\nSource of Spectrum\n\nForensic Spectral Research \n\nSource of Sample\n\nSteraloids Inc. \n\nCatalog Number\n\nP0300-000 \n\nLot Number\n\nB0172 \n\nCopyright\n\nCopyright © 2009-2025 John Wiley & Sons, Inc. All Rights Reserved. \n\nThumbnail\n\n[![Image 21: Thumbnail](https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4880960_1)](https://spectrabase.com/spectrum/7iCvY3D9gxQ)\n\nSpectraBase\n\n### 4.5 Raman Spectra[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Raman-Spectra&fullscreen=true \"Open this section in a new browser window\")\n\nTechnique\n\nFT-Raman \n\nSource of Spectrum\n\nForensic Spectral Research \n\nSource of Sample\n\nSteraloids Inc. \n\nCatalog Number\n\nP0300-000 \n\nLot Number\n\nB0172 \n\nCopyright\n\nCopyright © 2013-2025 John Wiley & Sons, Inc. All Rights Reserved. \n\nThumbnail\n\n[![Image 22: Thumbnail](https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/4880964_1)](https://spectrabase.com/spectrum/5zz6gxT4Z27)\n\nSpectraBase\n\n### 4.6 Other Spectra[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Other-Spectra&fullscreen=true \"Open this section in a new browser window\")\n\nIntense mass spectral peaks: 122 m/z, 147 m/z, 314 m/z, 372 m/z. \n\nPfleger, K., H. Maurer and A. Weber. Mass Spectral and GC Data of Drugs, Poisons and their Metabolites. Parts I and II. Mass Spectra Indexes. Weinheim, Federal Republic of Germany. 1985., p. 526\n\nHazardous Substances Data Bank (HSDB)\n\n5 Related Records[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Related-Records&fullscreen=true \"Open this section in a new browser window\")\n-------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 5.1 Related Compounds with Annotation[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Related-Compounds-with-Annotation&fullscreen=true \"Open this section in a new browser window\")\n\nFollow these links to [do a live 2D search](https://pubchem.ncbi.nlm.nih.gov/#query=CID5865%20structure&tab=similarity&sort=annothitcnt) or [do a live 3D search](https://pubchem.ncbi.nlm.nih.gov/#query=CID5865%20structure&tab=similarity_3d&sort=annothitcnt) for this compound, sorted by annotation score. This section is deprecated (see [the neighbor discontinuation help page](https://pubchem.ncbi.nlm.nih.gov/docs/neighbor-discontinuation) for details), but these live search links provide equivalent functionality to the table that was previously shown here.\n\nPubChem\n\n### 5.2 Related Compounds[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Related-Compounds&fullscreen=true \"Open this section in a new browser window\")\n\nSame Connectivity Count\n\n[47](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/5865/cids/JSON?cids_type=same_connectivity&list_return=redirect)\n\nSame Stereo Count\n\n[8](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/5865/cids/JSON?cids_type=same_stereo&list_return=redirect)\n\nSame Isotope Count\n\n[38](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/5865/cids/JSON?cids_type=same_isotopes&list_return=redirect)\n\nSame Parent, Connectivity Count\n\n[82](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/5865/cids/JSON?cids_type=same_parent_connectivity&list_return=redirect)\n\nSame Parent, Stereo Count\n\n[42](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/5865/cids/JSON?cids_type=same_parent_stereo&list_return=redirect)\n\nSame Parent, Isotope Count\n\n[73](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/5865/cids/JSON?cids_type=same_parent_isotopes&list_return=redirect)\n\nSame Parent, Exact Count\n\n[35](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/5865/cids/JSON?cids_type=same_parent&list_return=redirect)\n\nMixtures, Components, and Neutralized Forms Count\n\n[209](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/5865/cids/JSON?cids_type=component&list_return=redirect)\n\nSimilar Compounds (2D)\n\n[View in PubChem Search](https://pubchem.ncbi.nlm.nih.gov/#query=CID5865%20structure&tab=similarity)\n\nSimilar Conformers (3D)\n\n[View in PubChem Search](https://pubchem.ncbi.nlm.nih.gov/#query=CID5865%20structure&tab=similarity_3d)\n\nPubChem\n\n### 5.3 Substances[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Substances&fullscreen=true \"Open this section in a new browser window\")\n\n#### 5.3.1 PubChem Reference Collection SID[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=PubChem-Reference-Collection-SID&fullscreen=true \"Open this section in a new browser window\")\n\n[481107502](https://pubchem.ncbi.nlm.nih.gov/substance/481107502)\n\nPubChem\n\n#### 5.3.2 Related Substances[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Related-Substances&fullscreen=true \"Open this section in a new browser window\")\n\nAll Count\n\n[587](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/5865/sids/JSON?sids_type=all&list_return=redirect)\n\nSame Count\n\n[282](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/5865/sids/JSON?sids_type=standardized&list_return=redirect)\n\nMixture Count\n\n[305](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/5865/sids/JSON?sids_type=component&list_return=redirect)\n\nPubChem\n\n#### 5.3.3 Substances by Category[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Substances-by-Category&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 5.4 Other Relationships[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Other-Relationships&fullscreen=true \"Open this section in a new browser window\")\n\n*   [![Image 23](https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=s&cid=5755)Prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/5755) (has active moiety)\n*   [![Image 24](https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=s&cid=9878)Fluorometholone](https://pubchem.ncbi.nlm.nih.gov/compound/9878) (related)\n*   [![Image 25](https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=s&cid=5311067)Desoximetasone](https://pubchem.ncbi.nlm.nih.gov/compound/5311067) (related)\n*   [![Image 26](https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=s&cid=9053)Fluocortolone](https://pubchem.ncbi.nlm.nih.gov/compound/9053) (related)\n\nPubChem\n\n### 5.5 Entrez Crosslinks[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Entrez-Crosslinks&fullscreen=true \"Open this section in a new browser window\")\n\nPubMed Count\n\n[15143](https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_pubmed&db=pccompound&cmd=Link&from_uid=5865)\n\nProtein Structures Count\n\n[2](https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_structure&db=pccompound&cmd=Link&from_uid=5865)\n\nPubChem\n\n### 5.6 NCBI LinkOut[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=NCBI-LinkOut&fullscreen=true \"Open this section in a new browser window\")\n\nNCBI\n\n6 Chemical Vendors[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Chemical-Vendors&fullscreen=true \"Open this section in a new browser window\")\n---------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nPubChem\n\n7 Drug and Medication Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Drug-and-Medication-Information&fullscreen=true \"Open this section in a new browser window\")\n---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 7.1 Drug Indication[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Drug-Indication&fullscreen=true \"Open this section in a new browser window\")\n\nPrednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.\n\nDrugBank\n\nOpen Targets\n\nPrednisone is a synthetic, anti-inflammatory glucocorticoid that derives from [cortisone](https://pubchem.ncbi.nlm.nih.gov/compound/cortisone). It is biologically inert and converted to [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) in the liver. Prednisone is an FDA-approved, delayed-release corticosteroid indicated as an anti-inflammatory or immunosuppressive agent to treat a broad range of diseases, including immunosuppressive/endocrine, rheumatic, collagen, dermatologic, allergic states, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal (GI, acute exacerbations of multiple sclerosis, and as an anti-inflammatory and an antineoplastic agent. Prednisone is a corticosteroid ([cortisone](https://pubchem.ncbi.nlm.nih.gov/compound/cortisone)-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions. This medication is available only by prescription.\n\nStatPearls\n\n### 7.2 Drug Classes[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Drug-Classes&fullscreen=true \"Open this section in a new browser window\")\n\nBreast Feeding; Lactation; Milk, Human; Corticosteroids, Systemic; Glucocorticoids; Anti-Inflammatory Agents \n\nDrugs and Lactation Database (LactMed)\n\n### 7.3 Drug Transformations[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Drug-Transformations&fullscreen=true \"Open this section in a new browser window\")\n\nPrednisone is a known transformation product of [Prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisolone).\n\nS66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | [DOI:10.5281/zenodo.3754448](https://doi.org/DOI:10.5281/zenodo.3754448)\n\nNORMAN Suspect List Exchange\n\n### 7.4 WHO Essential Medicines[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=WHO-Essential-Medicines&fullscreen=true \"Open this section in a new browser window\")\n\nDrug\n\nDrug Classes\n\nFormulation\n\nIndication\n\nDrug\n\n[Prednisone](https://list.essentialmeds.org/medicines/635)\n\nDrug Classes\n\nAntiallergics and medicines used in anaphylaxis \n\nFormulation\n\nIndication\n\nAllergic or hypersensitivity conditions of unspecified type \n\nDrug\n\n[Prednisone](https://list.essentialmeds.org/medicines/635)\n\nDrug Classes\n\nHormones and antihormones \n\nFormulation\n\nIndication\n\n(1) Plasma cell myeloma; (2) Follicular lymphoma; (3) Lymphoid leukaemia, not elsewhere classified; (4) Malignant neoplasms of prostate; (5) Chronic lymphocytic leukaemia or small lymphocytic lymphoma; (6) Hodgkin lymphoma; (7) Diffuse large B-cell lymphomas; (8) Anaplastic large cell lymphoma, ALK-negative; (9) Anaplastic large cell lymphoma, ALK-positive; (10) Langerhans cell histiocytosis \n\nWHO Model Lists of Essential Medicines\n\n### 7.5 FDA Approved Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=FDA-Approved-Drugs&fullscreen=true \"Open this section in a new browser window\")\n\nDrugs@FDA\n\n### 7.6 FDA Orange Book[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=FDA-Orange-Book&fullscreen=true \"Open this section in a new browser window\")\n\nFDA Orange Book\n\n### 7.7 FDA National Drug Code Directory[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=FDA-National-Drug-Code-Directory&fullscreen=true \"Open this section in a new browser window\")\n\nNational Drug Code (NDC) Directory\n\n### 7.8 FDA Green Book[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=FDA-Green-Book&fullscreen=true \"Open this section in a new browser window\")\n\nFDA Approved Animal Drug Products (Green Book)\n\n### 7.9 Drug Labels[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Drug-Labels&fullscreen=true \"Open this section in a new browser window\")\n\nDrug and label\n\nDailyMed\n\nView More...\n\n### 7.10 Cancer Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Cancer-Drugs&fullscreen=true \"Open this section in a new browser window\")\n\nDrug Name\n\nPrednisone \n\nFDA Approved\n\nYes \n\nDrug Use\n\nPrednisone is approved to be used to reduce inflammation and suppress (lower) the body's immune response. It is used with other drugs to treat the following types of cancer:\n\n• Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). It is used as palliative therapy in adults and children.\n\n• Chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML). It is used as palliative therapy in adults.\n\n• Hodgkin lymphoma. It is used as palliative therapy in adults.\n\n• Mycosis fungoides (a type of cutaneous T-cell lymphoma).\n\n• Non-Hodgkin lymphoma. It is used as palliative therapy in adults.\n\nPrednisone is also used alone or with other drugs to prevent or treat the following conditions related to cancer:\n\n• Anemia.\n\n• Drug hypersensitivity (allergic reactions).\n\n• Hypercalcemia (high blood levels of [calcium](https://pubchem.ncbi.nlm.nih.gov/element/Calcium)).\n\n• Thrombocytopenia (low platelet levels) in adults.\n\nPrednisone is also used alone or with other drugs to treat many other diseases and conditions. The drug continues to be studied in the treatment of many types of cancer and other conditions.\n\nNCI Cancer Drugs\n\n### 7.11 Clinical Trials[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Clinical-Trials&fullscreen=true \"Open this section in a new browser window\")\n\n#### 7.11.1 ClinicalTrials.gov[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=ClinicalTrials-gov&fullscreen=true \"Open this section in a new browser window\")\n\nClinicalTrials.gov\n\n#### 7.11.2 EU Clinical Trials Register[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=EU-Clinical-Trials-Register&fullscreen=true \"Open this section in a new browser window\")\n\nEU Clinical Trials Register\n\n#### 7.11.3 NIPH Clinical Trials Search of Japan[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=NIPH-Clinical-Trials-Search-of-Japan&fullscreen=true \"Open this section in a new browser window\")\n\nNIPH Clinical Trials Search of Japan\n\n### 7.12 Therapeutic Uses[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Therapeutic-Uses&fullscreen=true \"Open this section in a new browser window\")\n\nAnti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Glucocorticoids \n\nNational Library of Medicine's Medical Subject Headings. Prednisone. Online file (MeSH, 2016). Available from, as of October 28, 2016: [https://www.nlm.nih.gov/mesh/2016/mesh_browser/MBrowser.html](https://www.nlm.nih.gov/mesh/2016/mesh_browser/MBrowser.html)\n\nHazardous Substances Data Bank (HSDB)\n\nPrednisone is usually considered the oral glucocorticoid of choice for anti-inflammatory or immunosuppressant effects. Because it has only minimal mineralocorticoid properties, the drug is inadequate alone for the management of adrenocortical insufficiency. If prednisone is used in the treatment of this condition, concomitant therapy with a mineralocorticoid is also required.\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 3122-3\n\nHazardous Substances Data Bank (HSDB)\n\nPrednisone tablets and solutions are indicated in the following conditions: Endocrine Disorders: Primary or secondary adrenocortical insufficiency ([hydrocortisone](https://pubchem.ncbi.nlm.nih.gov/compound/hydrocortisone) or [cortisone](https://pubchem.ncbi.nlm.nih.gov/compound/cortisone) is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. /Included in US product label/\n\nNIH; DailyMed. Current Medication Information for Prednisone (Pednisone Tablet) Prednisone (Prednisone Solution) Prednisone Intensol (Prednisone Intensol Solution, Concentrate) (Updated: July 2016). Available from, as of November 22, 2016: [https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3115aef0-fd50-4ec8-a064-3effb695f3f2](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3115aef0-fd50-4ec8-a064-3effb695f3f2)\n\nHazardous Substances Data Bank (HSDB)\n\nPrednisone tablets and solutions are indicated in the following conditions: Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), ankylosing spondylitis, acute and subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis. /Included in US product label/\n\nNIH; DailyMed. Current Medication Information for Prednisone (Pednisone Tablet) Prednisone (Prednisone Solution) Prednisone Intensol (Prednisone Intensol Solution, Concentrate) (Updated: July 2016). Available from, as of November 22, 2016: [https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3115aef0-fd50-4ec8-a064-3effb695f3f2](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3115aef0-fd50-4ec8-a064-3effb695f3f2)\n\nHazardous Substances Data Bank (HSDB)\n\nFor more Therapeutic Uses (Complete) data for PREDNISONE (19 total), please visit the [HSDB record page](https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3168#section=Therapeutic-Uses-(Complete)).\n\nHazardous Substances Data Bank (HSDB)\n\n### 7.13 Drug Warnings[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Drug-Warnings&fullscreen=true \"Open this section in a new browser window\")\n\nThe profound effects of prednisone on the immune system place patients at increased risk of developing infections of various types. Prednisone may mask some of the signs of infection, and may decrease host resistance and interfere with the ability to localize infections. During prednisone therapy, a polymorphonuclear leukocytosis may develop and may give rise to confusion in the diagnosis of infection. This elevation is dose-related.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\nPsychiatric reactions have been reported in 4-36% of patients. These disturbances may take various forms, for example, insomnia, changes in mood or psyche, and psychopathies of the manic-depressive or schizophrenic type. \n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\nOphthalmic complications include the development of posterior subcapsular cataracts, and increased intraocular pressure which may lead to glaucoma. In patients with ocular herpes simplex, it may cause corneal perforation. \n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\nThere are numerous endocrine side effects. Most frequent is development of the Cushingoid state. Fatty deposits in the mediastinum causing mediastinal widening may simulate mediastinal lymphadenopathy. Menstrual irregularities, including amenorrhoea, may occur. There may be secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness. The processes of recovery of normal pituitary and adrenal function require about 1 year in some patients. There may be stunted growth and delayed skeletal maturation in children. Prednisone causes decreased carbohydrate tolerance and may unmask the features of latent diabetes.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\nFor more Drug Warnings (Complete) data for PREDNISONE (38 total), please visit the [HSDB record page](https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3168#section=Drug-Warnings-(Complete)).\n\nHazardous Substances Data Bank (HSDB)\n\n8 Pharmacology and Biochemistry[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Pharmacology-and-Biochemistry&fullscreen=true \"Open this section in a new browser window\")\n-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 8.1 Pharmacodynamics[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Pharmacodynamics&fullscreen=true \"Open this section in a new browser window\")\n\nCorticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals. Prednisone has a short duration of action as the half life is 2-3 hours. Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces. Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.\n\nDrugBank\n\n### 8.2 MeSH Pharmacological Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=MeSH-Pharmacological-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nAnti-Inflammatory Agents\n\nSubstances that reduce or suppress INFLAMMATION. \n\nMedical Subject Headings (MeSH)\n\nGlucocorticoids\n\nA group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. \n\nMedical Subject Headings (MeSH)\n\nAntineoplastic Agents, Hormonal\n\nAntineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) \n\nMedical Subject Headings (MeSH)\n\n### 8.3 FDA Pharmacological Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=FDA-Pharmacological-Classification&fullscreen=true \"Open this section in a new browser window\")\n\n1 of 5 items\n\nFDA UNII\n\n3EN3HG4WSW \n\nActive Moiety\n\nPREDNISONE ANHYDROUS \n\nPharmacological Classes\n\nEstablished Pharmacologic Class [EPC] - Corticosteroid \n\nPharmacological Classes\n\nMechanisms of Action [MoA] - Corticosteroid Hormone Receptor Agonists \n\nFDA Pharmacology Summary\n\nPrednisone anhydrous is a Corticosteroid. The mechanism of action of prednisone anhydrous is as a Corticosteroid Hormone Receptor Agonist.\n\nFDA Pharm Classes\n\n2 of 5 items\n\nFDA UNII\n\nVB0R961HZT \n\nActive Moiety\n\nPREDNISONE \n\nPharmacological Classes\n\nEstablished Pharmacologic Class [EPC] - Corticosteroid \n\nPharmacological Classes\n\nMechanisms of Action [MoA] - Corticosteroid Hormone Receptor Agonists \n\nFDA Pharmacology Summary\n\nPrednisone is a Corticosteroid. The mechanism of action of prednisone is as a Corticosteroid Hormone Receptor Agonist.\n\nFDA Pharm Classes\n\n3 of 5 items\n\nNon-Proprietary Name\n\nPREDNISONE \n\nPharmacological Classes\n\nCorticosteroid Hormone Receptor Agonists [MoA]; Corticosteroid [EPC] \n\nNational Drug Code (NDC) Directory\n\n4 of 5 items\n\nNon-Proprietary Name\n\nPREDNISONE INTENSOL \n\nPharmacological Classes\n\nCorticosteroid Hormone Receptor Agonists [MoA]; Corticosteroid [EPC] \n\nNational Drug Code (NDC) Directory\n\n5 of 5 items\n\nNon-Proprietary Name\n\nDR ADAM AU \n\nPharmacological Classes\n\nCorticosteroid [EPC]; Corticosteroid Hormone Receptor Agonists [MoA] \n\nNational Drug Code (NDC) Directory\n\n### 8.4 ATC Code[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=ATC-Code&fullscreen=true \"Open this section in a new browser window\")\n\n[A](https://atcddd.fhi.no/atc_ddd_index/?code=A) - Alimentary tract and metabolism\n\n[A07](https://atcddd.fhi.no/atc_ddd_index/?code=A07) - Antidiarrheals, intestinal antiinflammatory/antiinfective agents\n\n[A07E](https://atcddd.fhi.no/atc_ddd_index/?code=A07E) - Intestinal antiinflammatory agents\n\n[A07EA](https://atcddd.fhi.no/atc_ddd_index/?code=A07EA) - Corticosteroids acting locally\n\n[A07EA03](https://atcddd.fhi.no/atc_ddd_index/?code=A07EA03) - Prednisone\n\nWHO Anatomical Therapeutic Chemical (ATC) Classification\n\n[H](https://atcddd.fhi.no/atc_ddd_index/?code=H) - Systemic hormonal preparations, excl. sex hormones and insulins\n\n[H02](https://atcddd.fhi.no/atc_ddd_index/?code=H02) - Corticosteroids for systemic use\n\n[H02A](https://atcddd.fhi.no/atc_ddd_index/?code=H02A) - Corticosteroids for systemic use, plain\n\n[H02AB](https://atcddd.fhi.no/atc_ddd_index/?code=H02AB) - Glucocorticoids\n\n[H02AB07](https://atcddd.fhi.no/atc_ddd_index/?code=H02AB07) - Prednisone\n\nWHO Anatomical Therapeutic Chemical (ATC) Classification\n\nATCvet Code\n\n[QA](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA) - Alimentary tract and metabolism\n\n[QA07](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07) - Antidiarrheals, intestinal anti-inflammatory/antiinfective agents\n\n[QA07E](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07E) - Intestinal antiinflammatory agents\n\n[QA07EA](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07EA) - Corticosteroids acting locally\n\n[QA07EA03](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07EA03) - Prednisone\n\nWHO ATCvet - Classification of Veterinary Medicines\n\nATCvet Code\n\n[QH](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QH) - Systemic hormonal preparations, excl. sex hormones and insulin\n\n[QH02](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QH02) - Corticosteroids for systemic use\n\n[QH02A](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QH02A) - Corticosteroids for systemic use, plain\n\n[QH02AB](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QH02AB) - Glucocorticoids\n\n[QH02AB07](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QH02AB07) - Prednisone\n\nWHO ATCvet - Classification of Veterinary Medicines\n\n### 8.5 Absorption, Distribution and Excretion[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Absorption-Distribution-and-Excretion&fullscreen=true \"Open this section in a new browser window\")\n\nAbsorption\n\nOral prednisone has a T max of 2 hours, while the delayed-release formulation has a T max of 6-6.5 hours. A 5mg dose of prednisone has an AUC of 572mL/min/1.73m 2, a 20mg dose of prednisone has an AUC of 1034mL/min/1.73m 2, and a 50mg dose of prednisone has an AUC of 2271mL/min/1.73m 2. Data regarding the C max of prednisone is not readily available.\n\nDrugBank\n\nRoute of Elimination\n\nPrednisone is excreted mainly in the urine as [sulfate](https://pubchem.ncbi.nlm.nih.gov/compound/sulfate) and glucuronide conjugates.\n\nDrugBank\n\nVolume of Distribution\n\nData regarding the volume of distribution for prednisone is not readily available. However, a 0.15mg/kg dose of [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) has a volume of distribution of 29.3L, while a 0.30mg/kg dose has a volume of distribution of 44.2L.\n\nDrugBank\n\nClearance\n\nData regarding the clearance of prednisone is not readily available. A 5.5µg/h/kg infusion of [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) has an average clearance of 0.066±0.12L/h/kg, while a 0.15±0.03L/h/kg infusion has an average clearance of 0.15L/h/kg.\n\nDrugBank\n\nThirty minutes after iv administration of (3)H-prednisone to a monkey, the concentration of prednisone was highest in the kidney. The drug was also found in the liver, spleen, lung, small intestine, serum and bile. The concentration of [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) was highest in the liver. It was also found in the kidney, pancreas, spleen, lung, small intestine, serum and bile.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\nPrednisone is readily absorbed from the gut. Serum concentrations of prednisone and [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone), its active metabolite, have been found to be maximal 1 hour after oral administration of a 5-mg tablet of prednisone to beagle dogs. Following both ip and oral administration of prednisone to mice, serum levels of prednisone, [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) and other metabolites were maximal at 15 min. These levels were higher in mice given ip injections of prednisone than in those receiving the same doses by the oral route. Oral administration of prednisone to dogs and monkeys led to serum levels comparable with those following iv injections, but individual variations were relatively large.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\nPrednisone is readily absorbed from the gut. In a series of 22 normal subjects, the mean peak serum concentration was 930 ug/L (range, 508-1579) following oral administration of a 50 mg tablet.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\nThe protein binding characteristics of prednisone and [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone), alone and together, in human and rabbit plasma and human serum albumin, are reported. The kinetics of [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) binding were nonlinear and those of prednisone were linear in both human and rabbit plasma; prednisone binding was linear with human serum albumin, although to a lesser degree. It is suggested that prednisone binds to proteins other than albumin in plasma. Binding of prednisone was not influenced by [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone). The results support the hypothesis that the protein binding characteristics of prednisone and [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) do not explain the reported nonlinear pharmacokinetics of prednisone.\n\n[PMID:3593903](https://pubmed.ncbi.nlm.nih.gov/3593903)\n\nFerry JJ, Wagner JG; Biopharm Drug Dispos 8 (3): 261-72 (1987)\n\nHazardous Substances Data Bank (HSDB)\n\nAdministration of physiologic doses unlikely to adversely affect infant. FDA Category: C (C = Studies in laboratory animals have revealed adverse effects on the fetus (teratogenic, embryocidal, etc.) but there are no controlled studies in pregnant women. The benefits from use of the drug in pregnant women may be acceptable despite its potential risks, or there are no laboratory animal studies or adequate studies in pregnant women.) /Adrenocorticosteroids/ /from table II/ \n\nStockton, D.L. and A.S. Paller. J Am Acad Dermatol 23 (1):87-103 (1990)\n\nHazardous Substances Data Bank (HSDB)\n\n### 8.6 Protein Binding[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Protein-Binding&fullscreen=true \"Open this section in a new browser window\")\n\nCorticosteroids are generally bound to corticosteroid binding globulin and serum albumin in plasma. Prednisone is <50% bound to protein in plasma.\n\nDrugBank\n\n### 8.7 Metabolism / Metabolites[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Metabolism-Metabolites&fullscreen=true \"Open this section in a new browser window\")\n\nPrednisone is metabolized to 17α,21-dihydroxy-pregnan-1,4,6-trien-3,11,30-trione (M-XVII), 20α-dihydro-prednisone (M-V), 6βhydroxy-prednisone (M-XII), 6α-hydroxy-prednisone (M-XIII), or 20β-dihydro-prednisone (M-IV).20β-dihydro-prednisone is metabolized to 17α,20ξ,21-trihydroxy-5ξ-pregn-1-en-3,11-dione(M-XVIII). Prednison is reversibly metabolized to [[prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone)].[Prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisolone) is metabolized to Δ6-[prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) (M-XI), 20α-dihydro-[prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) (M-III), 20β-dihydro-[prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) (M-II), 6αhydroxy-[prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) (M-VII), or 6βhydroxy-prednisolone(M-VI).6αhydroxy-[prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) is metabolized to 6α,11β,17α,20β,21-pentahydroxypregnan-1,4-diene-3-one (M-X).6βhydroxy-prednisolone is metabolized to 6β,11β,17α,20β,21-pentahydroxypregnan-1,4-diene-3-one (M-VIII), 6β,11β,17α,20α,21-pentahydroxypregnan-1,4-diene-3-one (M-IX), and 6β,11β,17α,21-tetrahydroxy-5ξ-pregn-1-en-3,20-dione (M-XIV).MVIII is metabolized to 6β,11β,17α,20β,21-pentahydroxy-5ξ-pregn-1-en-3-one (M-XV) and then to MXIV, while MIX is metabolized to 6β,11β,17α,20α,21-pentahydroxy-5ξ-pregn-1-en-3-one (M-XVI) and then to MXIV.These metabolites and their glucuronide conjugates are excreted predominantly in the urine.\n\nDrugBank\n\nIn one study after an oral dose of prednisone, the plasma [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) concentration peaked between 60 and 120 min and then declined exponentially. After rapid iv injection of steroid, the plasma [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) concentration peaked within 10 to 20 min. An initial rapid distribution phase succeeded by a slower decay phase was expressed by a biphasic exponential disappearance curve of the plasma [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) concentration versus time. Plasma [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) concentrations achieved with an oral dose of prednisone were in the same range as those obtained during the second phase after iv administration.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\nReduction of the 11-oxo to the 11alpha-hydroxyl group by the enzyme 11beta-hydroxydehydrogenase converts prednisone to [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone), its biologically active form. This reaction takes place mainly in the liver, and may proceed satisfactorily even in the presence of liver disease\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\nIn vitro, prednisone is converted to [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) by liver, lung and renal tissue. Conversely, [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) is converted to prednisone by renal tissue.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\n... The aim of this work was to evaluate the effects of these corticosteroids on the expression of several forms of cytochromes p450, including p450 1A2, 2D6, 2E1, and 3A, and on [cyclosporin A](https://pubchem.ncbi.nlm.nih.gov/compound/cyclosporin%20A) oxidase activity in human liver. For this purpose, human hepatocytes prepared from lobectomies were maintained in culture in a serum-free medium, in collagen-coated dishes, for 96-144 hr, in the absence or presence of 50-100 uM corticosteroids, [rifampicin](https://pubchem.ncbi.nlm.nih.gov/compound/rifampicin), or [dexamethasone](https://pubchem.ncbi.nlm.nih.gov/compound/dexamethasone). To mimic more closely the current clinical protocol, hepatocyte cultures were also co-treated with corticosteroids and [cyclosporin A](https://pubchem.ncbi.nlm.nih.gov/compound/cyclosporin%20A) or [ketoconazole](https://pubchem.ncbi.nlm.nih.gov/compound/ketoconazole) (a selective inhibitor of cytochromes p450 3A). [Cyclosporin A](https://pubchem.ncbi.nlm.nih.gov/compound/Cyclosporin%20A) oxidase activity, intracellular retention of [cyclosporin A](https://pubchem.ncbi.nlm.nih.gov/compound/cyclosporin%20A) oxidized metabolites within hepatocytes, accumulation of cytochromes p450 proteins and corresponding messages, and de novo synthesis and half-lives of these cytochromes p450 were measured in parallel in these cultures. Our results, obtained from seven different hepatocyte cultures, showed that 1) [dexamethasone](https://pubchem.ncbi.nlm.nih.gov/compound/dexamethasone) and prednisone, but not [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) or [methylprednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/methylprednisolone), were inducers of cytochrome p450 3A, at the level of protein and mRNA accumulation, as well as of [cyclosporin A](https://pubchem.ncbi.nlm.nih.gov/compound/cyclosporin%20A) oxidase activity, known to be predominantly catalyzed by these cytochromes p450; 2) although corticosteroids are known to be metabolized in human liver, notably by cytochrome p450 3A, partial or total inhibition of this cytochromes p450 by [cyclosporin](https://pubchem.ncbi.nlm.nih.gov/compound/cyclosporin) or [ketoconazole](https://pubchem.ncbi.nlm.nih.gov/compound/ketoconazole), respectively, did not affect the inducing efficiency of these molecules; 3) corticosteroids did not affect the half-life of cytochrome p450 3A or the accumulation of other forms of cytochromes p450, including 1A2, 2D6, and 2E1; 4) chronic treatment of cells with [cyclosporin](https://pubchem.ncbi.nlm.nih.gov/compound/cyclosporin) did not affect cytochrome p450 3A accumulation; 5) corticosteroids were all competitive inhibitors of [cyclosporin A](https://pubchem.ncbi.nlm.nih.gov/compound/cyclosporin%20A) oxidase in human liver microsomes, with Ki values of 61 + or - 12, 125 + or - 25, 190 + or - 38, and 210 + or - 42 uM for [dexamethasone](https://pubchem.ncbi.nlm.nih.gov/compound/dexamethasone), [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone), prednisone, and [methylprednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/methylprednisolone), respectively; and 6) chronic treatment of cells with corticosteroids did not influence the excretion of oxidized metabolites of [cyclosporin](https://pubchem.ncbi.nlm.nih.gov/compound/cyclosporin) from the cells.\n\n[PMID:1614409](https://pubmed.ncbi.nlm.nih.gov/1614409)\n\nPichard L et al; Mol Pharmacol 41 (6): 1047-55 (1992)\n\nHazardous Substances Data Bank (HSDB)\n\nPrednisone is completely converted to the active metabolite [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) by 11‘_-hydroxysteroid dehydrogenases. It is then further metabolized mainly in the liver. The exposure of [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) is 4-6 fold higher than that of prednisone. Route of Elimination: Excreted in the urine as [sulfate](https://pubchem.ncbi.nlm.nih.gov/compound/sulfate) and glucuronide conjugates. Half Life: Half life of both the immediate- and delayed- release formulation is 2 to 3 hours. \n\nToxin and Toxin Target Database (T3DB)\n\n### 8.8 Biological Half-Life[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Biological-Half-Life&fullscreen=true \"Open this section in a new browser window\")\n\nPrednisone and its active metabolite [[prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone)] have half lives of 2-3 hours from both immediate and delayed release preparations.\n\nDrugBank\n\nIn a series of 22 normal subjects, the mean peak serum concentration was 930 ug/L (range, 508-1579) following oral administration of a 50 mg tablet. The overall mean serum half-life was 2.95 hours \n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\n### 8.9 Mechanism of Action[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Mechanism-of-Action&fullscreen=true \"Open this section in a new browser window\")\n\nPrednisone is first metabolized in the liver to its active form, [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone), a glucocorticoid agonist corticosteroid. The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation. Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days. Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of [arachidonic acid](https://pubchem.ncbi.nlm.nih.gov/compound/arachidonic%20acid) derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10. Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive. High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising [sodium](https://pubchem.ncbi.nlm.nih.gov/element/Sodium) levels and decreasing [potassium](https://pubchem.ncbi.nlm.nih.gov/element/Potassium) levels.\n\nDrugBank\n\nIn physiologic doses, corticosteroids are administered to replace deficient endogenous hormones. In larger (pharmacologic) doses, glucocorticoids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing [histamine](https://pubchem.ncbi.nlm.nih.gov/compound/histamine) activity and release of kinin from substrates; reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation; and possibly by other mechanisms as yet unknown. The drugs suppress the immune response by reducing activity and volume of the lymphatic system, producing lymphocytopenia, decreasing immunoglobulin and complement concentrations, decreasing passage of immune complexes through basement membranes, and possibly by depressing reactivity of tissue to antigen-antibody interactions. Glucocorticoids stimulate erythroid cells of bone marrow, prolong survival time of erythrocytes and platelets, and produce neutrophilia and eosinopenia. Glucocorticoids promote gluconeogenesis, redistribution of fat from peripheral to central areas of the body, and protein catabolism, which results in negative [nitrogen](https://pubchem.ncbi.nlm.nih.gov/element/Nitrogen) balance. They reduce intestinal absorption and increase renal excretion of [calcium](https://pubchem.ncbi.nlm.nih.gov/element/Calcium). /Corticosteroids/\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 3097\n\nHazardous Substances Data Bank (HSDB)\n\nGlucocorticoids are capable of suppressing the inflammatory process through numerous pathways. They interact with specific intracellular receptor proteins in target tissues to alter the expression of corticosteroid-responsive genes. Glucocorticoid-specific receptors in the cell cytoplasm bind with steroid ligands to form hormone-receptor complexes that eventually translocate to the cell nucleus. There these complexes bind to specific DNA sequences and alter their expression. The complexes may induce the transcription of mRNA leading to synthesis of new proteins. Such proteins include lipocortin, a protein known to inhibit PLA2a and thereby block the synthesis of prostaglandins, leukotrienes, and PAF. Glucocorticoids also inhibit the production of other mediators including AA metabolites such as COX, cytokines, the interleukins, adhesion molecules, and enzymes such as collagenase. /Glucocorticoids/ \n\nKahn, C.M. (Ed.); The Merck Veterinary Manual 9th ed. Merck & Co. Whitehouse Station, NJ. 2005, p. 2128\n\nHazardous Substances Data Bank (HSDB)\n\n### 8.10 Human Metabolite Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Human-Metabolite-Information&fullscreen=true \"Open this section in a new browser window\")\n\n#### 8.10.1 Cellular Locations[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Cellular-Locations&fullscreen=true \"Open this section in a new browser window\")\n\n*   Cytoplasm \n*   Extracellular \n*   Membrane \n\nHuman Metabolome Database (HMDB)\n\n#### 8.10.2 Metabolite Pathways[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Metabolite-Pathways&fullscreen=true \"Open this section in a new browser window\")\n\n*   [Prednisone Action Pathway](http://smpdb.ca/view/SMP00440)\n*   [Prednisone Metabolism Pathway](http://smpdb.ca/view/SMP00631)\n\nHuman Metabolome Database (HMDB)\n\n### 8.11 Biochemical Reactions[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Biochemical-Reactions&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 8.12 Transformations[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Transformations&fullscreen=true \"Open this section in a new browser window\")\n\nChEMBL\n\nNORMAN Suspect List Exchange\n\n9 Use and Manufacturing[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Use-and-Manufacturing&fullscreen=true \"Open this section in a new browser window\")\n-------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 9.1 Uses[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Uses&fullscreen=true \"Open this section in a new browser window\")\n\nMEDICATION \n\nHazardous Substances Data Bank (HSDB)\n\nMEDICATION (VET) \n\nHazardous Substances Data Bank (HSDB)\n\nAnti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Glucocorticoids \n\nNational Library of Medicine's Medical Subject Headings. Prednisone. Online file (MeSH, 2016). Available from, as of October 28, 2016: [https://www.nlm.nih.gov/mesh/2016/mesh_browser/MBrowser.html](https://www.nlm.nih.gov/mesh/2016/mesh_browser/MBrowser.html)\n\nHazardous Substances Data Bank (HSDB)\n\nUse (kg) in Switzerland (2009): >100\n\nUse (kg; approx.) in Germany (2009): >500\n\nUse (kg) in USA (2002): 8040\n\nUse (kg) in France (2004): 1550\n\nConsumption (g per capita) in Switzerland (2009): 0.013\n\nConsumption (g per capita; approx.) in Germany (2009): 0.0061\n\nConsumption (g per capita) in the USA (2002): 0.029\n\nConsumption (g per capita) in France (2004): 0.026\n\nExcretion rate: 1\n\nCalculated removal (%): 45.8\n\n[DOI:10.1021/acs.est.5b03332](https://doi.org/DOI:10.1021/acs.est.5b03332)\n\nNORMAN Suspect List Exchange\n\nFor the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe (Stevens-Johnson syndrome) erythema multiforme, mycosis fungoides, pemphigus, severe psoriasis, acute adrenocortical insufficiency, Addison's disease, secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with neoplasms, nonsuppurative thyroiditis, ulceratice colitis, Crohn's disease, acquired hemolytic anemia, congenital hypoplastic anemia, erythroblastopenia, adult secondary thrombocytopenia, adult idiopathic thrombocytopenia purpura, acute or subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute or chronic lymphocytic leukemia, Hodgkin's or non-Hodgkin's lynphomas, Waldenstrom's macroglobulinemia, primary brain tumors (adjunct), nephrotic syndrome, tuberculous meningitis, multiple sclerosis, myasthenia gravis. cerebral edema, chorioretinitis, diffuse posterior choroiditis, aleergic conjunctivitis, Herpes zoster ophthalmicus, anterior segment inflammation, iridocyclitis, iritis, keratitis, optoc neuritis, sympathetic ophthalmia, corneal marginal allergic ulcers, symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy and aspiration pneumonitis. \n\nToxin and Toxin Target Database (T3DB)\n\n#### 9.1.1 Use Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Use-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nAnimal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients \n\nFDA Approved Animal Drug Products (Green Book)\n\nHuman Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients \n\nFDA Orange Book\n\nPharmaceuticals -> Alimentary tract and metabolism -> Glucocorticoides \n\nS66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | [DOI:10.5281/zenodo.3754448](https://doi.org/DOI:10.5281/zenodo.3754448)\n\nNORMAN Suspect List Exchange\n\nPharmaceuticals \n\nS72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | [DOI:10.5281/zenodo.3955664](https://doi.org/DOI:10.5281/zenodo.3955664)\n\nNORMAN Suspect List Exchange\n\n### 9.2 Methods of Manufacturing[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Methods-of-Manufacturing&fullscreen=true \"Open this section in a new browser window\")\n\nChemical synthesis of prednisone was first reported by introduction of the two double bonds in ring A by 2,4-dibromination of the 3-ketone and dehydrobromination, but the yields were only 10-15%. Prednisone is prepared more efficiently microbiologically by the dehydrogenation of [cortisone](https://pubchem.ncbi.nlm.nih.gov/compound/cortisone): a pure culture of Corynebacterium simplex is grown in a sterilized nutrient medium of yeast extract, and [cortisone](https://pubchem.ncbi.nlm.nih.gov/compound/cortisone) is added. The C. simplex selectively dehydrogenates the [cortisone](https://pubchem.ncbi.nlm.nih.gov/compound/cortisone). When the reaction is complete, the fermentation broth is extracted and purified to give prednisone in good yield.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\nPreparation: Oliveto, Gould, United States of America patent 2897216 (1959 to Schering); Microbiological preparation: ... Nobile, United States of America patents 2837464 and 3134718 (1958, 1964 both to Shering). \n\nO'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 1431\n\nHazardous Substances Data Bank (HSDB)\n\n[Prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisolone) (alcohol oxidation)\n\nAshford, R.D. Ashford's Dictionary of Industrial Chemicals. London, England: Wavelength Publications Ltd., 1994., p. 761\n\nHazardous Substances Data Bank (HSDB)\n\n### 9.3 Formulations / Preparations[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Formulations-Preparations&fullscreen=true \"Open this section in a new browser window\")\n\nOral: 1 mg, 2 mg, 5 mg, Rayos\n\nNIH; DailyMed. Current Medication Information for Rayos (Prednisone) Tablet, Delayed Release (Updated: July 2016). Available from, as of November 2, 2016: [https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=281ab967-7565-4bef-9c0c-a646589c671e](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=281ab967-7565-4bef-9c0c-a646589c671e)\n\nHazardous Substances Data Bank (HSDB)\n\nTable: Prednisone Preparations \n\nRoute of Administration\n\nDosage Form\n\nStrength\n\nBrand or Generic Form (Manufacturer)\n\nRoute of Administration\n\nOral\n\nDosage Form\n\nSolution\n\nStrength\n\n5 mg/5 mL\n\nBrand or Generic Form (Manufacturer)\n\nPrednisone Oral Solution (Roxane)\n\nRoute of Administration\n\nOral\n\nDosage Form\n\nSolution, concentrate\n\nStrength\n\n5 mg/mL\n\nBrand or Generic Form (Manufacturer)\n\nPrednisone Intensol (Roxane)\n\nRoute of Administration\n\nOral\n\nDosage Form\n\nTablets\n\nStrength\n\n1 mg\n\nBrand or Generic Form (Manufacturer)\n\nPrednisone Tablets (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name)\n\nRoute of Administration\n\nOral\n\nDosage Form\n\nTablets\n\nStrength\n\n2.5 mg\n\nBrand or Generic Form (Manufacturer)\n\nPrednisone Tablets (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name)\n\nRoute of Administration\n\nOral\n\nDosage Form\n\nTablets\n\nStrength\n\n5 mg\n\nBrand or Generic Form (Manufacturer)\n\nSterapred 5 mg Unipak (Merz)\n\nRoute of Administration\n\nOral\n\nDosage Form\n\nTablets\n\nStrength\n\n5 mg\n\nBrand or Generic Form (Manufacturer)\n\nSterapred 5 mg 12 Day Unipak (Merz)\n\nRoute of Administration\n\nOral\n\nDosage Form\n\nTablets\n\nStrength\n\n5 mg\n\nBrand or Generic Form (Manufacturer)\n\n(Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name)\n\nRoute of Administration\n\nOral\n\nDosage Form\n\nTablets\n\nStrength\n\n10 mg\n\nBrand or Generic Form (Manufacturer)\n\nSterapred DS Unipak (Merz)\n\nRoute of Administration\n\nOral\n\nDosage Form\n\nTablets\n\nStrength\n\n10 mg\n\nBrand or Generic Form (Manufacturer)\n\nSterapred DS 12 Day Unipak (Merz)\n\nRoute of Administration\n\nOral\n\nDosage Form\n\nTablets\n\nStrength\n\n10 mg\n\nBrand or Generic Form (Manufacturer)\n\n(Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name)\n\nRoute of Administration\n\nOral\n\nDosage Form\n\nTablets\n\nStrength\n\n20 mg\n\nBrand or Generic Form (Manufacturer)\n\nPrednisone Tablets (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name)\n\nRoute of Administration\n\nOral\n\nDosage Form\n\nTablets\n\nStrength\n\n50 mg\n\nBrand or Generic Form (Manufacturer)\n\nPrednisone Tablets (Available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name)\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 3124\n\nHazardous Substances Data Bank (HSDB)\n\n### 9.4 U.S. Production[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=U-S-Production&fullscreen=true \"Open this section in a new browser window\")\n\n(1991) Exceeded 5000 lb or US $5000 in value \n\nSRI. 1992 Directory of Chemical Producers-United States of America. Menlo Park, CA: SRI International, 1992., p. 766\n\nHazardous Substances Data Bank (HSDB)\n\n### 9.5 General Manufacturing Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=General-Manufacturing-Information&fullscreen=true \"Open this section in a new browser window\")\n\nEPA TSCA Commercial Activity Status\n\n[Pregna-1,4-diene-3,11,20-trione](https://pubchem.ncbi.nlm.nih.gov/compound/Pregna-1%2C4-diene-3%2C11%2C20-trione), 17,21-dihydroxy-: INACTIVE\n\nEPA Chemicals under the TSCA\n\nGeneric name for an analog of [cortisone](https://pubchem.ncbi.nlm.nih.gov/compound/cortisone).\n\nLarranaga, M.D., Lewis, R.J. Sr., Lewis, R.A.; Hawley's Condensed Chemical Dictionary 16th Edition. John Wiley & Sons, Inc. Hoboken, NJ 2016., p. 1131\n\nHazardous Substances Data Bank (HSDB)\n\nSolar simulator irradiation of an aqueous suspension of prednisone, a widely prescribed drug, produces seven photochemical derivatives. ...\n\nDellaGreca M et al; Environ Toxicol Chem 22 (3): 534-9 (2003)\n\nHazardous Substances Data Bank (HSDB)\n\n10 Identification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Identification&fullscreen=true \"Open this section in a new browser window\")\n------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 10.1 Analytic Laboratory Methods[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Analytic-Laboratory-Methods&fullscreen=true \"Open this section in a new browser window\")\n\nA differential pulse polarographic method for the determination of [fluoxymesterone](https://pubchem.ncbi.nlm.nih.gov/compound/fluoxymesterone), [norethandrolone](https://pubchem.ncbi.nlm.nih.gov/compound/norethandrolone), [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone), and prednisone in tablets is described. This method is more sensitive than dc polarography, and the measurement of diffusion current is greatly simplified. Sorensen [phosphate](https://pubchem.ncbi.nlm.nih.gov/compound/phosphate) buffer, pH 5.6, was used as the supporting electrolyte. No apparent interference was observed from tablet excipients; the method is rapid, simple, and relatively precise.\n\n[PMID:641746](https://pubmed.ncbi.nlm.nih.gov/641746)\n\nYadav RN, Tearne FW; J Pharm Sci 67 (3): 436-8 (1978)\n\nHazardous Substances Data Bank (HSDB)\n\nMethod: differential pulse polarography; Analyte: prednisone; Matrix: tablets; Detection Limit: 5 ug/mL.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\nPrednisone in drugs is determined by using Semiautomated method. Alcohol solution of drug is extracted with [trichloromethane](https://pubchem.ncbi.nlm.nih.gov/compound/trichloromethane) and reacted with [tetramethylammonium hydroxide](https://pubchem.ncbi.nlm.nih.gov/compound/tetramethylammonium%20hydroxide) and blue [tetrazolium](https://pubchem.ncbi.nlm.nih.gov/compound/tetrazolium). Sample of resulting complex is read in flowcell at 525 nm.\n\nAssociation of Official Analytical Chemists. Official Methods of Analysis. 15th ed. and Supplements. Washington, DC: Association of Analytical Chemists, 1990, p. VI 616\n\nHazardous Substances Data Bank (HSDB)\n\nAnalyte: prednisone; matrix: chemical identification; procedure: infrared absorption spectrophotometry with comparison to standards\n\nU.S. Pharmacopeia. The United States Pharmacopeia, USP 30/The National Formulary, NF 25; Rockville, MD: U.S. Pharmacopeial Convention, Inc., p.3010 (2007)\n\nHazardous Substances Data Bank (HSDB)\n\nFor more Analytic Laboratory Methods (Complete) data for PREDNISONE (14 total), please visit the [HSDB record page](https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3168#section=Analytic-Laboratory-Methods-(Complete)).\n\nHazardous Substances Data Bank (HSDB)\n\n### 10.2 Clinical Laboratory Methods[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Clinical-Laboratory-Methods&fullscreen=true \"Open this section in a new browser window\")\n\nCorticosteroids are extracted from plasma into ether, and the extract is purified either by passing through a [magnesium silicate](https://pubchem.ncbi.nlm.nih.gov/compound/magnesium%20silicate) column or by solvent partitioning. Interference from endogenous [hydrocortisone](https://pubchem.ncbi.nlm.nih.gov/compound/hydrocortisone) is removed by selective derivatization with [Girard Reagent T](https://pubchem.ncbi.nlm.nih.gov/compound/Girard%20Reagent%20T). Following derivatization, [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) can be quantitatively separated from the [water](https://pubchem.ncbi.nlm.nih.gov/compound/water)-soluble [hydrocortisone](https://pubchem.ncbi.nlm.nih.gov/compound/hydrocortisone) derivative by simple solvent partitioning. The extracted prednisone and [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) are converted to their corresponding methoxyimino trimethylsilyl derivatives, and subjected to GLC-mass spectrometry. Prednisone and [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) plasma profiles following a 15-mg oral dose of prednisone in a human volunteer are presented. The method can measure prednisone and [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) in plasma at the nanogram per milliliter level.\n\n[PMID:660509](https://pubmed.ncbi.nlm.nih.gov/660509)\n\nMatin SB, Amos B; J Pharm Sci 67 (7): 923-6 (1978)\n\nHazardous Substances Data Bank (HSDB)\n\nMethod: gas chromatography with chemical ionization mass spectrometry; Analyte: prednisone; Matrix: blood plasma; Detection Limit: 10 nanogram/mL.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\nMethod: radioimmunoassay; Analyte: prednisone; Matrix: serum; Detection Limit: 25 picogram.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\nAnalyte: prednisone; matrix: blood (serum); procedure: reversed-phase high-performance liquid chromatography with ultraviolet detection at 245 nm; limit of detection: 1-10 ng/mL\n\nVolin P; J Chromatogr B 666: 347-353 (1995). As cited in: Lunn G; HPLC and CE Methods for Pharmaceutical Analysis. CD-ROM. New York, NY: John Wiley & Sons (2000)\n\nHazardous Substances Data Bank (HSDB)\n\nFor more Clinical Laboratory Methods (Complete) data for PREDNISONE (12 total), please visit the [HSDB record page](https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3168#section=Clinical-Laboratory-Methods-(Complete)).\n\nHazardous Substances Data Bank (HSDB)\n\n11 Safety and Hazards[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Safety-and-Hazards&fullscreen=true \"Open this section in a new browser window\")\n--------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 11.1 Hazards Identification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Hazards-Identification&fullscreen=true \"Open this section in a new browser window\")\n\n#### 11.1.1 GHS Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=GHS-Classification&fullscreen=true \"Open this section in a new browser window\")\n\n1 of 2 items\n\n[View All](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=GHS-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nPictogram(s)\n\n![Image 27: Health Hazard](https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS08.svg)\n\nSignal\n\nDanger\n\nGHS Hazard Statements\n\nH360 (33.7%): May damage fertility or the unborn child [Danger Reproductive toxicity]\n\nH361 (65.1%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]\n\nH372 (32%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]\n\nH373 (20.1%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]\n\nPrecautionary Statement Codes\n\n[P203](https://pubchem.ncbi.nlm.nih.gov/ghs/#P203), [P260](https://pubchem.ncbi.nlm.nih.gov/ghs/#P260), [P264](https://pubchem.ncbi.nlm.nih.gov/ghs/#P264), [P270](https://pubchem.ncbi.nlm.nih.gov/ghs/#P270), [P280](https://pubchem.ncbi.nlm.nih.gov/ghs/#P280), [P318](https://pubchem.ncbi.nlm.nih.gov/ghs/#P318), [P319](https://pubchem.ncbi.nlm.nih.gov/ghs/#P319), [P405](https://pubchem.ncbi.nlm.nih.gov/ghs/#P405), and [P501](https://pubchem.ncbi.nlm.nih.gov/ghs/#P501)\n\nECHA C&L Notifications Summary\n\n_Aggregated GHS information provided per 169 reports by companies from 21 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies._\n\n_Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit [ECHA C&L website.](https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/13900)_\n\nEuropean Chemicals Agency (ECHA)\n\n#### 11.1.2 Hazard Classes and Categories[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Hazard-Classes-and-Categories&fullscreen=true \"Open this section in a new browser window\")\n\nRepr. 1B (33.7%)\n\nRepr. 2 (65.1%)\n\nSTOT RE 1 (32%)\n\nSTOT RE 2 (20.1%)\n\nEuropean Chemicals Agency (ECHA)\n\n#### 11.1.3 Health Hazards[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Health-Hazards&fullscreen=true \"Open this section in a new browser window\")\n\nSYMPTOMS: Implicated in aplastic anemia.\n\nACUTE/CHRONIC HAZARDS: Toxic. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\nCAMEO Chemicals\n\n### 11.2 First Aid Measures[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=First-Aid-Measures&fullscreen=true \"Open this section in a new browser window\")\n\n#### 11.2.1 First Aid[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=First-Aid&fullscreen=true \"Open this section in a new browser window\")\n\nEYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) or [normal saline](https://pubchem.ncbi.nlm.nih.gov/compound/normal%20saline) solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.\n\nSKIN: IMMEDIATELY flood affected skin with [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and [water](https://pubchem.ncbi.nlm.nih.gov/compound/water). If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.\n\nINHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) should be used; if not available, use a level of protection greater than or equal to that advised under Protective Clothing.\n\nINGESTION: DO NOT INDUCE VOMITING. If the victim is conscious and not convulsing, give 1 or 2 glasses of [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) to dilute the chemical and IMMEDIATELY call a hospital or poison control center. Be prepared to transport the victim to a hospital if advised by a physician. If the victim is convulsing or unconscious, do not give anything by mouth, ensure that the victim's airway is open and lay the victim on his/her side with the head lower than the body. DO NOT INDUCE VOMITING. IMMEDIATELY transport the victim to a hospital. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\nCAMEO Chemicals\n\n### 11.3 Fire Fighting[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Fire-Fighting&fullscreen=true \"Open this section in a new browser window\")\n\nTo extinguish a fire involving this chemical you may use a dry chemical, [carbon dioxide](https://pubchem.ncbi.nlm.nih.gov/compound/carbon%20dioxide), foam or [halon](https://pubchem.ncbi.nlm.nih.gov/compound/halon) extinguisher; a [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) spray may also be used. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\nCAMEO Chemicals\n\n#### 11.3.1 Fire Fighting Procedures[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Fire-Fighting-Procedures&fullscreen=true \"Open this section in a new browser window\")\n\nSuitable extinguishing media: Use [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) spray, alcohol-resistant foam, dry chemical or [carbon dioxide](https://pubchem.ncbi.nlm.nih.gov/compound/carbon%20dioxide).\n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\nAdvice for firefighters: Wear self-contained breathing apparatus for firefighting if necessary. \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\n### 11.4 Accidental Release Measures[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Accidental-Release-Measures&fullscreen=true \"Open this section in a new browser window\")\n\n#### 11.4.1 Cleanup Methods[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Cleanup-Methods&fullscreen=true \"Open this section in a new browser window\")\n\nACCIDENTAL RELEASE MEASURES: Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust. Environmental precautions: Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Methods and materials for containment and cleaning up: Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal. \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\n#### 11.4.2 Disposal Methods[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Disposal-Methods&fullscreen=true \"Open this section in a new browser window\")\n\nSRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator. \n\nHazardous Substances Data Bank (HSDB)\n\nProduct: Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber; Contaminated packaging: Dispose of as unused product. \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\n#### 11.4.3 Preventive Measures[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Preventive-Measures&fullscreen=true \"Open this section in a new browser window\")\n\nACCIDENTAL RELEASE MEASURES: Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust. Environmental precautions: Prevent further leakage or spillage if safe to do so. Do not let product enter drains. \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\nPrecautions for safe handling: Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection. \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\nAppropriate engineering controls: Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday. \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\nGloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\nSRP: Local exhaust ventilation should be applied wherever there is an incidence of point source emissions or dispersion of regulated contaminants in the work area. Ventilation control of the contaminant as close to its point of generation is both the most economical and safest method to minimize personnel exposure to airborne contaminants. Ensure that the local ventilation moves the contaminant away from the worker. \n\nHazardous Substances Data Bank (HSDB)\n\n### 11.5 Handling and Storage[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Handling-and-Storage&fullscreen=true \"Open this section in a new browser window\")\n\n#### 11.5.1 Nonfire Spill Response[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Nonfire-Spill-Response&fullscreen=true \"Open this section in a new browser window\")\n\nSMALL SPILLS AND LEAKAGE: Should a spill occur while you are handling this chemical, you should dampen the solid spill material with alcohol, then transfer the dampened material to a suitable container. Use absorbent paper dampened with alcohol to pick up any remaining material. Seal the absorbent paper, and any of your clothes, which may be contaminated, in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with alcohol followed by washing with a strong soap and [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) solution. Do not reenter the contaminate area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.\n\nSTORAGE PRECAUTIONS: You should keep this material in a tightly-closed container under an inert atmosphere, and store it in a freezer. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\nCAMEO Chemicals\n\n#### 11.5.2 Storage Conditions[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Storage-Conditions&fullscreen=true \"Open this section in a new browser window\")\n\nKeep container tightly closed in a dry and well-ventilated place. \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\nPrednisone tablets should be stored in well closed containers at a temperature less than 40 °C, preferably between 15-30 °C. Prednisone syrup should be stored in tight containers. Prednisone oral solution and oral concentrate solution should be stored in tight containers at 15-30 °C.\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 3124\n\nHazardous Substances Data Bank (HSDB)\n\n### 11.6 Exposure Control and Personal Protection[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Exposure-Control-and-Personal-Protection&fullscreen=true \"Open this section in a new browser window\")\n\n#### 11.6.1 Personal Protective Equipment (PPE)[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Personal-Protective-Equipment-PPE&fullscreen=true \"Open this section in a new browser window\")\n\nRECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter.\n\nRECOMMENDED GLOVE MATERIALS: Permeation data indicate that [neoprene](https://pubchem.ncbi.nlm.nih.gov/compound/neoprene) gloves may provide protection to contact with this compound. [Neoprene](https://pubchem.ncbi.nlm.nih.gov/compound/Neoprene) over latex gloves is recommended. However, if this chemical makes direct contact with your gloves, or if a tear, puncture or hole develops, remove them at once. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\nCAMEO Chemicals\n\nEye/face protection: Safety glasses with side-shields conforming to EN166. Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU). \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\nSkin protection: Handle with gloves. \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\nBody Protection: Impervious clothing. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace. \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\nRespiratory protection: Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\n### 11.7 Stability and Reactivity[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Stability-and-Reactivity&fullscreen=true \"Open this section in a new browser window\")\n\n#### 11.7.1 Air and Water Reactions[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Air-and-Water-Reactions&fullscreen=true \"Open this section in a new browser window\")\n\nVery slightly [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) soluble (NTP, 1992).\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\nCAMEO Chemicals\n\n#### 11.7.2 Reactive Group[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Reactive-Group&fullscreen=true \"Open this section in a new browser window\")\n\nAlcohols and Polyols\n\nKetones\n\nHydrocarbons, Aliphatic Unsaturated\n\nCAMEO Chemicals\n\n#### 11.7.3 Hazardous Reactivities and Incompatibilities[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Hazardous-Reactivities-and-Incompatibilities&fullscreen=true \"Open this section in a new browser window\")\n\nIncompatible materials: Strong oxidizing agents \n\nSigma-Aldrich; Safety Data Sheet for Prednisone. Product Number: P6254, Version 4.4 (Revision Date 10/12/2016). Available from, as of November 15, 2016: [https://www.sigmaaldrich.com/safety-center.html](https://www.sigmaaldrich.com/safety-center.html)\n\nHazardous Substances Data Bank (HSDB)\n\n### 11.8 Regulatory Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Regulatory-Information&fullscreen=true \"Open this section in a new browser window\")\n\nNew Zealand EPA Inventory of Chemical Status\n\nPrednisone: Does not have an individual approval but may be used under an appropriate group standard\n\nNew Zealand Environmental Protection Authority (EPA)\n\n#### 11.8.1 FDA Requirements[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=FDA-Requirements&fullscreen=true \"Open this section in a new browser window\")\n\nThe Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including prednisone, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.\n\nDHHS/FDA; Electronic Orange Book-Approved Drug Products with Therapeutic Equivalence Evaluations. Available from, as of November 7, 2016: [https://www.fda.gov/cder/ob/](https://www.fda.gov/cder/ob/)\n\nHazardous Substances Data Bank (HSDB)\n\nThe Generic Animal Drug and Patent Restoration act requires that each sponsor of an approved animal drug must submit to the FDA certain information regarding patents held for the animal drug or its method of use. The Act requires that this information, as well as a list of all animal drug products approved for safety and effectiveness, be made available to the public. Prednisone is included on this list.\n\nUS FDA/Center for Veterinary Medicine; The Green Book - On Line, Active Ingredients. Prednisone (53-03-2). Available from, as of November 7, 2016: [https://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/default.htm](https://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/default.htm)\n\nHazardous Substances Data Bank (HSDB)\n\nImplantation or injectable dosage form new animal drugs. Sterile prednisone suspension. ... Indications for use: It is used /in horses, dogs and cats/ for conditions requiring an anti-inflammatory agent. ... Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.\n\n21 CFR 522.1890 (USFDA); U.S. National Archives and Records Administration's Electronic Code of Federal Regulations. Available from, as of November 7, 2016: [https://www.ecfr.gov](https://www.ecfr.gov/)\n\nHazardous Substances Data Bank (HSDB)\n\n### 11.9 Other Safety Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Other-Safety-Information&fullscreen=true \"Open this section in a new browser window\")\n\nChemical Assessment\n\nIMAP assessments - [Pregna-1,4-diene-3,11,20-trione](https://pubchem.ncbi.nlm.nih.gov/compound/Pregna-1%2C4-diene-3%2C11%2C20-trione), 17,21-dihydroxy-: Environment tier I assessment\n\nIMAP assessments - [Pregna-1,4-diene-3,11,20-trione](https://pubchem.ncbi.nlm.nih.gov/compound/Pregna-1%2C4-diene-3%2C11%2C20-trione), 17,21-dihydroxy-: Human health tier I assessment\n\nAustralian Industrial Chemicals Introduction Scheme (AICIS)\n\n#### 11.9.1 Special Reports[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Special-Reports&fullscreen=true \"Open this section in a new browser window\")\n\nWeisburger EK; Bioassay Program for Carcinogenic Hazards of Cancer Chemotherapeutic Agents; Cancer 40: 1935-49 (1977). Route: intraperitoneal injection; Species: rats and mice. \n\nHazardous Substances Data Bank (HSDB)\n\n12 Toxicity[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Toxicity&fullscreen=true \"Open this section in a new browser window\")\n------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 12.1 Toxicological Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Toxicological-Information&fullscreen=true \"Open this section in a new browser window\")\n\n#### 12.1.1 Toxicity Summary[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Toxicity-Summary&fullscreen=true \"Open this section in a new browser window\")\n\nIDENTIFICATION AND USE: Prednisone is white crystalline powder with a persistent bitter after-taste. It is glucocorticoid, anti-inflammatory agent and antineoplastic agent. HUMAN EXPOSURE AND TOXICITY: Prednisone causes profound and varied metabolic effects when used at therapeutic doses, given on a continuous basis. When given in large doses it can induce cardiac complications. In addition, it modifies the body's immune response to diverse stimuli; among the changes that occur are lymphopenia, monocytopenia and suppression of delayed hypersensitivity skin tests. Fluid and electrolyte disturbances may occur, including [sodium](https://pubchem.ncbi.nlm.nih.gov/element/Sodium) and fluid retention, which may lead to congestive heart failure and hypertension. With large doses, [potassium](https://pubchem.ncbi.nlm.nih.gov/element/Potassium) loss, hypokalemic alkalosis, and increased [calcium](https://pubchem.ncbi.nlm.nih.gov/element/Calcium) excretion may occur. Glucocorticoids may cause fetal damage when administered to pregnant women. One retrospective study of 260 women who received pharmacologic dosages of glucocorticoids during pregnancy revealed 2 instances of cleft palate, 8 stillbirths, 1 spontaneous abortion, and 15 premature births. Another study reported 2 cases of cleft palate in 86 births. No chromosomal damage was detected in peripheral lymphocytes of patients treated with 3 mg/kg bw per day prednisone alone for 28 days and then with 0.5-1 mg/kg bw per day for 18-120 months. ANIMAL STUDIES: Carcinogenicity studies have been conducted in rats and mice. Of treated males, 7/20 developed tumors, among which were 3 pituitary tumors and 1 tumor of the breast; 16/18 female rats developed tumors, 8 of the breast, 5 of the pituitary, 2 of the adrenal and 1 of the liver. The overall tumor incidence in females was 1.5-2-fold higher than that in controls. However in mice, the tumor incidence in treated males was 4/19 (21%), with 2 lymphosarcomas and 2 lung tumors, and that in treated females was 8/27 (30%), with 4 lung tumors, 2 lymphosarcomas and 2 uterine tumors. These incidences were not significantly greater than those in controls. Prednisone given to rats from the 11th day of pregnancy until parturition at daily doses of 2.5 or 5 mg was reported to inhibit the growth of the fetal thymus and spleen. Prednisone was not mutagenic in Escherichia coli, and it caused no chromosomal damage when administered to rats. ECOTOXICITY STUDIES: The rotifer Brachionus calyciflorus and two crustaceans, the cladoceran Daphnia magna and the anostracan Thamnocephalus platyurus, were used to perform acute toxicity tests. Chronic toxicity tests have been performed on the alga Pseudokirchneriella subcapitata and the crustacean Ceriodaphnia dubia. The results showed low acute and chronic toxicity of prednisone. Some of the photoproducts had high toxic effects on C. dubia.\n\nHazardous Substances Data Bank (HSDB)\n\nLike any anti-inflammatory agent, steroid toxicity is treated similarly to any non-steroidal anti-inflammatory drug overdose or toxicity. Although the frequency of life-threatening complications from steroids and NSAID overdose is low, the overdose response ranges from no symptoms to death despite intensive-care treatment. Most symptoms are an excess of the pharmacological action of steroids and NSAIDs and include abdominal pain, nausea, vomiting, drowsiness, dizziness, headache, ear ringing, and nystagmus. A significant dose-response relationship occurs with the long-term use of systemic corticosteroids and the development of systemic corticosteroid-related complications for patients with severe asthma, resulting in an increased burden and costs on the health care system. \n\nStatPearls\n\nPrednisone is a glucocorticoid receptor agonist. It is first metabolized in the liver to its active form, [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone). [Prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisolone) crosses cell membranes and binds with high affinity to specific cytoplasmic receptors. The result includes inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids. Prednisone has slight mineralocorticoid activity, whereby entry of [sodium](https://pubchem.ncbi.nlm.nih.gov/element/Sodium) into cells and loss of intracellular [potassium](https://pubchem.ncbi.nlm.nih.gov/element/Potassium) is stimulated. This is particularly evident in the kidney, where rapid ion exchange leads to [sodium](https://pubchem.ncbi.nlm.nih.gov/element/Sodium) retention and hypertension.\n\nToxin and Toxin Target Database (T3DB)\n\n#### 12.1.2 USGS Health-Based Screening Levels for Evaluating Water-Quality[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=USGS-Health-Based-Screening-Levels-for-Evaluating-Water-Quality&fullscreen=true \"Open this section in a new browser window\")\n\nChemical\n\nPrednisone \n\nChemical Classes\n\nPharmaceutical \n\nReference\n\nSmith, C.D. and Nowell, L.H., 2024. Health-Based Screening Levels for evaluating [water](https://pubchem.ncbi.nlm.nih.gov/compound/water)-quality data (3rd ed.). DOI:10.5066/F71C1TWP\n\nUSGS Health-Based Screening Levels for Evaluating Water-Quality Data\n\n#### 12.1.3 Drug Induced Liver Injury[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Drug-Induced-Liver-Injury&fullscreen=true \"Open this section in a new browser window\")\n\nCompound\n\nprednisone \n\nDILI Annotation\n\nLess-DILI-Concern \n\nSeverity Grade\n\n3 \n\nLabel Section\n\nAdverse reactions \n\nReferences\n\nM Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. [PMID:21624500](https://pubmed.ncbi.nlm.nih.gov/21624500/)[DOI:10.1016/j.drudis.2011.05.007](https://doi.org/10.1016/j.drudis.2011.05.007)\n\nM Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. [PMID:26948801](https://pubmed.ncbi.nlm.nih.gov/26948801/)[DOI:10.1016/j.drudis.2016.02.015](https://doi.org/10.1016/j.drudis.2016.02.015)\n\nFDA Liver Toxicity Knowledge Base (LTKB)\n\n#### 12.1.4 Evidence for Carcinogenicity[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Evidence-for-Carcinogenicity&fullscreen=true \"Open this section in a new browser window\")\n\nInadequate evidence of carcinogenicity in humans. Inadequate evidence of carcinogenicity in animals. OVERALL EVALUATION: Group 3: The agent is not classifiable as to its carcinogenicity to humans. \n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.1.5 Carcinogen Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Carcinogen-Classification&fullscreen=true \"Open this section in a new browser window\")\n\n1 of 2 items\n\nIARC Carcinogenic Agent\n\nPrednisone \n\nIARC Carcinogenic Classes\n\nGroup 3: Not classifiable as to its carcinogenicity to humans \n\nIARC Monographs\n\n[Volume 26](http://publications.iarc.who.int/44): (1981) Some Antineoplastic and Immunosuppressive Agents\n\n[Volume Sup 7](http://publications.iarc.who.int/139): Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42, 1987; 440 pages; ISBN 92-832-1411-0 (out of print)\n\nInternational Agency for Research on Cancer (IARC)\n\n2 of 2 items\n\nCarcinogen Classification\n\nPrednisone is not classifiable as to its carcinogenicity to humans (Group 3). Prednisone is part of MOPP, a combination chemotherapy regimen that is carcinogenic to humans (Group 1). (L135)\n\nToxin and Toxin Target Database (T3DB)\n\n#### 12.1.6 Effects During Pregnancy and Lactation[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Effects-During-Pregnancy-and-Lactation&fullscreen=true \"Open this section in a new browser window\")\n\n◉ Summary of Use during Lactation\n\nAmounts of prednisone in breastmilk are very low. No adverse effect have been reported in breastfed infants with maternal use of any corticosteroid during breastfeeding. Although it is often recommended to avoid breastfeeding for 4 hours after a dose this maneuver is not necessary because prednisone milk levels are very low. Medium to large doses of corticosteroids given systemically or injected into joints or the breast have been reported to cause temporary reduction of lactation.\n\n◉ Effects in Breastfed Infants\n\nNone reported with prednisone or any other corticosteroid. In a prospective follow-up study, six nursing mothers reported taking prednisone (dosage unspecified) with no adverse infant effects.\n\nThere are several reports of mothers breastfeeding during long-term use of corticosteroids with no adverse infant effects: prednisone 10 mg daily (2 infants) and [prednisolone](https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone) 5 to 7.5 mg daily (14 infants).\n\nA woman with Crohn's disease used prednisone 60 mg daily in a tapering schedule immediately postpartum during breastfeeding (extent not stated). She also received [sulfasalazine](https://pubchem.ncbi.nlm.nih.gov/compound/sulfasalazine) 4 grams daily and infliximab 5 mg/kg every 8 weeks during pregnancy and postpartum. At 6 months of age, the infant was asymptomatic with regular weight gain.\n\nThe National Transplantation Pregnancy Registry reports that as of December 2013, 124 women with transplants have taken prednisone while breastfeeding 169 infants for periods as long as 48 months, with no apparent infant harm.\n\n◉ Effects on Lactation and Breastmilk\n\nPublished information on the effects of prednisone on serum prolactin or on lactation in nursing mothers was not found as of the revision date. Medium to large doses of corticosteroids given systemically or injected into joints or the breast have been reported to cause temporary reduction of lactation.\n\nA study of 46 women who delivered an infant before 34 weeks of gestation found that a course of another corticosteroid ([betamethasone](https://pubchem.ncbi.nlm.nih.gov/compound/betamethasone), 2 intramuscular injections of 11.4 mg of [betamethasone](https://pubchem.ncbi.nlm.nih.gov/compound/betamethasone) 24 hours apart) given between 3 and 9 days before delivery resulted in delayed lactogenesis II and lower average milk volumes during the 10 days after delivery. Milk volume was not affected if the infant was delivered less than 3 days or more than 10 days after the mother received the corticosteroid. An equivalent dosage regimen of prednisone might have the same effect.\n\nA study of 87 pregnant women found that [betamethasone](https://pubchem.ncbi.nlm.nih.gov/compound/betamethasone) given as above during pregnancy caused a premature stimulation of [lactose](https://pubchem.ncbi.nlm.nih.gov/compound/lactose) secretion during pregnancy. Although the increase was statistically significant, the clinical importance appears to be minimal. An equivalent dosage regimen of prednisone might have the same effect.\n\nDrugs and Lactation Database (LactMed)\n\n#### 12.1.7 Exposure Routes[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Exposure-Routes&fullscreen=true \"Open this section in a new browser window\")\n\nReadily absorbed from the gastrointestinal tract. Rayos, the delayed-release formulation, has a 4-hour release time. To compare, the delayed-release formulation has a Tmax of 6.0 - 6.5 hours in healthy male subjects, whereas the immediate-release formulation has a Tmax of 2.0 hours. The rate of absorption, Cmax, and exposure is comparable between formulations. \n\nToxin and Toxin Target Database (T3DB)\n\n#### 12.1.8 Adverse Effects[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Adverse-Effects&fullscreen=true \"Open this section in a new browser window\")\n\nThe primary adverse effects of prednisone include hyperglycemia, insomnia, increased appetite, hypertension, osteoporosis, edema, adrenal suppression, cataracts, and delayed wound healing.\n\nAdverse effects are common in patients receiving glucocorticoids in high doses or over a long period. High-dose prednisone is 40 mg/d or more. Potential adverse effects include skin fragility, weight gain, increased risk of infections, and fractures. Significant cardiovascular and metabolic effects are hypertension, hyperglycemia, and dyslipidemia.\n\nOther adverse reactions include adrenal insufficiency, particularly when undergoing stressful procedures or during sepsis; this is typically diagnosable when the patient is hypotensive and not responsive to fluids, vasopressors, or cardiogenic medications. Once suspicion of adrenal insufficiency exists, treatment should be administered right away with a dose of 100 mg of [hydrocortisone](https://pubchem.ncbi.nlm.nih.gov/compound/hydrocortisone) every eight hours.\n\nPatients on high doses of glucocorticoids for 5 days or more should be tapered off the medication.\n\nStatPearls\n\n#### 12.1.9 Acute Effects[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Acute-Effects&fullscreen=true \"Open this section in a new browser window\")\n\nChemIDplus\n\n#### 12.1.10 Interactions[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Interactions&fullscreen=true \"Open this section in a new browser window\")\n\nConcomitant use of anticholinesterase agents (e.g., [neostigmine](https://pubchem.ncbi.nlm.nih.gov/compound/neostigmine), [pyridostigmine](https://pubchem.ncbi.nlm.nih.gov/compound/pyridostigmine)) and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. If concomitant therapy must occur, it should take place under close supervision and the need for respiratory support should be anticipated. /Corticosteroids/\n\nNIH; DailyMed. Current Medication Information for Prednisone (Pednisone Tablet) Prednisone (Prednisone Solution) Prednisone Intensol (Prednisone Intensol Solution, Concentrate) (Updated: July 2016). Available from, as of November 22, 2016: [https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3115aef0-fd50-4ec8-a064-3effb695f3f2](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3115aef0-fd50-4ec8-a064-3effb695f3f2)\n\nHazardous Substances Data Bank (HSDB)\n\nCo-administration of corticosteroids and [warfarin](https://pubchem.ncbi.nlm.nih.gov/compound/warfarin) usually results in inhibition of response to [warfarin](https://pubchem.ncbi.nlm.nih.gov/compound/warfarin), although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. /Corticosteroids/\n\nNIH; DailyMed. Current Medication Information for Prednisone (Pednisone Tablet) Prednisone (Prednisone Solution) Prednisone Intensol (Prednisone Intensol Solution, Concentrate) (Updated: July 2016). Available from, as of November 22, 2016: [https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3115aef0-fd50-4ec8-a064-3effb695f3f2](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3115aef0-fd50-4ec8-a064-3effb695f3f2)\n\nHazardous Substances Data Bank (HSDB)\n\nBecause corticosteroids may increase blood [glucose](https://pubchem.ncbi.nlm.nih.gov/compound/glucose) concentrations, dosage adjustments of antidiabetic agents may be required. /Corticosteroids/\n\nNIH; DailyMed. Current Medication Information for Prednisone (Pednisone Tablet) Prednisone (Prednisone Solution) Prednisone Intensol (Prednisone Intensol Solution, Concentrate) (Updated: July 2016). Available from, as of November 22, 2016: [https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3115aef0-fd50-4ec8-a064-3effb695f3f2](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3115aef0-fd50-4ec8-a064-3effb695f3f2)\n\nHazardous Substances Data Bank (HSDB)\n\nCholestyramine may increase the clearance of corticosteroids. /Corticosteroids/ \n\n[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3115aef0-fd50-4ec8-a064-3effb695f3f2](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3115aef0-fd50-4ec8-a064-3effb695f3f2)\n\nHazardous Substances Data Bank (HSDB)\n\nFor more Interactions (Complete) data for PREDNISONE (25 total), please visit the [HSDB record page](https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3168#section=Interactions-(Complete)).\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.1.11 Antidote and Emergency Treatment[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Antidote-and-Emergency-Treatment&fullscreen=true \"Open this section in a new browser window\")\n\n/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing [water](https://pubchem.ncbi.nlm.nih.gov/compound/water). Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/\n\nCurrance, P.L. Clements, B., Bronstein, A.C. (Eds).; Emergency Care For Hazardous Materials Exposure. 3rd revised edition, Elsevier Mosby, St. Louis, MO 2007, p. 160\n\nHazardous Substances Data Bank (HSDB)\n\n/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer [oxygen](https://pubchem.ncbi.nlm.nih.gov/element/Oxygen) by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with [water](https://pubchem.ncbi.nlm.nih.gov/compound/water). Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/\n\nCurrance, P.L. Clements, B., Bronstein, A.C. (Eds).; Emergency Care For Hazardous Materials Exposure. 3rd revised edition, Elsevier Mosby, St. Louis, MO 2007, p. 160\n\nHazardous Substances Data Bank (HSDB)\n\n/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as [albuterol](https://pubchem.ncbi.nlm.nih.gov/compound/albuterol) for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W TKO /SRP: \"To keep open\", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's (LR) if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with [diazepam](https://pubchem.ncbi.nlm.nih.gov/compound/diazepam) or [lorazepam](https://pubchem.ncbi.nlm.nih.gov/compound/lorazepam) ... . Use [proparacaine hydrochloride](https://pubchem.ncbi.nlm.nih.gov/compound/proparacaine%20hydrochloride) to assist eye irrigation ... . /Poisons A and B/\n\nCurrance, P.L. Clements, B., Bronstein, A.C. (Eds).; Emergency Care For Hazardous Materials Exposure. 3rd revised edition, Elsevier Mosby, St. Louis, MO 2007, p. 160-1\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.1.12 Human Toxicity Excerpts[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Human-Toxicity-Excerpts&fullscreen=true \"Open this section in a new browser window\")\n\n/SIGNS AND SYMPTOMS/ Prednisone causes profound and varied metabolic effects when used at therapeutic doses, given on a continuous basis. When given in large doses it can induce cardiac complications. In addition, it modifies the body's immune response to diverse stimuli; among the changes that occur are lymphopenia, monocytopenia and suppression of delayed hypersensitivity skin tests. Fluid and electrolyte disturbances may occur, including [sodium](https://pubchem.ncbi.nlm.nih.gov/element/Sodium) and fluid retention, which may lead to congestive heart failure and hypertension. With large doses, [potassium](https://pubchem.ncbi.nlm.nih.gov/element/Potassium) loss, hypokalemic alkalosis, and increased [calcium](https://pubchem.ncbi.nlm.nih.gov/element/Calcium) excretion may occur.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\n/SIGNS AND SYMPTOMS/ Moderate- to high-dose glucocorticoid therapy is associated with loss of bone and an increased risk of fracture. There also is evidence that long-term, low-dose (e.g., mean of 5.6 mg of prednisone daily) glucocorticoid therapy is associated with a risk of bone loss. Thus, while the American College of Rheumatology (ACR) previously considered patients who received at least 7.5 mg of prednisone (or its equivalent) daily for 6 months or longer to be at risk for glucocorticoid-induced osteoporosis, they currently consider patients receiving or planning to receive at least 5 mg of prednisone daily for 3 months or longer to be at risk for such bone loss. Skeletal wasting is most rapid during the initial 6 months of therapy, and trabecular bone is affected to a greater degree than is cortical bone. The adverse skeletal effects of glucocorticoids appear to be both dose and duration dependent, with prednisone dosages of at least 7.5 mg daily for 6 months or longer often resulting in clinically important bone loss and increased fracture risk.\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 3092\n\nHazardous Substances Data Bank (HSDB)\n\n/SIGNS AND SYMPTOMS/ Children with acute lymphoblastic leukemia (ALL) receive as part of induction therapy a 4-week course of high-dose glucocorticoid, which is either abruptly discontinued or shortly tapered. The aim of this study was to evaluate the signs and symptoms of steroid withdrawal syndrome and performance status (according to Lansky scale) during the 9-day tapering period and 1 week after withdrawal of the steroid in 63 children randomly allocated to receive prednisone or [dexamethasone](https://pubchem.ncbi.nlm.nih.gov/compound/dexamethasone) as part of induction treatment according the AIEOP ALL 2000 protocol. Twenty of 28 (75%) patients on [dexamethasone](https://pubchem.ncbi.nlm.nih.gov/compound/dexamethasone) versus 18 of 35 (51.4%) on prednisone (P < 0.05) developed at least one steroid withdrawal symptom during the study period. Three or more symptoms were observed in 39.3% (11/28) of the dexamethasone group and 8.6% (3/35) of the prednisone group (P < 0.05). Dexamethasone patients developed clinical signs earlier (within 3 days from the steroid tapering) than symptomatic prednisone patients. In the prednisone group, the symptoms were less severe and the performance status was higher (P < 0.05). ...\n\n[PMID:15750445](https://pubmed.ncbi.nlm.nih.gov/15750445)\n\nSaracco P et al; J Pediatr Hematol Oncol 27 (3):141-4 (2005)\n\nHazardous Substances Data Bank (HSDB)\n\n/SIGNS AND SYMPTOMS/ Glucocorticoids, especially in large doses, increase susceptibility to and mask symptoms of infection. Infections with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic infections in any organ system, may be associated with glucocorticoids alone or in combination with other immunosuppressive agents. These infections may be mild, but they can be severe or fatal, and localized infections may disseminate. Patients who become immunosuppressed while receiving glucocorticoids have increased susceptibility to infections compared with healthy individuals. Some infections such as varicella (chickenpox) and measles can have a more serious or even fatal outcome in such patients, particularly in children. /Corticosteroids/ \n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 3093\n\nHazardous Substances Data Bank (HSDB)\n\nFor more Human Toxicity Excerpts (Complete) data for PREDNISONE (21 total), please visit the [HSDB record page](https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3168#section=Human-Toxicity-Excerpts-(Complete)).\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.1.13 Non-Human Toxicity Excerpts[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Non-Human-Toxicity-Excerpts&fullscreen=true \"Open this section in a new browser window\")\n\n/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Two groups, each of 25 male and 25-28 female 6-week-old Sprague-Dawley derived Charles River (CD) rats, were given ip injections of 11 or 22 (males, 11 or 45) mg/kg bw prednisone at a concentration of 0.25 mL/100 g bw in saline 3 times weekly for 6 months. Animals that survived over 100 days were observed for 12 further months, at which time they were killed. Untreated rats served as controls: spontaneous tumors were reported in 60/179 (34%) male and 105/181 (58%) female controls. The survival times of the treated animals were reported as percentages of that of the controls (no precise definition of the mode of calculation was given): the survival times of treated males were 23 and 100%, respectively, that of controls; and treated females of both dose groups had the same survival time as controls, i.e., 100%. Of treated males, 7/20 developed tumors, among which were 3 pituitary tumors and 1 tumor of the breast; 16/18 (89%) female rats developed tumors, 8 of the breast, 5 of the pituitary, 2 of the adrenal and 1 of the liver. The authors reported that the overall tumor incidence in females was 1.5-2-fold higher than that in controls\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\n/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Two groups, each of 25 male and 25 female 6-week-old outbred Swiss-Webster derived mice were given i.p. injections of 6 or 12 (females, 6 or 25) mg/kg bw prednisone at a concentration of 0.1 mL/10 g bw in saline 3 times weekly for 6 months. Animals that survived over 100 days were observed for 12 further months, at which time they were killed. Untreated mice served as controls: spontaneous tumors were reported in 28/101 (28%) male and 38/153 (25%) female controls. The survival times of the treated animals were reported as percentages of that of the controls [no precise definition of the mode of calculation was given]: the survival time of treated males of both dose groups was 34% that of controls and that of females was 34% and 100%, respectively. The tumor incidence in treated males was 4/19 (21%), with 2 lymphosarcomas and 2 lung tumors, and that in treated females was 8/27 (30%), with 4 lung tumors, 2 lymphosarcomas and 2 uterine tumors. These incidences were not significantly greater than those in controls.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\n/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Prednisone given to rats from the 11th day of pregnancy until parturition at daily doses of 2.5 or 5 mg was reported to inhibit the growth of the fetal thymus and spleen.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\n/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Prednisone was evaluated using the Chernoff/Kavlock in vivo teratology screen procedure. End points analyzed as part of this assay were maternal toxicity and early postnatal growth/viability in the offspring. Thirty pregnant CD-1 mice were given 20 mg/kg/day prednisone ip on days 8-12 of gestation and allowed to deliver. Forty vehicle-treated animals served as controls. There were no observable toxic effects in treated dams or their offspring when compared to controls.\n\n[PMID:2884745](https://pubmed.ncbi.nlm.nih.gov/2884745)\n\nKavlock RJ et al; Teratog Carcinog Mutagen 7 (1): 7-16 (1987)\n\nHazardous Substances Data Bank (HSDB)\n\n/GENOTOXICITY/ Prednisone was not mutagenic in Escherichia coli, and it caused no chromosomal damage when administered to Wistar rats.\n\nIARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work).\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.1.14 Non-Human Toxicity Values[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Non-Human-Toxicity-Values&fullscreen=true \"Open this section in a new browser window\")\n\nLD50 Mouse im 600 mg/kg \n\nLewis, R.J. Sr. (ed) Sax's Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley & Sons, Inc. Hoboken, NJ. 2004., p. 3048\n\nHazardous Substances Data Bank (HSDB)\n\nLD50 Mouse sc 101 mg/kg \n\nLewis, R.J. Sr. (ed) Sax's Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley & Sons, Inc. Hoboken, NJ. 2004., p. 3048\n\nHazardous Substances Data Bank (HSDB)\n\nLD50 Mouse ip 135 mg/kg \n\nLewis, R.J. Sr. (ed) Sax's Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley & Sons, Inc. Hoboken, NJ. 2004., p. 3048\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.1.15 Ongoing Test Status[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Ongoing-Test-Status&fullscreen=true \"Open this section in a new browser window\")\n\nEPA has released the Interactive Chemical Safety for Sustainability (iCSS) Dashboard. The iCSS Dashboard provides an interactive tool to explore rapid, automated (or in vitro high-throughput) chemical screening data generated by the Toxicity Forecaster (ToxCast) project and the federal Toxicity Testing in the 21st century (Tox21) collaboration. /The title compound was tested by ToxCast and/or Tox21 assays/[USEPA; ICSS Dashboard Application; Available from, as of October 28, 2016: http://actor.epa.gov/dashboard/] \n\nHazardous Substances Data Bank (HSDB)\n\nThe following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page, which tabulates all of the \"Short-Term Toxicity Studies,\" \"Long-Term Carcinogenicity Studies,\" and \"Genetic Toxicology Studies\" performed with this chemical. Clicking on the \"Testing Status\" link will take the user to the status (i.e., in review, in progress, in preparation, on test, completed, etc.) and results of all the studies that the NTP has done on this chemical.[Available from: http://ntp.niehs.nih.gov/testing/status/agents/ts-10936-e.html] \n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.1.16 Populations at Special Risk[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Populations-at-Special-Risk&fullscreen=true \"Open this section in a new browser window\")\n\nGlucocorticoids should be used with caution in patients with hypothyroidism or cirrhosis, because such patients often show exaggerated response to the drugs. Glucocorticoids should be used with caution in psychotic patients or patients with hypertension or congestive heart failure. /Corticosteroids/ \n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 3095\n\nHazardous Substances Data Bank (HSDB)\n\nBecause an apparent association has been suggested between use of corticosteroids and left ventricular free-wall rupture after a recent myocardial infarction, corticosteroids should be used with extreme caution in these patients. /Corticosteroids/ \n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 3095\n\nHazardous Substances Data Bank (HSDB)\n\nBecause glucocorticoids increase susceptibility to and mask symptoms of infection, the drugs should not be used, except in life-threatening situations, in patients with viral infections or bacterial infections not controlled by anti-infectives. Manufacturers state that glucocorticoid oral inhalation therapy should be used with caution, if at all, in patients with untreated systemic fungal, bacterial, viral, or parasitic infections. Patients whose susceptibility to infection is high, such as those receiving glucocorticoids as immunosuppressive therapy, are especially likely to develop secondary infections. Patients receiving glucocorticoids who are potentially immunosuppressed should be warned of the risk of exposure to certain infections (e.g., chickenpox, measles) and of the importance of obtaining medical advice if such exposure occurs. Since glucocorticoid therapy can reactivate tuberculosis, treatment of latent tuberculosis infection should be included in the regimen of patients with a history of active tuberculosis undergoing prolonged glucocorticoid therapy. If glucocorticoids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary. Use of glucocorticoids in patients with active tuberculosis should be restricted to those with fulminating or disseminated tuberculosis in which glucocorticoids are used in conjunction with appropriate antimycobacterial chemotherapy. Manufacturers state that glucocorticoid oral inhalation therapy should be used with caution, if at all, in patients with clinical or asymptomatic Mycobacterium tuberculosis infections of the respiratory tract. Since glucocorticoids can reactivate latent amebiasis, any patient who has been in the tropics or who has unexplained diarrhea should be evaluated for amebiasis to exclude these patients prior to initiating therapy. In the treatment of acute or disseminated tuberculosis, glucocorticoids should only be used as part of a total antituberculosis regimen. ... /Corticosteroids/ \n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 3095\n\nHazardous Substances Data Bank (HSDB)\n\nGlucocorticoids should be used cautiously in patients with myasthenia gravis, particularly in those receiving anticholinesterase therapy. /Corticosteroids/ \n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 3095\n\nHazardous Substances Data Bank (HSDB)\n\nFor more Populations at Special Risk (Complete) data for PREDNISONE (9 total), please visit the [HSDB record page](https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3168#section=Populations-at-Special-Risk-(Complete)).\n\nHazardous Substances Data Bank (HSDB)\n\n### 12.2 Ecological Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Ecological-Information&fullscreen=true \"Open this section in a new browser window\")\n\n#### 12.2.1 Ecotoxicity Excerpts[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Ecotoxicity-Excerpts&fullscreen=true \"Open this section in a new browser window\")\n\n/AQUATIC SPECIES/ Solar simulator irradiation of an aqueous suspension of prednisone, a widely prescribed drug, produces seven photochemical derivatives. The compounds have been identified on the basis of their physical features. All the chemicals have been tested to evaluate their toxic effects on freshwater organisms from different trophic levels. The rotifer Brachionus calyciflorus and two crustaceans, the cladoceran Daphnia magna and the anostracan Thamnocephalus platyurus, were used to perform acute toxicity tests. Chronic toxicity tests have been performed on the alga Pseudokirchneriella subcapitata (formerly known as Selenastrum capricornutum) and the crustacean Ceriodaphnia dubia. The results showed low acute and chronic toxicity of prednisone. Some of the photoproducts had high toxic effects on C. dubia.\n\nDellaGreca M et al; Environ Toxicol Chem 22 (3): 534-9 (2003)\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.2.2 Environmental Fate / Exposure Summary[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Environmental-Fate-Exposure-Summary&fullscreen=true \"Open this section in a new browser window\")\n\nPrednisone's production and administration as human and veterinary medication may result in its release to the environment through various waste streams. If released to air, an estimated vapor pressure of 3.8X10-13 mm Hg at 25 °C indicates prednisone will exist solely in the particulate phase in the atmosphere. Particulate-phase prednisone will be removed from the atmosphere by wet and dry deposition. Prednisone contains chromophores that absorb at wavelengths >290 nm and, therefore, may be susceptible to direct photolysis by sunlight. If released to soil, prednisone is expected to have high mobility based upon an estimated Koc of 110. Volatilization from moist soil surfaces is not expected to be an important fate process based upon an estimated Henry's Law constant of 2.8X10-10 atm-cu m/mole. Prednisone is not expected to volatilize from dry soil surfaces based upon its vapor pressure. Biodegradation data in soil or [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) were not available. If released into [water](https://pubchem.ncbi.nlm.nih.gov/compound/water), prednisone is not expected to adsorb to suspended solids and sediment based upon the estimated Koc. Volatilization from [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) surfaces is not expected to be an important fate process based upon this compound's estimated Henry's Law constant. An estimated BCF of 4 suggests the potential for bioconcentration in aquatic organisms is low. Hydrolysis is not expected to be an important environmental fate process since this compound lacks functional groups that hydrolyze under environmental conditions (pH 5 to 9). Occupational exposure to prednisone may occur through inhalation and dermal contact with this compound at workplaces where prednisone is produced or used. Limited monitoring data indicate that the general population may be exposed to prednisone via ingestion of and dermal contact with contaminated [water](https://pubchem.ncbi.nlm.nih.gov/compound/water). Exposure to prednisone among the general population will also occur to those administered the drug (Prednisone Tablets), a glucocorticoid. (SRC)\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.2.3 Artificial Pollution Sources[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Artificial-Pollution-Sources&fullscreen=true \"Open this section in a new browser window\")\n\nPrednisone's production and use as a glucocorticoid, veterinary adrenocortical steroid, veterinary glucocorticoid, and veterinary anti-inflammatory(1) may result in its release to the environment through various waste streams(SRC).\n\n(1) O'Neil MJ, ed; The Merck Index. 15th ed. Cambridge, UK: Royal Soc Chem. p. 1432 (2013)\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.2.4 Environmental Fate[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Environmental-Fate&fullscreen=true \"Open this section in a new browser window\")\n\nTERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 110(SRC), determined from a structure estimation method(2), indicates that prednisone is expected to have high mobility in soil(SRC). Volatilization of prednisone from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 2.8X10-10 atm-cu m/mole(SRC), using a fragment constant estimation method(3). Prednisone is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 3.8X10-13 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2016).\n\n(1) Swann RL et al; Res Rev 85: 17-28 (1983)\n\n(2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Nov 17, 2016: [https://www2.epa.gov/tsca-screening-tools](https://www2.epa.gov/tsca-screening-tools)\n\n(3) Meylan WM, Howard PH; Environ Toxicol Chem 10: 1283-93 (1991)\n\nHazardous Substances Data Bank (HSDB)\n\nAQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 110(SRC), determined from a structure estimation method(2), indicates that prednisone is not expected to adsorb to suspended solids and sediment(SRC). Volatilization from [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) surfaces is not expected(3) based upon an estimated Henry's Law constant of 2.8X10-10 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). According to a classification scheme(5), an estimated BCF of 4(SRC), from its log Kow of 1.46(6) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data in [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) were not available(SRC, 2016).\n\n(1) Swann RL et al; Res Rev 85: 17-28 (1983)\n\n(2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Nov 17, 2016: [https://www2.epa.gov/tsca-screening-tools](https://www2.epa.gov/tsca-screening-tools)\n\n(3) Lyman WJ et al; Handbook of Chemical Property Estimation Methods. Washington, DC: Amer Chem Soc pp. 15-1 to 15-29 (1990)\n\n(4) Meylan WM, Howard PH; Environ Toxicol Chem 10: 1283-93 (1991)\n\n(5) Franke C et al; Chemosphere 29: 1501-14 (1994)\n\n(6) Hansch C et al; Exploring QSAR. Hydrophobic, Electronic, and Steric Constants. ACS Prof Ref Book. Heller SR, consult. ed., Washington, DC: Amer Chem Soc p. 173 (1995)\n\nHazardous Substances Data Bank (HSDB)\n\nATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), prednisone, which has an estimated vapor pressure of 3.8X10-13 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase prednisone may be removed from the air by wet and dry deposition(SRC). Prednisone contains chromophores that absorb at wavelengths >290 nm(3) and, therefore, may be susceptible to direct photolysis by sunlight(SRC).\n\n(1) Bidleman TF; Environ Sci Technol 22: 361-367 (1988)\n\n(2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Nov 17, 2016: [https://www2.epa.gov/tsca-screening-tools](https://www2.epa.gov/tsca-screening-tools)\n\n(3) Lyman WJ et al; Handbook of Chemical Property Estimation Methods. Washington, DC: Amer Chem Soc pp. 8-12 (1990)\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.2.5 Environmental Abiotic Degradation[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Environmental-Abiotic-Degradation&fullscreen=true \"Open this section in a new browser window\")\n\nPrednisone is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(1). Prednisone contains chromophores that absorb at wavelengths >290 nm(1) and, therefore, may be susceptible to direct photolysis by sunlight(SRC). A suspension of 100 mg of prednisone in 500 mL [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) was irradiated by a solar simulator for 8 hours; 60% was transformed into seven photochemical derivatives which included a [bicyclo(5.3.0)decane](https://pubchem.ncbi.nlm.nih.gov/compound/bicyclo%285.3.0%29decane) and 5alpha,17alpha,21-trihydroxy-pregn-1-ene-3,11,20-trione(2).\n\n(1) Lyman WJ et al; Handbook of Chemical Property Estimation Methods. Washington, DC: Amer Chem Soc pp. 7-4, 7-5, 8-12 (1990)\n\n(2) DellaGreca M et al; Environ Toxicol Chem 22: 534-9 (2003)\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.2.6 Environmental Bioconcentration[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Environmental-Bioconcentration&fullscreen=true \"Open this section in a new browser window\")\n\nAn estimated BCF of 4 was calculated in fish for prednisone(SRC), using a log Kow of 1.46(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).\n\n(1) Hansch C et al; Exploring QSAR. Hydrophobic, Electronic, and Steric Constants. ACS Prof Ref Book. Heller SR, consult. ed., Washington, DC: Amer Chem Soc p. 173 (1995)\n\n(2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Nov 17, 2016: [https://www2.epa.gov/tsca-screening-tools](https://www2.epa.gov/tsca-screening-tools)\n\n(3) Franke C et al; Chemosphere 29: 1501-14 (1994)\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.2.7 Soil Adsorption / Mobility[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Soil-Adsorption-Mobility&fullscreen=true \"Open this section in a new browser window\")\n\nUsing a structure estimation method based on molecular connectivity indices(1), the Koc of prednisone can be estimated to be 110(SRC). According to a classification scheme(2), this estimated Koc value suggests that prednisone is expected to have high mobility in soil\n\n(1) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Nov 17, 2016: [https://www2.epa.gov/tsca-screening-tools](https://www2.epa.gov/tsca-screening-tools)\n\n(2) Swann RL et al; Res Rev 85: 17-28 (1983)\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.2.8 Volatilization from Water / Soil[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Volatilization-from-Water-Soil&fullscreen=true \"Open this section in a new browser window\")\n\nThe Henry's Law constant for prednisone is estimated as 2.8X10-10 atm-cu m/mole(SRC) using a fragment constant estimation method(1). This Henry's Law constant indicates that prednisone is expected to be essentially nonvolatile from [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) and moist soil surfaces(2). Prednisone is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 3.8X10-13 mm Hg(SRC), determined from a fragment constant method(3).\n\n(1) Meylan WM, Howard PH; Environ Toxicol Chem 10: 1283-93 (1991)\n\n(2) Lyman WJ et al; Handbook of Chemical Property Estimation Methods. Washington, DC: Amer Chem Soc pp. 15-1 to 15-29 (1990)\n\n(3) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Nov 17, 2016: [https://www2.epa.gov/tsca-screening-tools](https://www2.epa.gov/tsca-screening-tools)\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.2.9 Environmental Water Concentrations[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Environmental-Water-Concentrations&fullscreen=true \"Open this section in a new browser window\")\n\nGROUNDWATER: Prednisone was detected in a groundwater sample collected from the Borrego Valley, California on June 17, 2003, at a concentration <168 ng/L(1).\n\n(1) USGS; Borrego Valley Groundwater Conditions. Datasets. State Well No. 011S006E23J001S (2015). Available from, as of Jan 16, 2017: [https://ca.water.usgs.gov/projects/borrego](https://ca.water.usgs.gov/projects/borrego)\n\nHazardous Substances Data Bank (HSDB)\n\nSURFACE [WATER](https://pubchem.ncbi.nlm.nih.gov/compound/WATER): Prednisone was detected in 23 of 37 [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) samples collected from the River Wenyu and tributaries, Beijing China between Aug 9-12, 2006 at concentrations ranging from not detected to 0.25 ng/L. No farms or livestock areas were located within the sampling area(1).\n\n(1) Chang H et al; Environ Sci Technol 43(20): 7691-7698 (2009)\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.2.10 Effluent Concentrations[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Effluent-Concentrations&fullscreen=true \"Open this section in a new browser window\")\n\nPrednisone concentration in sewage influent samples in the Ebre, Ter and Llobregat Rivers, Tarragona area, Spain ranged from 21-285 ng/L(1). Prednisone was detected in 23 of 37 [water](https://pubchem.ncbi.nlm.nih.gov/compound/water) samples collected from the River Wenyu and tributaries, Beijing China between Aug 9-12, 2006 at concentrations ranging from not detected to 0.25 ng/L. No farms or livestock areas were located within the sampling area(2).\n\n(1) Herrero P et al; J Chromatogr A 1225: 19-26 (2012). Available from, as of Jan 17, 2017: [https://www.ncbi.nlm.nih.gov/pubmed/22226553](https://www.ncbi.nlm.nih.gov/pubmed/22226553)\n\n(2) Chang H et al; Environ Sci Technol 43: 7691-7698 (2009)\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.2.11 Milk Concentrations[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Milk-Concentrations&fullscreen=true \"Open this section in a new browser window\")\n\nIt passes into breast milk in small amounts. /Adrenocorticosteroids/ /from table II/ \n\nStockton, D.L. and A.S. Paller. J Am Acad Dermatol 23 (1):87-103 (1990)\n\nHazardous Substances Data Bank (HSDB)\n\n#### 12.2.12 Probable Routes of Human Exposure[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Probable-Routes-of-Human-Exposure&fullscreen=true \"Open this section in a new browser window\")\n\nNIOSH (NOES Survey 1981-1983) has statistically estimated that 1,266 workers (725 of these are female) are potentially exposed to prednisone in the US(1). Occupational exposure to prednisone may occur through inhalation and dermal contact with this compound at workplaces where prednisone is produced or used(SRC). Limited monitoring data indicate that the general population may be exposed to prednisone via ingestion of and dermal contact with contaminated [water](https://pubchem.ncbi.nlm.nih.gov/compound/water). Exposure to prednisone among the general population will also occur to those administered the drug (Prednisone Tablets), a glucocorticoid(SRC).\n\n(1) NIOSH; NOES. National Occupational Exposure Survey conducted from 1981-1983. Estimated numbers of employees potentially exposed to specific agents by 2-digit standard industrial classification (SIC). Available from, as of Oct 10, 2007: [https://www.cdc.gov/noes/](https://www.cdc.gov/noes/)\n\nHazardous Substances Data Bank (HSDB)\n\n13 Associated Disorders and Diseases[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Associated-Disorders-and-Diseases&fullscreen=true \"Open this section in a new browser window\")\n--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nOpen Targets; Therapeutic Target Database (TTD)\n\n14 Literature[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Literature&fullscreen=true \"Open this section in a new browser window\")\n----------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 14.1 Consolidated References[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Consolidated-References&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 14.2 NLM Curated PubMed Citations[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=NLM-Curated-PubMed-Citations&fullscreen=true \"Open this section in a new browser window\")\n\nMedical Subject Headings (MeSH)\n\n### 14.3 Springer Nature References[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Springer-Nature-References&fullscreen=true \"Open this section in a new browser window\")\n\nSpringer Nature\n\nSpringer Nature\n\n### 14.4 Thieme References[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Thieme-References&fullscreen=true \"Open this section in a new browser window\")\n\nThieme Chemistry\n\n### 14.5 Nature Journal References[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Nature-Journal-References&fullscreen=true \"Open this section in a new browser window\")\n\n[Nippa et al. Enabling late-stage drug diversification by high-throughput experimentation with geometric deep learning. Nature Chemistry, DOI: 10.1038/s41557-023-01360-5, published online 23 November 2023](https://www.nature.com/articles/s41557-023-01360-5)\n\nNature Chemistry\n\n### 14.6 Chemical Co-Occurrences in Literature[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Chemical-Co-Occurrences-in-Literature&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 14.7 Chemical-Gene Co-Occurrences in Literature[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Chemical-Gene-Co-Occurrences-in-Literature&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 14.8 Chemical-Disease Co-Occurrences in Literature[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Chemical-Disease-Co-Occurrences-in-Literature&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 14.9 Chemical-Organism Co-Occurrences in Literature[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Chemical-Organism-Co-Occurrences-in-Literature&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n15 Patents[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Patents&fullscreen=true \"Open this section in a new browser window\")\n----------------------------------------------------------------------------------------------------------------------------------------------\n\n*   [US9186332](https://pubchem.ncbi.nlm.nih.gov/patent/US9186332)\n*   [US8168218](https://pubchem.ncbi.nlm.nih.gov/patent/US8168218)\n*   [US8309124](https://pubchem.ncbi.nlm.nih.gov/patent/US8309124)\n*   [US8394407](https://pubchem.ncbi.nlm.nih.gov/patent/US8394407)\n*   [US9040085](https://pubchem.ncbi.nlm.nih.gov/patent/US9040085)\n*   [US6488960](https://pubchem.ncbi.nlm.nih.gov/patent/US6488960)\n*   [US6677326](https://pubchem.ncbi.nlm.nih.gov/patent/US6677326)\n*   [US9504699](https://pubchem.ncbi.nlm.nih.gov/patent/US9504699)\n\nDrugBank\n\n### 15.1 Depositor-Supplied Patent Identifiers[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Depositor-Supplied-Patent-Identifiers&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n[Link to all deposited patent identifiers](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/5865/xrefs/PatentID/TXT)\n\nPubChem\n\n### 15.2 WIPO PATENTSCOPE[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=WIPO-PATENTSCOPE&fullscreen=true \"Open this section in a new browser window\")\n\nPatents are available for this chemical structure:\n\n[https://patentscope.wipo.int/search/en/result.jsf?inchikey=XOFYZVNMUHMLCC-ZPOLXVRWSA-N](https://patentscope.wipo.int/search/en/result.jsf?inchikey=XOFYZVNMUHMLCC-ZPOLXVRWSA-N)\n\nPATENTSCOPE (WIPO)\n\n### 15.3 FDA Orange Book Patents[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=FDA-Orange-Book-Patents&fullscreen=true \"Open this section in a new browser window\")\n\nFDA Orange Book\n\n### 15.4 Chemical Co-Occurrences in Patents[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Chemical-Co-Occurrences-in-Patents&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 15.5 Chemical-Disease Co-Occurrences in Patents[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Chemical-Disease-Co-Occurrences-in-Patents&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 15.6 Chemical-Gene Co-Occurrences in Patents[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Chemical-Gene-Co-Occurrences-in-Patents&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 15.7 Chemical-Organism Co-Occurrences in Patents[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Chemical-Organism-Co-Occurrences-in-Patents&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n16 Interactions and Pathways[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Interactions-and-Pathways&fullscreen=true \"Open this section in a new browser window\")\n----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 16.1 Protein Bound 3D Structures[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Protein-Bound-3D-Structures&fullscreen=true \"Open this section in a new browser window\")\n\n[View 2 proteins in NCBI Structure](https://www.ncbi.nlm.nih.gov/structure?cmd=Link&LinkName=pccompound_structure&from_uid=5865)\n\nPubChem\n\n### 16.2 Chemical-Target Interactions[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Chemical-Target-Interactions&fullscreen=true \"Open this section in a new browser window\")\n\nChEMBL; Drug Gene Interaction database (DGIdb); IUPHAR/BPS Guide to PHARMACOLOGY; Therapeutic Target Database (TTD); Toxin and Toxin Target Database (T3DB)\n\nDrugBank\n\n### 16.3 Drug-Drug Interactions[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Drug-Drug-Interactions&fullscreen=true \"Open this section in a new browser window\")\n\nDrugBank\n\n### 16.4 Drug-Food Interactions[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Drug-Food-Interactions&fullscreen=true \"Open this section in a new browser window\")\n\n*   Avoid alcohol. \n*   Take with food. Food reduces irritation. \n\nDrugBank\n\n### 16.5 Pathways[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Pathways&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n17 Biological Test Results[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Biological-Test-Results&fullscreen=true \"Open this section in a new browser window\")\n------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 17.1 BioAssay Results[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=BioAssay-Results&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n18 Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Classification&fullscreen=true \"Open this section in a new browser window\")\n------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 18.1 MeSH Tree[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=MeSH-Tree&fullscreen=true \"Open this section in a new browser window\")\n\nMedical Subject Headings (MeSH)\n\n### 18.2 NCI Thesaurus Tree[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=NCI-Thesaurus-Tree&fullscreen=true \"Open this section in a new browser window\")\n\nNCI Thesaurus (NCIt)\n\n### 18.3 LIPID MAPS Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=LIPID-MAPS-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nLIPID MAPS\n\n### 18.4 KEGG: Lipid[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=KEGG-Lipid&fullscreen=true \"Open this section in a new browser window\")\n\nKEGG\n\n### 18.5 KEGG: ATC[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=KEGG-ATC&fullscreen=true \"Open this section in a new browser window\")\n\nKEGG\n\n### 18.6 KEGG: Drug Groups[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=KEGG-Drug-Groups&fullscreen=true \"Open this section in a new browser window\")\n\nKEGG\n\n### 18.7 WHO ATC Classification System[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=WHO-ATC-Classification-System&fullscreen=true \"Open this section in a new browser window\")\n\nWHO Anatomical Therapeutic Chemical (ATC) Classification\n\n### 18.8 FDA Pharm Classes[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=FDA-Pharm-Classes&fullscreen=true \"Open this section in a new browser window\")\n\nFDA Pharm Classes\n\n### 18.9 ChemIDplus[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=ChemIDplus&fullscreen=true \"Open this section in a new browser window\")\n\nChemIDplus\n\n### 18.10 CAMEO Chemicals[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=CAMEO-Chemicals&fullscreen=true \"Open this section in a new browser window\")\n\nCAMEO Chemicals\n\n### 18.11 IUPHAR / BPS Guide to PHARMACOLOGY Target Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=IUPHAR-BPS-Guide-to-PHARMACOLOGY-Target-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nIUPHAR/BPS Guide to PHARMACOLOGY\n\n### 18.12 ChEMBL Target Tree[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=ChEMBL-Target-Tree&fullscreen=true \"Open this section in a new browser window\")\n\nChEMBL\n\n### 18.13 UN GHS Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=UN-GHS-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nGHS Classification (UNECE)\n\n### 18.14 NORMAN Suspect List Exchange Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=NORMAN-Suspect-List-Exchange-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nNORMAN Suspect List Exchange\n\n### 18.15 CCSBase Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=CCSBase-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nCCSbase\n\n### 18.16 EPA DSSTox Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=EPA-DSSTox-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nEPA DSSTox\n\n### 18.17 International Agency for Research on Cancer (IARC) Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=International-Agency-for-Research-on-Cancer-IARC-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nInternational Agency for Research on Cancer (IARC)\n\n### 18.18 EPA TSCA and CDR Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=EPA-TSCA-and-CDR-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nEPA Chemicals under the TSCA\n\n### 18.19 FDA Drug Type and Pharmacologic Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=FDA-Drug-Type-and-Pharmacologic-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nNational Drug Code (NDC) Directory\n\n### 18.20 CCS Classification - Baker Lab[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=CCS-Classification-Baker-Lab&fullscreen=true \"Open this section in a new browser window\")\n\nBaker Lab, Chemistry Department, The University of North Carolina at Chapel Hill\n\n### 18.21 MolGenie Organic Chemistry Ontology[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=MolGenie-Organic-Chemistry-Ontology&fullscreen=true \"Open this section in a new browser window\")\n\nMolGenie\n\n### 18.22 Chemicals in PubChem from Regulatory Sources[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Chemicals-in-PubChem-from-Regulatory-Sources&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 18.23 ATCvet Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=ATCvet-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nWHO ATCvet - Classification of Veterinary Medicines\n\n### 18.24 HTS Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=HTS-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nUSITC Harmonized Tariff Schedule\n\n19 Information Sources[](https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone#section=Information-Sources&fullscreen=true \"Open this section in a new browser window\")\n----------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nFilter by Source \n\n1.   [Australian Industrial Chemicals Introduction Scheme (AICIS)](https://pubchem.ncbi.nlm.nih.gov/source/Australian%20Industrial%20Chemicals%20Introduction%20Scheme%20(AICIS))LICENSE [https://www.industrialchemicals.gov.au/copyright](https://www.industrialchemicals.gov.au/copyright) Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- [https://services.industrialchemicals.gov.au/search-assessments/](https://services.industrialchemicals.gov.au/search-assessments/) \n2.   [CAMEO Chemicals](https://pubchem.ncbi.nlm.nih.gov/source/CAMEO%20Chemicals)LICENSE CAMEO Chemicals and all other CAMEO products are available at no charge to those organizations and individuals (recipients) responsible for the safe handling of chemicals. However, some of the chemical data itself is subject to the copyright restrictions of the companies or organizations that provided the data. [https://cameochemicals.noaa.gov/help/reference/terms_and_conditions.htm?d_f=false](https://cameochemicals.noaa.gov/help/reference/terms_and_conditions.htm?d_f=false) PREDNISONE [https://cameochemicals.noaa.gov/chemical/20949](https://cameochemicals.noaa.gov/chemical/20949) CAMEO Chemical Reactivity Classification [https://cameochemicals.noaa.gov/browse/react](https://cameochemicals.noaa.gov/browse/react) \n3.   [CAS Common Chemistry](https://pubchem.ncbi.nlm.nih.gov/source/CAS%20Common%20Chemistry)LICENSE The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. [https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/) Prednisone [https://commonchemistry.cas.org/detail?cas_rn=53-03-2](https://commonchemistry.cas.org/detail?cas_rn=53-03-2) \n4.   [ChemIDplus](https://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus)LICENSE [https://www.nlm.nih.gov/copyright.html](https://www.nlm.nih.gov/copyright.html) Prednisone [USP:INN:BAN] [https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0000053032](https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0000053032) ChemIDplus Chemical Information Classification [https://pubchem.ncbi.nlm.nih.gov/source/chemidplus](https://pubchem.ncbi.nlm.nih.gov/source/chemidplus) \n5.   [DrugBank](https://pubchem.ncbi.nlm.nih.gov/source/DrugBank)LICENSE Creative Common's Attribution-NonCommercial 4.0 International License ([http://creativecommons.org/licenses/by-nc/4.0/legalcode](http://creativecommons.org/licenses/by-nc/4.0/legalcode))  [https://www.drugbank.ca/legal/terms_of_use](https://www.drugbank.ca/legal/terms_of_use) Prednisone [https://www.drugbank.ca/drugs/DB00635](https://www.drugbank.ca/drugs/DB00635) \n6.   [DTP/NCI](https://pubchem.ncbi.nlm.nih.gov/source/DTP/NCI)LICENSE Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source. [https://www.cancer.gov/policies/copyright-reuse](https://www.cancer.gov/policies/copyright-reuse) prednisone [https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=10023](https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=10023) \n7.   [EPA Chemicals under the TSCA](https://pubchem.ncbi.nlm.nih.gov/source/EPA%20Chemicals%20under%20the%20TSCA)LICENSE [https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources](https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources) Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- [https://www.epa.gov/chemicals-under-tsca](https://www.epa.gov/chemicals-under-tsca) EPA TSCA Classification [https://www.epa.gov/tsca-inventory](https://www.epa.gov/tsca-inventory) \n8.   [EPA DSSTox](https://pubchem.ncbi.nlm.nih.gov/source/EPA%20DSSTox)LICENSE [https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources](https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources) Prednisone [https://comptox.epa.gov/dashboard/DTXSID4021185](https://comptox.epa.gov/dashboard/DTXSID4021185) CompTox Chemicals Dashboard Chemical Lists [https://comptox.epa.gov/dashboard/chemical-lists/](https://comptox.epa.gov/dashboard/chemical-lists/) \n9.   [European Chemicals Agency (ECHA)](https://pubchem.ncbi.nlm.nih.gov/source/European%20Chemicals%20Agency%20(ECHA))LICENSE Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: \"Source: European Chemicals Agency, [http://echa.europa.eu/](http://echa.europa.eu/)\". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.  [https://echa.europa.eu/web/guest/legal-notice](https://echa.europa.eu/web/guest/legal-notice) Prednisone [https://chem.echa.europa.eu/100.000.147](https://chem.echa.europa.eu/100.000.147) Prednisone (EC: 200-160-3) [https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/13900](https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/13900) \n10.   [FDA Global Substance Registration System (GSRS)](https://pubchem.ncbi.nlm.nih.gov/source/FDA%20Global%20Substance%20Registration%20System%20(GSRS))LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) Prednisone [https://gsrs.ncats.nih.gov/ginas/app/beta/substances/VB0R961HZT](https://gsrs.ncats.nih.gov/ginas/app/beta/substances/VB0R961HZT) \n11.   [Hazardous Substances Data Bank (HSDB)](https://pubchem.ncbi.nlm.nih.gov/source/Hazardous%20Substances%20Data%20Bank%20(HSDB))LICENSE [https://www.nlm.nih.gov/web_policies.html](https://www.nlm.nih.gov/web_policies.html) PREDNISONE [https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3168](https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3168) \n12.   [Human Metabolome Database (HMDB)](https://pubchem.ncbi.nlm.nih.gov/source/Human%20Metabolome%20Database%20(HMDB))LICENSE HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications. [https://www.hmdb.ca/citing](https://www.hmdb.ca/citing) Prednisone [http://www.hmdb.ca/metabolites/HMDB0014773](http://www.hmdb.ca/metabolites/HMDB0014773) HMDB0014773_msms_2226306 [https://hmdb.ca/metabolites/HMDB0014773#spectra](https://hmdb.ca/metabolites/HMDB0014773#spectra) \n13.   [New Zealand Environmental Protection Authority (EPA)](https://pubchem.ncbi.nlm.nih.gov/source/New%20Zealand%20Environmental%20Protection%20Authority%20(EPA))LICENSE This work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International licence. [https://www.epa.govt.nz/about-this-site/general-copyright-statement/](https://www.epa.govt.nz/about-this-site/general-copyright-statement/) Prednisone [https://www.epa.govt.nz/industry-areas/hazardous-substances/guidance-for-importers-and-manufacturers/hazardous-substances-databases/](https://www.epa.govt.nz/industry-areas/hazardous-substances/guidance-for-importers-and-manufacturers/hazardous-substances-databases/) \n14.   [Baker Lab, Chemistry Department, The University of North Carolina at Chapel Hill](https://pubchem.ncbi.nlm.nih.gov/source/Baker%20Lab,%20Chemistry%20Department,%20The%20University%20of%20North%20Carolina%20at%20Chapel%20Hill)LICENSE CC-BY 4.0 [https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/) Prednisone  CCS Classification - Baker Lab [https://tarheels.live/bakerlab/](https://tarheels.live/bakerlab/) \n15.   [CCSbase](https://pubchem.ncbi.nlm.nih.gov/source/CCSbase)CCSbase Classification [https://ccsbase.net/](https://ccsbase.net/) \n16.   [ChEBI](https://pubchem.ncbi.nlm.nih.gov/source/ChEBI)Prednisone [https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8382](https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8382) \n17.   [FDA Pharm Classes](https://pubchem.ncbi.nlm.nih.gov/source/FDA%20Pharm%20Classes)LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) PREDNISONE ANHYDROUS [https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm](https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm) FDA Pharmacological Classification [https://www.fda.gov/industry/structured-product-labeling-resources/pharmacologic-class](https://www.fda.gov/industry/structured-product-labeling-resources/pharmacologic-class) \n18.   [NCI Thesaurus (NCIt)](https://pubchem.ncbi.nlm.nih.gov/source/NCI%20Thesaurus%20(NCIt))LICENSE Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source. [https://www.cancer.gov/policies/copyright-reuse](https://www.cancer.gov/policies/copyright-reuse) [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C770](https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C770) NCI Thesaurus [https://ncit.nci.nih.gov](https://ncit.nci.nih.gov/) \n19.   [Open Targets](https://pubchem.ncbi.nlm.nih.gov/source/Open%20Targets)LICENSE Datasets generated by the Open Targets Platform are freely available for download. [https://platform-docs.opentargets.org/licence](https://platform-docs.opentargets.org/licence) PREDNISONE [https://platform.opentargets.org/drug/CHEMBL635](https://platform.opentargets.org/drug/CHEMBL635) \n20.   [Toxin and Toxin Target Database (T3DB)](https://pubchem.ncbi.nlm.nih.gov/source/Toxin%20and%20Toxin%20Target%20Database%20(T3DB))LICENSE T3DB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (T3DB) and the original publication. [http://www.t3db.ca/downloads](http://www.t3db.ca/downloads) Prednisone [http://www.t3db.ca/toxins/T3D4710](http://www.t3db.ca/toxins/T3D4710) \n21.   [ChEMBL](https://pubchem.ncbi.nlm.nih.gov/source/ChEMBL)LICENSE Access to the web interface of ChEMBL is made under the EBI's Terms of Use ([http://www.ebi.ac.uk/Information/termsofuse.html](http://www.ebi.ac.uk/Information/termsofuse.html)). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License ([http://creativecommons.org/licenses/by-sa/3.0/](http://creativecommons.org/licenses/by-sa/3.0/)).  [http://www.ebi.ac.uk/Information/termsofuse.html](http://www.ebi.ac.uk/Information/termsofuse.html) [https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL635](https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL635) ChEMBL Protein Target Tree [https://www.ebi.ac.uk/chembl/g/#browse/targets](https://www.ebi.ac.uk/chembl/g/#browse/targets) \n22.   [Drug Gene Interaction database (DGIdb)](https://pubchem.ncbi.nlm.nih.gov/source/Drug%20Gene%20Interaction%20database%20(DGIdb))LICENSE The data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section. [http://www.dgidb.org/downloads](http://www.dgidb.org/downloads) PREDNISONE [https://www.dgidb.org/drugs/rxcui:8640](https://www.dgidb.org/drugs/rxcui:8640) \n23.   [IUPHAR/BPS Guide to PHARMACOLOGY](https://pubchem.ncbi.nlm.nih.gov/source/IUPHAR/BPS%20Guide%20to%20PHARMACOLOGY)LICENSE The Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) [https://opendatacommons.org/licenses/odbl/](https://opendatacommons.org/licenses/odbl/). Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License ([http://creativecommons.org/licenses/by-sa/4.0/](http://creativecommons.org/licenses/by-sa/4.0/))  [https://www.guidetopharmacology.org/about.jsp#license](https://www.guidetopharmacology.org/about.jsp#license) prednisone [https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7096](https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7096) Guide to Pharmacology Target Classification [https://www.guidetopharmacology.org/targets.jsp](https://www.guidetopharmacology.org/targets.jsp) \n24.   [Therapeutic Target Database (TTD)](https://pubchem.ncbi.nlm.nih.gov/source/Therapeutic%20Target%20Database%20(TTD))Prednisone [https://ttd.idrblab.cn/data/drug/details/D0IL7L](https://ttd.idrblab.cn/data/drug/details/D0IL7L) Prednisone/ dipyridamole [https://ttd.idrblab.cn/data/drug/details/D0R4NR](https://ttd.idrblab.cn/data/drug/details/D0R4NR) Prednisone [https://ttd.idrblab.cn/data/drug/details/D0E3JP](https://ttd.idrblab.cn/data/drug/details/D0E3JP) \n25.   [NORMAN Suspect List Exchange](https://pubchem.ncbi.nlm.nih.gov/source/NORMAN%20Suspect%20List%20Exchange)LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 [https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/) PREDNISONE  NORMAN Suspect List Exchange Classification [https://www.norman-network.com/nds/SLE/](https://www.norman-network.com/nds/SLE/) \n26.   [ClinicalTrials.gov](https://pubchem.ncbi.nlm.nih.gov/source/ClinicalTrials.gov)LICENSE The ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use. [https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use](https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use) [https://clinicaltrials.gov/](https://clinicaltrials.gov/) \n27.   [DailyMed](https://pubchem.ncbi.nlm.nih.gov/source/DailyMed)LICENSE [https://www.nlm.nih.gov/copyright.html](https://www.nlm.nih.gov/copyright.html) PREDNISONE [https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=PREDNISONE](https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=PREDNISONE) \n28.   [StatPearls](https://pubchem.ncbi.nlm.nih.gov/source/StatPearls)LICENSE This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.   Prednisone [https://www.ncbi.nlm.nih.gov/books/n/statpearls/article-35621/](https://www.ncbi.nlm.nih.gov/books/n/statpearls/article-35621/) \n29.   [Drugs and Lactation Database (LactMed)](https://pubchem.ncbi.nlm.nih.gov/source/Drugs%20and%20Lactation%20Database%20(LactMed))LICENSE [https://www.nlm.nih.gov/copyright.html](https://www.nlm.nih.gov/copyright.html) Prednisone [https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM224/](https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM224/) \n30.   [Drugs@FDA](https://pubchem.ncbi.nlm.nih.gov/source/Drugs@FDA)LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) PREDNICEN-M [https://www.accessdata.fda.gov/scripts/cder/daf/](https://www.accessdata.fda.gov/scripts/cder/daf/) \n31.   [WHO Model Lists of Essential Medicines](https://pubchem.ncbi.nlm.nih.gov/source/WHO%20Model%20Lists%20of%20Essential%20Medicines)LICENSE Permission from WHO is not required for the use of WHO materials issued under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Intergovernmental Organization (CC BY-NC-SA 3.0 IGO) license. [https://www.who.int/about/policies/publishing/copyright](https://www.who.int/about/policies/publishing/copyright) Prednisone [https://list.essentialmeds.org/medicines/635](https://list.essentialmeds.org/medicines/635) \n32.   [EU Clinical Trials Register](https://pubchem.ncbi.nlm.nih.gov/source/EU%20Clinical%20Trials%20Register)[https://www.clinicaltrialsregister.eu/](https://www.clinicaltrialsregister.eu/) \n33.   [FDA Approved Animal Drug Products (Green Book)](https://pubchem.ncbi.nlm.nih.gov/source/FDA%20Approved%20Animal%20Drug%20Products%20(Green%20Book))LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) Prednisone [https://www.fda.gov/animal-veterinary/products/approved-animal-drug-products-green-book](https://www.fda.gov/animal-veterinary/products/approved-animal-drug-products-green-book) \n34.   [FDA Orange Book](https://pubchem.ncbi.nlm.nih.gov/source/FDA%20Orange%20Book)LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) PREDNISONE [https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book](https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book) \n35.   [FDA Liver Toxicity Knowledge Base (LTKB)](https://pubchem.ncbi.nlm.nih.gov/source/FDA%20Liver%20Toxicity%20Knowledge%20Base%20(LTKB))LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) prednisone [https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset](https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset) \n36.   [National Drug Code (NDC) Directory](https://pubchem.ncbi.nlm.nih.gov/source/National%20Drug%20Code%20(NDC)%20Directory)LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) PREDNISONE [https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory](https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory) \n37.   [MassBank of North America (MoNA)](https://pubchem.ncbi.nlm.nih.gov/source/MassBank%20of%20North%20America%20(MoNA))LICENSE The content of the MoNA database is licensed under CC BY 4.0. [https://mona.fiehnlab.ucdavis.edu/documentation/license](https://mona.fiehnlab.ucdavis.edu/documentation/license) prednisone [https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=exists(compound.metaData.name:%27InChIKey%27%20and%20compound.metaData.value:%27XOFYZVNMUHMLCC-ZPOLXVRWSA-N%27)](https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=exists(compound.metaData.name:%27InChIKey%27%20and%20compound.metaData.value:%27XOFYZVNMUHMLCC-ZPOLXVRWSA-N%27)) \n38.   [International Agency for Research on Cancer (IARC)](https://pubchem.ncbi.nlm.nih.gov/source/International%20Agency%20for%20Research%20on%20Cancer%20(IARC))LICENSE Materials made available by IARC/WHO enjoy copyright protection under the Berne Convention for the Protection of Literature and Artistic Works, under other international conventions, and under national laws on copyright and neighbouring rights. IARC exercises copyright over its Materials to make sure that they are used in accordance with the Agency's principles. All rights are reserved. [https://publications.iarc.who.int/Terms-Of-Use](https://publications.iarc.who.int/Terms-Of-Use) Prednisone [https://monographs.iarc.who.int/list-of-classifications](https://monographs.iarc.who.int/list-of-classifications) IARC Classification [https://www.iarc.who.int/](https://www.iarc.who.int/) \n39.   [Japan Chemical Substance Dictionary (Nikkaji)](https://pubchem.ncbi.nlm.nih.gov/source/Japan%20Chemical%20Substance%20Dictionary%20(Nikkaji))[http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J4.137H](http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J4.137H) \n40.   [KEGG](https://pubchem.ncbi.nlm.nih.gov/source/KEGG)LICENSE Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license [https://www.kegg.jp/kegg/legal.html](https://www.kegg.jp/kegg/legal.html) [https://www.kegg.jp/entry/C07370](https://www.kegg.jp/entry/C07370) Lipids [http://www.genome.jp/kegg-bin/get_htext?br08002.keg](http://www.genome.jp/kegg-bin/get_htext?br08002.keg) Anatomical Therapeutic Chemical (ATC) classification [http://www.genome.jp/kegg-bin/get_htext?br08303.keg](http://www.genome.jp/kegg-bin/get_htext?br08303.keg) Drug Groups [http://www.genome.jp/kegg-bin/get_htext?br08330.keg](http://www.genome.jp/kegg-bin/get_htext?br08330.keg) \n41.   [LIPID MAPS](https://pubchem.ncbi.nlm.nih.gov/source/LIPID%20MAPS)ST 21:5;O5 [https://lipidmaps.org/databases/lmsd/LMST02030180](https://lipidmaps.org/databases/lmsd/LMST02030180) Lipid Classification [https://www.lipidmaps.org/](https://www.lipidmaps.org/) \n42.   [MassBank Europe](https://pubchem.ncbi.nlm.nih.gov/source/MassBank%20Europe)LICENSE [https://github.com/MassBank/MassBank-web/blob/main/MassBank-Project/LICENSE.txt](https://github.com/MassBank/MassBank-web/blob/main/MassBank-Project/LICENSE.txt) Prednisone [https://massbank.eu/MassBank/search?inchi_key=XOFYZVNMUHMLCC-ZPOLXVRWSA-N](https://massbank.eu/MassBank/search?inchi_key=XOFYZVNMUHMLCC-ZPOLXVRWSA-N) \n43.   [Metabolomics Workbench](https://pubchem.ncbi.nlm.nih.gov/source/Metabolomics%20Workbench)Prednisone [https://www.metabolomicsworkbench.org/data/StructureData.php?RegNo=35459](https://www.metabolomicsworkbench.org/data/StructureData.php?RegNo=35459) \n44.   [Nature Chemistry](https://pubchem.ncbi.nlm.nih.gov/source/Nature%20Chemistry)[https://pubchem.ncbi.nlm.nih.gov/substance/489166430](https://pubchem.ncbi.nlm.nih.gov/substance/489166430) \n45.   [NCI Cancer Drugs](https://pubchem.ncbi.nlm.nih.gov/source/NCI%20Cancer%20Drugs)LICENSE [https://www.cancer.gov/policies/copyright-reuse](https://www.cancer.gov/policies/copyright-reuse) Prednisone [https://www.cancer.gov/about-cancer/treatment/drugs/prednisone](https://www.cancer.gov/about-cancer/treatment/drugs/prednisone) \n46.   [NIAID ChemDB](https://pubchem.ncbi.nlm.nih.gov/source/NIAID%20ChemDB)LICENSE The NIAID ChemDB information received cannot be sold and is only to be used for research purposes.  (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione [https://pubchem.ncbi.nlm.nih.gov/substance/?source=niaid&sourceid=184445](https://pubchem.ncbi.nlm.nih.gov/substance/?source=niaid&sourceid=184445) \n47.   [NIPH Clinical Trials Search of Japan](https://pubchem.ncbi.nlm.nih.gov/source/NIPH%20Clinical%20Trials%20Search%20of%20Japan)[https://rctportal.niph.go.jp/en/](https://rctportal.niph.go.jp/en/) \n48.   [NLM RxNorm Terminology](https://pubchem.ncbi.nlm.nih.gov/source/NLM%20RxNorm%20Terminology)LICENSE The RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license. [https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html](https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html) prednisone [https://rxnav.nlm.nih.gov/id/rxnorm/8640](https://rxnav.nlm.nih.gov/id/rxnorm/8640) \n49.   [PharmGKB](https://pubchem.ncbi.nlm.nih.gov/source/PharmGKB)LICENSE PharmGKB data are subject to the Creative Commons Attribution-ShareALike 4.0 license ([https://creativecommons.org/licenses/by-sa/4.0/](https://creativecommons.org/licenses/by-sa/4.0/)).  [https://www.pharmgkb.org/page/policies](https://www.pharmgkb.org/page/policies) prednisone [https://www.pharmgkb.org/chemical/PA451100](https://www.pharmgkb.org/chemical/PA451100) \n50.   [Pharos](https://pubchem.ncbi.nlm.nih.gov/source/Pharos)LICENSE Data accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution. [https://pharos.nih.gov/about](https://pharos.nih.gov/about) prednisone [https://pharos.nih.gov/ligands/62BR9C5ANC22](https://pharos.nih.gov/ligands/62BR9C5ANC22) \n51.   [SpectraBase](https://pubchem.ncbi.nlm.nih.gov/source/SpectraBase)Prednisone [https://spectrabase.com/spectrum/2yM3So9r0r7](https://spectrabase.com/spectrum/2yM3So9r0r7) Prednisone [https://spectrabase.com/spectrum/7iCvY3D9gxQ](https://spectrabase.com/spectrum/7iCvY3D9gxQ) Prednisone [https://spectrabase.com/spectrum/JZ9JwLRAM85](https://spectrabase.com/spectrum/JZ9JwLRAM85) Prednisone [https://spectrabase.com/spectrum/9siTYwh3f4L](https://spectrabase.com/spectrum/9siTYwh3f4L) Prednisone [https://spectrabase.com/spectrum/5zz6gxT4Z27](https://spectrabase.com/spectrum/5zz6gxT4Z27) Prednisone [https://spectrabase.com/spectrum/EfYuJ78PNr1](https://spectrabase.com/spectrum/EfYuJ78PNr1) PREDNISONE U.S.P. [https://spectrabase.com/spectrum/AYFozxCHyD1](https://spectrabase.com/spectrum/AYFozxCHyD1) \n52.   [Springer Nature](https://pubchem.ncbi.nlm.nih.gov/source/Springer%20Nature)[https://pubchem.ncbi.nlm.nih.gov/substance/341186504](https://pubchem.ncbi.nlm.nih.gov/substance/341186504) [https://pubchem.ncbi.nlm.nih.gov/substance/341139615](https://pubchem.ncbi.nlm.nih.gov/substance/341139615) \n53.   [SpringerMaterials](https://pubchem.ncbi.nlm.nih.gov/source/SpringerMaterials)(8S,10R,13S,17R)-17-Hydroxy-17-(2-hydroxy-acetyl)-10,13-dimethyl-7,8,9,10,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,11-dione [https://materials.springer.com/substanceprofile/docs/smsid_vmhadjufiuojiuof](https://materials.springer.com/substanceprofile/docs/smsid_vmhadjufiuojiuof) \n54.   [The Cambridge Structural Database](https://pubchem.ncbi.nlm.nih.gov/source/The%20Cambridge%20Structural%20Database)[https://www.ccdc.cam.ac.uk/structures/Search?Ccdcid=681818](https://www.ccdc.cam.ac.uk/structures/Search?Ccdcid=681818) \n55.   [Thieme Chemistry](https://pubchem.ncbi.nlm.nih.gov/source/Thieme%20Chemistry)LICENSE The Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated. [https://creativecommons.org/licenses/by-nc-nd/4.0/](https://creativecommons.org/licenses/by-nc-nd/4.0/) [https://pubchem.ncbi.nlm.nih.gov/substance/516854526](https://pubchem.ncbi.nlm.nih.gov/substance/516854526) \n56.   [USGS Health-Based Screening Levels for Evaluating Water-Quality Data](https://pubchem.ncbi.nlm.nih.gov/source/USGS%20Health-Based%20Screening%20Levels%20for%20Evaluating%20Water-Quality%20Data)LICENSE [https://www.usgs.gov/legal](https://www.usgs.gov/legal) Prednisone [https://water.usgs.gov/water-resources/hbsl/index.html](https://water.usgs.gov/water-resources/hbsl/index.html) \n57.   [USITC Harmonized Tariff Schedule](https://pubchem.ncbi.nlm.nih.gov/source/USITC%20Harmonized%20Tariff%20Schedule)LICENSE [https://www.usitc.gov/disclaimers.htm](https://www.usitc.gov/disclaimers.htm) Prednisone [https://hts.usitc.gov/search?query=2937.21.00.30](https://hts.usitc.gov/search?query=2937.21.00.30) HTS Classification [https://hts.usitc.gov/](https://hts.usitc.gov/) \n58.   [WHO Anatomical Therapeutic Chemical (ATC) Classification](https://pubchem.ncbi.nlm.nih.gov/source/WHO%20Anatomical%20Therapeutic%20Chemical%20(ATC)%20Classification)LICENSE Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed. [https://www.whocc.no/copyright_disclaimer/](https://www.whocc.no/copyright_disclaimer/) Prednisone [https://atcddd.fhi.no/atc_ddd_index/?code=A07EA03](https://atcddd.fhi.no/atc_ddd_index/?code=A07EA03) Prednisone [https://atcddd.fhi.no/atc_ddd_index/?code=H02AB07](https://atcddd.fhi.no/atc_ddd_index/?code=H02AB07) ATC Classification [https://atcddd.fhi.no/atc_ddd_index/](https://atcddd.fhi.no/atc_ddd_index/) \n59.   [WHO ATCvet - Classification of Veterinary Medicines](https://pubchem.ncbi.nlm.nih.gov/source/WHO%20ATCvet%20-%20Classification%20of%20Veterinary%20Medicines)LICENSE Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed. [https://atcddd.fhi.no/copyright_disclaimer/](https://atcddd.fhi.no/copyright_disclaimer/) Prednisone [https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07EA03](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QA07EA03) Prednisone [https://atcddd.fhi.no/atcvet/atcvet_index/?code=QH02AB07](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QH02AB07) ATCvet Classification [https://atcddd.fhi.no/atcvet/atcvet/](https://atcddd.fhi.no/atcvet/atcvet/) \n60.   [Wikidata](https://pubchem.ncbi.nlm.nih.gov/source/Wikidata)LICENSE CCZero [https://creativecommons.org/publicdomain/zero/1.0/](https://creativecommons.org/publicdomain/zero/1.0/) prednisone [https://www.wikidata.org/wiki/Q424972](https://www.wikidata.org/wiki/Q424972) \n61.   [Wikipedia](https://pubchem.ncbi.nlm.nih.gov/source/Wikipedia)Prednisone [https://en.wikipedia.org/wiki/Prednisone](https://en.wikipedia.org/wiki/Prednisone) \n62.   [Medical Subject Headings (MeSH)](https://pubchem.ncbi.nlm.nih.gov/source/Medical%20Subject%20Headings%20(MeSH))LICENSE Works produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S. [https://www.nlm.nih.gov/copyright.html](https://www.nlm.nih.gov/copyright.html) Prednisone [https://id.nlm.nih.gov/mesh/M0017465.html](https://id.nlm.nih.gov/mesh/M0017465.html) deltacortene [https://id.nlm.nih.gov/mesh/M0362194.html](https://id.nlm.nih.gov/mesh/M0362194.html) Deltasone [https://id.nlm.nih.gov/mesh/M0351400.html](https://id.nlm.nih.gov/mesh/M0351400.html) Liquid Pred [https://id.nlm.nih.gov/mesh/M0351413.html](https://id.nlm.nih.gov/mesh/M0351413.html) Meticorten [https://id.nlm.nih.gov/mesh/M0351867.html](https://id.nlm.nih.gov/mesh/M0351867.html) Cortan [https://id.nlm.nih.gov/mesh/M0475829.html](https://id.nlm.nih.gov/mesh/M0475829.html) Decortin [https://id.nlm.nih.gov/mesh/M0475831.html](https://id.nlm.nih.gov/mesh/M0475831.html) Decortisyl [https://id.nlm.nih.gov/mesh/M0475832.html](https://id.nlm.nih.gov/mesh/M0475832.html) Orasone [https://id.nlm.nih.gov/mesh/M0475833.html](https://id.nlm.nih.gov/mesh/M0475833.html) Prednidib [https://id.nlm.nih.gov/mesh/M0475836.html](https://id.nlm.nih.gov/mesh/M0475836.html) Predniment [https://id.nlm.nih.gov/mesh/M0475841.html](https://id.nlm.nih.gov/mesh/M0475841.html) Sterapred [https://id.nlm.nih.gov/mesh/M0475848.html](https://id.nlm.nih.gov/mesh/M0475848.html) MeSH Tree [https://www.nlm.nih.gov/mesh/meshhome.html](https://www.nlm.nih.gov/mesh/meshhome.html) Anti-Inflammatory Agents [https://id.nlm.nih.gov/mesh/M0001333.html](https://id.nlm.nih.gov/mesh/M0001333.html) Glucocorticoids [https://id.nlm.nih.gov/mesh/M0009322.html](https://id.nlm.nih.gov/mesh/M0009322.html) Antineoplastic Agents, Hormonal [https://id.nlm.nih.gov/mesh/M0028300.html](https://id.nlm.nih.gov/mesh/M0028300.html) \n63.   PubChem[https://pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/) \n64.   [GHS Classification (UNECE)](https://pubchem.ncbi.nlm.nih.gov/source/GHS%20Classification%20(UNECE))GHS Classification [https://unece.org/about-ghs](https://unece.org/about-ghs) \n65.   [MolGenie](https://pubchem.ncbi.nlm.nih.gov/source/MolGenie)LICENSE CC-BY 4.0 [https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/) MolGenie Organic Chemistry Ontology [https://github.com/MolGenie/ontology/](https://github.com/MolGenie/ontology/) \n66.   [PATENTSCOPE (WIPO)](https://pubchem.ncbi.nlm.nih.gov/source/PATENTSCOPE%20(WIPO))SID 403029459 [https://pubchem.ncbi.nlm.nih.gov/substance/403029459](https://pubchem.ncbi.nlm.nih.gov/substance/403029459) \n67.   NCBI[https://www.ncbi.nlm.nih.gov/projects/linkout](https://www.ncbi.nlm.nih.gov/projects/linkout) \n\nCite\n\nDownload\n\nCONTENTS\n\n*   Title and Summary \n*   1 Structures Expand this menu \n*   2 Names and Identifiers Expand this menu \n*   3 Chemical and Physical Properties Expand this menu \n*   4 Spectral Information Expand this menu \n*   5 Related Records Expand this menu \n*   6 Chemical Vendors \n*   7 Drug and Medication Information Expand this menu \n*   8 Pharmacology and Biochemistry Expand this menu \n*   9 Use and Manufacturing Expand this menu \n*   10 Identification Expand this menu \n*   11 Safety and Hazards Expand this menu \n*   12 Toxicity Expand this menu \n*   13 Associated Disorders and Diseases \n*   14 Literature Expand this menu \n*   15 Patents Expand this menu \n*   16 Interactions and Pathways Expand this menu \n*   17 Biological Test Results Expand this menu \n*   18 Classification Expand this menu \n*   19 Information Sources \n\nConnect with NLM\n\n*   [Twitter](https://twitter.com/NLM_NIH \"SM-Twitter\")\n*   [Facebook](https://www.facebook.com/nationallibraryofmedicine \"SM-Facebook\")\n*   [YouTube](https://www.youtube.com/user/NLMNIH \"SM-Youtube\")\n\n[National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323)\n\n[Web Policies](https://www.nlm.nih.gov/web_policies.html)\n\n[FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office)\n\n[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n[Help](https://support.nlm.nih.gov/?pagename=pc-rest-compounds%3Apubchem%3Asummary%3ANONE)\n\n[Accessibility](https://www.nlm.nih.gov/accessibility.html)\n\n[Careers](https://www.nlm.nih.gov/careers/careers.html)\n\n*   [NLM](https://www.nlm.nih.gov/)\n*   [NIH](https://www.nih.gov/)\n*   [HHS](https://www.hhs.gov/)\n*   [USA.gov](https://www.usa.gov/)"
      },
      {
        "title": "Prednisone - StatPearls - NCBI Bookshelf - NIH",
        "url": "https://www.ncbi.nlm.nih.gov/books/NBK534809/",
        "content": "Prednisone is an FDA-approved, delayed-release corticosteroid indicated as an anti-inflammatory or immunosuppressive agent to treat a broad range of diseases, including immunosuppressive/endocrine, rheumatic, collagen, dermatologic, allergic states, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, acute exacerbations of multiple sclerosis, and as an anti-inflammatory and an antineoplastic agent. Prednisone is a corticosteroid (cortisone-like medicine or steroid). This medication acts on the immune system to help relieve swelling, redness, itching, and allergic reactions and is available only by prescription.(#article-35621.r1) According to the Endocrine Society's clinical practice guidelines for the perioperative evaluation and management of patients [...] ## Continuing Education Activity\n\nPrednisone is a synthetic glucocorticoid converted in the liver to the active metabolite prednisolone. This agent exerts anti-inflammatory and immunosuppressive effects by modulating immune activity and reducing inflammation. Indicated for various conditions—including endocrine, rheumatic, allergic, dermatologic, ophthalmic, respiratory, hematologic, neoplastic, and gastrointestinal disorders—prednisone remains a cornerstone in managing chronic and acute inflammatory diseases. Delayed-release formulations allow for timing flexibility in symptom control, particularly in conditions with circadian variation. [...] ## Mechanism of Action",
        "raw_content": "**Warning:**\nThe NCBI web site requires JavaScript to function.\n[more...](/guide/browsers/#enablejs \"Learn how to enable JavaScript\")\n\n![U.S. flag](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png)\n\nAn official website of the United States government\n\n![Dot gov](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg)\n\n**The .gov means it's official.**\n  \nFederal government websites often end in .gov or .mil. Before\nsharing sensitive information, make sure you're on a federal\ngovernment site.\n\n![Https](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg)\n\n**The site is secure.**\n  \nThe **https://** ensures that you are connecting to the\nofficial website and that any information you provide is encrypted\nand transmitted securely.\n\n![NIH NLM Logo](https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg)\n\n#### Account\n\n# [Bookshelf](/books/ \"Bookshelf home\")\n\n## \n\nNCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.\n\nStatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.\n\n![Cover of StatPearls](/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-statpearls-lrg.png)\n\n## StatPearls [Internet].\n\n# Prednisone\n\nYana Puckett; Preeti Patel; Abdullah A. Bokhari.\n\n#### Authors\n\nYana Puckett1; Preeti Patel; Abdullah A. Bokhari2.\n\n#### Authors\n\n#### Affiliations\n\nLast Update: April 26, 2025.\n\n## Continuing Education Activity\n\nPrednisone is a synthetic glucocorticoid converted in the liver to the active metabolite prednisolone. This agent exerts anti-inflammatory and immunosuppressive effects by modulating immune activity and reducing inflammation. Indicated for various conditions—including endocrine, rheumatic, allergic, dermatologic, ophthalmic, respiratory, hematologic, neoplastic, and gastrointestinal disorders—prednisone remains a cornerstone in managing chronic and acute inflammatory diseases. Delayed-release formulations allow for timing flexibility in symptom control, particularly in conditions with circadian variation.\n\nThis educational activity provides an in-depth review of prednisone's mechanism of action, pharmacokinetics, dosing strategies, and clinical applications. Special attention is given to drug interactions, contraindications, and adverse effects, including risks such as immunosuppression, osteoporosis, and glucose intolerance. Emphasis is placed on tailoring prednisone therapy to patient-specific variables and disease severity to enhance therapeutic benefit while minimizing harm. This activity reinforces the importance of interprofessional collaboration in monitoring and managing therapy across care settings. Understanding prednisone's pharmacological properties and clinical implications supports evidence-based decision-making and improves patient outcomes.\n\n**Objectives:**\n\n* Evaluate the mechanism of action of prednisone.\n* Identify the FDA-approved indications and off-label uses for prednisone.\n* Screen patients for contraindications associated with prednisone.\n* Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from prednisone therapy.\n\n[Access free multiple choice questions on this topic.](https://www.statpearls.com/account/trialuserreg/?articleid=35621&utm_source=pubmed&utm_campaign=reviews&utm_content=35621)\n\n## Indications\n\nPrednisone is a synthetic, anti-inflammatory glucocorticoid that is derived from cortisone. Prednisone is biologically inert and converted to prednisolone in the liver.\n\n**FDA-Approved Indications**\n\nPrednisone is an FDA-approved, delayed-release corticosteroid indicated as an anti-inflammatory or immunosuppressive agent to treat a broad range of diseases, including immunosuppressive/endocrine, rheumatic, collagen, dermatologic, allergic states, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, acute exacerbations of multiple sclerosis, and as an anti-inflammatory and an antineoplastic agent. Prednisone is a corticosteroid (cortisone-like medicine or steroid). This medication acts on the immune system to help relieve swelling, redness, itching, and allergic reactions and is available only by prescription.[[1]](#article-35621.r1) According to the Endocrine Society's clinical practice guidelines for the perioperative evaluation and management of patients receiving glucocorticoid therapy, continuation of the patient's usual daily glucocorticoid regimen, supplemented with a brief perioperative course of intravenous glucocorticoids tailored to the expected degree of surgical stress, is considered sufficient.[[2]](#article-35621.r2) Prednisone is also used as a treatment for urticaria.[[3]](#article-35621.r3)[[4]](#article-35621.r4) The Global Initiative for Asthma guidelines suggest prednisone use in asthma exacerbations.[[5]](#article-35621.r5) COPD exacerbations may also be treated with prednisone.[[6]](#article-35621.r6)\n\n**Off-Label Uses**\n\nPrednisone is commonly prescribed for other indications or in a different dosage than described in the label information. These are called off-label uses or non-FDA-approved indications. Other countries may mention \"approved\" or \"licensed\" indications that do not apply in the United States.[[7]](#article-35621.r7) Various corticosteroids have been used as part of treatment regimens during the COVID-19 pandemic. The Infectious Disease Society of America endorses dexamethasone for critically ill hospitalized patients. If dexamethasone is unavailable, equivalent total daily doses of alternative glucocorticoids (eg, methylprednisolone or prednisone) can be administered.[[8]](#article-35621.r8) For patients with giant cell arteritis, the American College of Rheumatology endorses the use of prednisone. For patients with threatened or imminent vision loss, IV glucocorticoids followed by high-dose steroids such as prednisone are used.[[9]](#article-35621.r9) As described in the KDIGO (Kidney Disease: Improving Global Outcomes) guidelines, for patients with proliferative lupus nephritis (LN), reduced-dose glucocorticoids following a short initial course of methylprednisolone pulses can be tried if kidney and extrarenal disease manifestations are adequately improving. Unless prescribed for extrarenal manifestations, maintenance phase doses of glucocorticoids should be tapered to the lowest effective dose and discontinued completely should complete clinical renal response be achieved for a minimum of 12 months. The tapering regimen typically begins with large doses (0.8 to 1.0 mg/kg, up to 80 mg) and tapers to <5 mg by week 24, depending on response.[[10]](#article-35621.r10)[[11]](#article-35621.r11)\n\n## Mechanism of Action\n\nSteroids like prednisone reduce inflammation by inhibiting phospholipase A2 (PLA2), an enzyme that releases arachidonic acid from cell membranes. This prevents the production of pro-inflammatory mediators like prostaglandins and leukotrienes.[[12]](#article-35621.r12) Prednisone reduces inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing increased capillary permeability. Prednisone also suppresses the immune system by decreasing the activity and volume of the immune system. The antineoplastic effects may correlate with inhibiting glucose transport, phosphorylation, or induction of cell death in immature lymphocytes. Prednisone may also demonstrate antiemetic effects by blocking the emetic center's cerebral innervation via prostaglandin inhibition.\n\nPrednisone is a prodrug to prednisolone, which mediates its glucocorticoid effects.[[13]](#article-35621.r13) Prednisone is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.\n\nAfter cell surface receptor attachment and entry into the cell, prednisone enters the nucleus, binds, and activates specific nuclear receptors, resulting in altered gene expression and inhibiting pro-inflammatory cytokine production. This agent decreases the number of circulating lymphocytes, inducing cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. The effects of glucocorticoids are subject to mediation by mechanisms that alter DNA replication within the nucleus.[[14]](#article-35621.r14)\n\n**Pharmacokinetics**\n\n**Absorption:** Prednisone is rapidly absorbed and metabolized to its active metabolite, prednisolone. The IR formulations achieve peak concentrations in about 2 hours, while the sustained-release formulations are designed to take effect in about 6 hours.\n\n**Distribution:**Prednisolone's distribution increases with dosage; a 0.15 mg/kg dose corresponds to a volume of distribution of 29.3 L, while a 0.30 mg/kg dose is associated with a volume of 44.2 L. Following IV administration, high concentrations are found in the kidneys, liver, spleen, lungs, small intestine, and bile.\n\n**Metabolism:** Prednisone is primarily converted into prednisolone in the liver.[[15]](#article-35621.r15) This drug is metabolized into other compounds, such as 6β-hydroxy-prednisone and 20α-dihydro-prednisone.\n\n**Elimination:** Prednisone metabolites, conjugated with sulfates and glucuronides, are excreted via the kidneys.[[16]](#article-35621.r16) Trace amounts of prednisone and its metabolites are excreted in bile.\n\n## Administration\n\n**Available Dosage Forms and Strengths**\n\nThe oral concentrate is available in a 30 mL bottle at 5 mg/mL; the oral solution is 5 mg/5 mL. Oral tablets are available in various strengths: 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 50 mg. A delayed-release oral tablet comes in 1 mg, 2 mg, and 5 mg strengths. Prednisone is also available in oral therapy pack forms for tapering/customized regimens.\n\n**Adult Dosage**\n\nPrednisone may be administered orally with food or milk to decrease gastrointestinal upset. Maximal adrenal cortex activity occurs between 2:00 AM and 8:00 AM, and minimal between 4:00 PM and midnight. Exogenous corticosteroids suppress endogenous adrenocortical activity the least when administered during the period of maximal activity (early morning) for single-dose administration. Therefore, prednisone should be administered in the morning before 9:00 AM. When administering large doses, the patient should use antacids between meals to help prevent peptic ulcers. Multiple-dose therapy should involve an even dose distribution in evenly spaced daily intervals. Antacids may also be administered between meals to help prevent peptic ulcers.[[17]](#article-35621.r17)\n\nThe delayed-release tablets should be swallowed whole without breaking, dividing, crushing, or chewing. The oral solution should be administered with the provided calibrated dropper only. Other forms of steroids may be available if the oral formulation is not well-tolerated, such as intramuscular (IM) or subcutaneous (SQ) administration. Depending on the disease process, topical steroids may also be an option. Best results occur when this medicine is taken with food. The medicine should be stored in a tightly closed container at room temperature, away from heat, moisture, and direct light. The oral liquid should not be frozen. Other routes of administration include liquid, solution, syrup, tablet, delayed-release tablets, nasal, rectal, injection, and intravenous. The dosage for individual conditions should be according to clinical condition and institutional protocol.\n\n**Specific Patient Populations**\n\n**Hepatic impairment:** Corticosteroid biotransformation is decreased in patients with cirrhosis; thus, half-life and bioavailability are increased.[[18]](#article-35621.r18)\n\n**Renal impairment:** In patients with renal dysfunction, specific dose adjustments are not outlined in the prescribing information. However, existing studies suggest that prednisolone may offer protective benefits for patients with IgA nephropathy.[[19]](#article-35621.r19)\n\n**Pregnancy considerations:**Fluorinated glucocorticoids, like dexamethasone and betamethasone, cross the placenta; however, prednisone and prednisolone are mostly metabolized before reaching the fetus.[[20]](#article-35621.r20) Prednisone may be administered for antiphospholipid syndrome in pregnant women.[[21]](#article-35621.r21) High-dose corticosteroids can increase the risk of hypertension and diabetes. However, when administered at lower doses (≤10 mg/kg daily), they are generally considered safe and are associated with minimal risk of adverse effects. In one study, researchers examined the risk of preterm birth in women with rheumatoid arthritis who were receiving prednisone. Higher doses (>10 mg/kg daily) correlated with an increased risk of preterm birth, while lower doses did not have the same risk.\n\nThe placenta helps break down non-fluorinated glucocorticoids, so only about 10% of the inactive metabolites pass into the fetal circulation when the maternal dose is <20 mg.[[22]](#article-35621.r22) Patients with immune thrombocytopenia (ITP) should be initiated on prednisone at 20 mg/d, adjusting to the minimum effective dose. Post-delivery, clinicians should monitor platelet count and taper corticosteroids slowly to prevent rapid declines and protect the mother's mental health.[[23]](#article-35621.r23) Corticosteroids are often necessary during pregnancy to manage conditions like rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. Some evidence suggests a slight increase in risk of conditions involving a cleft lip or palate during the first trimester. However, the review found no strong evidence linking systemic corticosteroid use during pregnancy to increased risks of low birth weight, preterm birth, or preeclampsia.[[24]](#article-35621.r24)\n\n**Breastfeeding considerations:**Prednisone levels in breast milk are low, with no reported adverse effects on breastfed infants. Clinicians are advised to wait 4 hours after a dose before breastfeeding. Higher corticosteroid doses can cause a temporary reduction in lactation when administered systemically.[[25]](#article-35621.r25)\n\n**Pediatric patients:**According to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, oral prednisone or pulsed intravenous methylprednisolone should be administered to children with mild or moderate immunoglobulin-A vasculitis–associated nephritis (IgAVN).[[26]](#article-35621.r26)\n\n**Older patients:**Clinicians should administer the lowest effective dose possible.\n\n## Adverse Effects\n\nAdverse effects are common in patients receiving glucocorticoids in high doses or over a long period. Regimens involving prednisone administration of ≥40 mg daily are considered \"high-dose.\" The primary adverse effects associated with prednisone therapy include hyperglycemia, insomnia, increased appetite, hypertension, osteoporosis, edema, adrenal suppression, cataracts, delayed wound healing, skin fragility, weight gain, increased risk of infections, and fractures. Potential cardiovascular and metabolic effects include hypertension, hyperglycemia, and dyslipidemia.[[27]](#article-35621.r27)\n\nOther adverse reactions include adrenal insufficiency, particularly for patients with sepsis or undergoing stressful procedures; this is typically diagnosable when the patient is hypotensive and not responsive to fluids, vasopressors, or cardiogenic medications. Once adrenal insufficiency is suspected, treatment should be initiated immediately with a dose of 100 mg of hydrocortisone every 8 hours. Osteonecrosis of the femoral head has also been reported.[[28]](#article-35621.r28)\n\n**Drug-Drug Interactions**\n\n## Contraindications\n\nPrednisone is contraindicated for patients with documented hypersensitivity to the drug or formulation components and systemic fungal infections.[[30]](#article-35621.r30)[[31]](#article-35621.r31) Administering live or live-attenuated vaccines is also contraindicated during immunosuppressive prednisone therapy.\n\n**Warnings and Precautions**\n\n## Monitoring\n\nPatients receiving prednisone are at an increased risk for allergic reactions (itching or hives, swelling in the face or hands, swelling or tingling in the mouth or throat, chest tightness, trouble breathing), dark freckles, skin color changes, coldness, weakness, tiredness, nausea, vomiting, weight loss, rapid weight gain, depression, unusual thoughts, feelings, or behaviors, difficulty sleeping, fever, chills, cough, sore throat, and body aches, muscle pain or weakness, severe stomach pain, red or black stools, skin changes or growths, vision changes, eye pain, or headache.\n\nClinicians must monitor patients with giant cell arteritis because increased cumulative glucocorticoid exposure is associated with an increased risk of glucocorticoid-related adverse effects.[[39]](#article-35621.r39)\n\nDoctors can also track serum glucose, blood pressure, electrolytes, weight, bone mineral density, hemoglobin, occult blood loss, growth in pediatric patients, and infections. The HPA axis suppression should also be assessed using the morning cortisol test, adrenocorticotropic hormone stimulation test, and the urinary free cortisol test.\n\nWhen monitoring, it is essential to remember that the elimination half-life of prednisone is 3 to 4 hours in adults and 1 to 2 hours in children.\n\nMore common symptoms to monitor include aggression, agitation, blurred vision, a decrease in the amount of urine, dizziness, irregular heartbeat or pulse, headache, irritability, mood changes, irregular breathing, numbness or tingling in the arms or legs, pounding in the ears, shortness of breath, swelling of the fingers, hands, feet, or lower legs, trouble thinking, speaking, or walking, difficulty with breathing at rest, or weight gain.\n\nMonitoring patients receiving glucocorticoid therapy involves measuring weight, height, body mass index (BMI), and blood pressure. The routine investigations are complete blood count (CBC), glucose levels, and lipid profiles. Bone health should be assessed annually with bone mineral density (BMD) checks, particularly 12 months after starting glucocorticoids. Lateral spine X-rays are recommended for adults older than 65, and FRAX can be used to estimate fracture risk. For children, baseline BMD and X-rays are advised after 3 months of glucocorticoid use, with follow-ups if risk factors persist. HPA-axis functioning and growth in children and adolescents should be closely monitored, with referrals to specialists made for any growth issues. Lipid levels and cardiovascular risk should be assessed at 1 month and then every 6 to 12 months, using the Framingham Risk Score to evaluate cardiovascular risk. Hyperglycemia and diabetes should be monitored through regular glucose screenings, with annual checks recommended for at-risk children. Annual ophthalmologic exams are recommended, with earlier referrals for those at risk of glaucoma or other eye conditions.[[40]](#article-35621.r40)\n\n## Toxicity\n\n**Signs and Symptoms of Overdose**\n\nLike any anti-inflammatory agent, steroid toxicity is treated similarly to any non-steroidal anti-inflammatory drug overdose or toxicity. Although the frequency of life-threatening complications from steroids and NSAID overdose is low, the overdose response ranges from no symptoms to death despite intensive-care treatment. Most symptoms are due to the excessive pharmacological action of steroids and NSAIDs and include abdominal pain, nausea, vomiting, drowsiness, dizziness, headache, ear ringing, and nystagmus. A significant dose-response relationship occurs with the long-term use of systemic corticosteroids and the development of systemic corticosteroid-related complications for patients with severe asthma, resulting in an increased burden and costs on the healthcare system.[[41]](#article-35621.r41)\n\n**Management of Overdose**\n\nAssessment of all organ systems can help identify problems. If necessary, hypertension and salt retention should be treated with salt restriction and diuretics.[[42]](#article-35621.r42) Gastrointestinal perforation requires surgical intervention. Antibiotics and antifungals should be prescribed for infections. An iatrogenic crushing syndrome caused by a supplement containing dexamethasone has been reported.[[43]](#article-35621.r43) Gradual tapering of corticosteroids is advisable to prevent adrenal insufficiency. Potent proton pump inhibitors should be prescribed for gastroprotection. Hypokalemia can be treated by replacement. Steroid-induced psychosis can be managed with antipsychotics.[[44]](#article-35621.r44) Hyperglycemia should be treated with insulin in critically ill patients. After stabilization, patients should be prescribed vitamin D and calcium. Mitotane and ketoconazole decrease cortisol production and should be used only under the supervision of an endocrinologist.[[45]](#article-35621.r45)\n\n## Enhancing Healthcare Team Outcomes\n\nThe management of adverse drug reactions induced by steroids requires an interprofessional team of healthcare professionals, including a nurse, laboratory technologists, pharmacists, and several physicians in different specialties. Without proper management, the adverse effects of prednisone overdose are high. Systemic corticosteroids have extensive use in the treatment of various autoimmune and inflammatory disorders. Prolonged use, especially at high doses of 40 mg daily, can cause serious adverse effects. The most common systems involved include the gastrointestinal (GI), musculoskeletal, endocrine, cardiovascular, and central nervous system (CNS). Prednisone's adverse effects can be minimized by monitoring the patient and putting preventative measures in place. Some of these preventive measures include using lower-potency dosages and starting patients on the lowest effective dosage, as per guidelines. The patient needs to be informed of the adverse effects so they may understand and be aware of making the proper lifestyle modifications to help reduce the risk of adverse effects. Patients should receive counsel to seek medical attention if they experience any of these known adverse effects. A steroid treatment card can be recommended to show to all healthcare professionals involved in their care and management. The differences in monitoring and care between adults and children should be noted, particularly regarding growth curve complications, adrenal suppression, and osteoporosis.[[40]](#article-35621.r40)\n\nTo achieve this, interprofessional collaboration is essential. Clinicians prescribe the drug and need to inform the patients about the adverse event profile; this is often the task of the nursing staff. They can also assess patient compliance and inform the prescribing clinician about any potential issues. Pharmacists can counsel patients on proper administration and reinforce the importance of reporting adverse events. Pharmacists must also perform medication reconciliation and report any potential interactions to the prescribing office.[[46]](#article-35621.r46) An interprofessional team approach with open communication among physicians, advanced practice providers, nurses, and pharmacists can enhance patient outcomes and mitigate the adverse reactions associated with prednisone therapy.\n\n## Review Questions\n\n## References\n\n**Disclosure:** Yana Puckett declares no relevant financial relationships with ineligible companies.\n\n**Disclosure:** Preeti Patel declares no relevant financial relationships with ineligible companies.\n\n**Disclosure:** Abdullah Bokhari declares no relevant financial relationships with ineligible companies.\n\nThis book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)\n([http://creativecommons.org/licenses/by-nc-nd/4.0/](https://creativecommons.org/licenses/by-nc-nd/4.0/)), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.\n\n### Views\n\n### In this Page\n\n### Related information\n\n### Similar articles in PubMed\n\n### Recent Activity\n\nYour browsing activity is empty.\n\nActivity recording is turned off.\n\n[Turn recording back on](javascript:historyDisplayState('HTOn'))\n\n[Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html)\n\nNational Library of Medicine  \n[8600 Rockville Pike  \nBethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323)\n\n[Web Policies](https://www.nlm.nih.gov/web_policies.html)  \n[FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office)  \n[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n[Help](https://support.nlm.nih.gov/)  \n[Accessibility](https://www.nlm.nih.gov/accessibility.html)  \n[Careers](https://www.nlm.nih.gov/careers/careers.html)\n\n![statistics](/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK534809&ncbi_domain=statpearls&ncbi_report=record&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK534809/&ncbi_pagename=Prednisone - StatPearls - NCBI Bookshelf&ncbi_bookparttype=chapter&ncbi_app=bookshelf)"
      },
      {
        "title": "Prednisone: MedlinePlus Drug Information",
        "url": "https://www.nlm.nih.gov/medlineplus/druginfo/meds/a601102.html",
        "content": "Prednisone is used alone or with other medications to treat the symptoms of low corticosteroid levels (lack of certain substances that are usually produced by the body and are needed for normal body functioning). Prednisone is also used to treat other conditions in patients with normal corticosteroid levels. These conditions include certain types of arthritis; severe allergic reactions; multiple sclerosis (a disease in which the nerves do not function properly); lupus (a disease in which the body attacks many of its own organs); and certain conditions that affect the lungs, skin, eyes, kidneys blood, thyroid, stomach, and intestines. Prednisone is also sometimes used to treat the symptoms of certain types of cancer. Prednisone is in a class of medications called corticosteroids. It works [...] in a class of medications called corticosteroids. It works to treat patients with low levels of corticosteroids by replacing steroids that are normally produced naturally by the body. It works to treat other conditions by reducing swelling and redness and by changing the way the immune system works. [...] vision problems\n eye pain, redness, or tearing\n sore throat, fever, chills, cough, or other signs of infection\n seizures\n depression\n loss of contact with reality\n confusion\n muscle twitching or tightening\n shaking of the hands that you cannot control\n numbness, burning, or tingling in the face, arms, legs, feet, or hands\n upset stomach\n vomiting\n lightheadedness\n irregular heartbeat\n sudden weight gain\n shortness of breath, especially during the night\n dry, hacking cough\n swelling or pain in the stomach\n swelling of the eyes, face, lips, tongue, throat, arms, hands, feet, ankles, or lower legs\n difficulty breathing or swallowing\n rash\n hives\n itching",
        "raw_content": "[Skip navigation](#start)\n\nAn official website of the United States government\n\nHere’s how you know\n\n**Official websites use .gov**  \nA **.gov** website belongs to an official government organization in the United States.\n\n**Secure .gov websites use HTTPS**  \nA **lock** ( ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.\n\n[National Library of Medicine](https://www.nlm.nih.gov/)\n\n* [Health Topics](https://medlineplus.gov/healthtopics.html)\n* [Drugs & Supplements](https://medlineplus.gov/druginformation.html)\n* [Genetics](https://medlineplus.gov/genetics/)\n* [Medical Tests](https://medlineplus.gov/lab-tests/)\n* [Medical Encyclopedia](https://medlineplus.gov/encyclopedia.html)\n* [About MedlinePlus](https://medlineplus.gov/about/)\n\n* [About MedlinePlus](https://medlineplus.gov/about/)\n* [What's New](https://medlineplus.gov/whatsnew/)\n* [Site Map](https://medlineplus.gov/sitemap.html)\n* [Customer Support](https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01231&category=medlineplus&from=https%3A//medlineplus.gov/skincancer.html)\n\n* [Health Topics](https://medlineplus.gov/healthtopics.html)\n* [Drugs & Supplements](https://medlineplus.gov/druginformation.html)\n* [Genetics](https://medlineplus.gov/genetics/)\n* [Medical Tests](https://medlineplus.gov/lab-tests/)\n* [Medical Encyclopedia](https://medlineplus.gov/encyclopedia.html)\n\n[Español](../../spanish/druginfo/meds/a601102-es.html \"Español\")\n\nYou Are Here:\n\n[Home](https://medlineplus.gov) →\n\n[Drugs, Herbs and Supplements](https://medlineplus.gov/druginformation.html) →\n\nPrednisone\n\nURL of this page: https://medlineplus.gov/druginfo/meds/a601102.html\n\n# Prednisone\n\npronounced as (pred' ni sone)\n\n* [Why is this medication prescribed?](#why)\n* [How should this medicine be used?](#how)\n* [Other uses for this medicine](#other-uses)\n* [What special precautions should I follow?](#precautions)\n* [What special dietary instructions should I follow?](#special-dietary)\n* [What should I do if I forget a dose?](#if-i-forget)\n* [What side effects can this medication cause?](#side-effects)\n* [What should I know about storage and disposal of this medication?](#storage-conditions)\n* [In case of emergency/overdose](#overdose)\n* [What other information should I know?](#other-information)\n* [Brand names](#brand-name-1)\n\n## Why is this medication prescribed?\n\nPrednisone is used alone or with other medications to treat the symptoms of low corticosteroid levels (lack of certain substances that are usually produced by the body and are needed for normal body functioning). Prednisone is also used to treat other conditions in patients with normal corticosteroid levels. These conditions include certain types of arthritis; severe allergic reactions; multiple sclerosis (a disease in which the nerves do not function properly); lupus (a disease in which the body attacks many of its own organs); and certain conditions that affect the lungs, skin, eyes, kidneys blood, thyroid, stomach, and intestines. Prednisone is also sometimes used to treat the symptoms of certain types of cancer. Prednisone is in a class of medications called corticosteroids. It works to treat patients with low levels of corticosteroids by replacing steroids that are normally produced naturally by the body. It works to treat other conditions by reducing swelling and redness and by changing the way the immune system works.\n\n## How should this medicine be used?\n\nPrednisone comes as a tablet, delayed-release tablet, as a solution (liquid), and as a concentrated solution to take by mouth. Prednisone is usually taken with food one to four times a day or once every other day. Your doctor will probably tell you to take your dose(s) of prednisone at certain time(s) of day every day. Your personal dosing schedule will depend on your condition and on how you respond to treatment. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take prednisone exactly as directed. Do not take more or less of it or take it more often or for a longer period of time than prescribed by your doctor.\n\nIf you are taking the concentrated solution, use the specially marked dropper that comes with the medication to measure your dose. You may mix the concentrated solution with juice, other flavored liquids, or soft foods such as applesauce.\n\nSwallow the delayed-release tablet whole; do not chew or crush it.\n\nYour doctor may change your dose of prednisone often during your treatment to be sure that you are always taking the lowest dose that works for you. Your doctor may also need to change your dose if you experience unusual stress on your body such as surgery, illness, infection, or a severe asthma attack. Tell your doctor if your symptoms improve or get worse or if you get sick or have any changes in your health during your treatment.\n\nIf you are taking prednisone to treat a long-lasting disease, the medication may help control your condition but will not cure it. Continue to take prednisone even if you feel well. Do not stop taking prednisone without talking to your doctor. If you suddenly stop taking prednisone, your body may not have enough natural steroids to function normally. This may cause symptoms such as extreme tiredness, weakness, slowed movements, upset stomach, weight loss, changes in skin color, sores in the mouth, and craving for salt. Call your doctor if you experience these or other unusual symptoms while you are taking decreasing doses of prednisone or after you stop taking the medication.\n\n## Other uses for this medicine\n\nPrednisone is also sometimes used with antibiotics to treat a certain type of pneumonia in patients with acquired immunodeficiency syndrome (AIDS). Talk to your doctor about the risks of using this drug for your condition.\n\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\n\n## What special precautions should I follow?\n\n### Before taking prednisone,\n\n* tell your doctor and pharmacist if you are allergic to prednisone, any other medications, or any of the inactive ingredients in prednisone tablets or solutions. Ask your doctor or pharmacist for a list of the inactive ingredients.\n* tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take while taking prednisone. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.)\n* the following nonprescription or herbal products may interact with prednisone: St. John's wort, cimetidine (Tagamet), aspirin. Be sure to let your doctor and pharmacist know that you are taking these medications before you start taking prednisone. Do not start any of these medications while taking prednisone without discussing with your healthcare provider..\n* tell your doctor if you have an eye infection now or have ever had eye infections that come and go and if you have or have ever had threadworms (a type of worm that can live inside the body); diabetes; high blood pressure; emotional problems; mental illness; myasthenia gravis (a condition in which the muscles become weak); osteoporosis (condition in which the bones become weak and fragile and can break easily); seizures; tuberculosis (TB); ulcers; or liver, kidney, intestinal, heart, or thyroid disease.\n* tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking prednisone, call your doctor.\n* if you are having surgery, including dental surgery, or need emergency medical treatment, tell the doctor, dentist, or medical staff that you are taking or have recently stopped taking prednisone. You should carry a card or wear a bracelet with this information in case you are unable to speak in a medical emergency.\n* do not have any vaccinations (shots to prevent diseases) without talking to your doctor.\n* you should know that prednisone may decrease your ability to fight infection and may prevent you from developing symptoms if you get an infection. Stay away from people who are sick and wash your hands often while you are taking this medication. Be sure to avoid people who have chicken pox or measles. Call your doctor immediately if you think you may have been around someone who had chicken pox or measles.\n\n## What special dietary instructions should I follow?\n\nYour doctor may instruct you to follow a low-salt, high potassium, or high calcium diet. Your doctor may also prescribe or recommend a calcium or potassium supplement. Follow these directions carefully.\n\nTalk to your doctor about eating grapefruit and drinking grapefruit juice while you are taking this medication.\n\n## What should I do if I forget a dose?\n\nWhen you start to take prednisone, ask your doctor what to do if you forget to take a dose. Write down these instructions so that you can refer to them later. Call your doctor or pharmacist if you miss a dose and do not know what to do. Do not take a double dose to make up for a missed dose.\n\n## What side effects can this medication cause?\n\n### Prednisone may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\n\n* headache\n* dizziness\n* difficulty falling asleep or staying asleep\n* inappropriate happiness\n* extreme changes in mood\n* changes in personality\n* bulging eyes\n* acne\n* thin, fragile skin\n* red or purple blotches or lines under the skin\n* slowed healing of cuts and bruises\n* increased hair growth\n* changes in the way fat is spread around the body\n* extreme tiredness\n* weak muscles\n* irregular or absent menstrual periods\n* decreased sexual desire\n* heartburn\n* increased sweating\n\n### Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately:\n\n* vision problems\n* eye pain, redness, or tearing\n* sore throat, fever, chills, cough, or other signs of infection\n* seizures\n* depression\n* loss of contact with reality\n* confusion\n* muscle twitching or tightening\n* shaking of the hands that you cannot control\n* numbness, burning, or tingling in the face, arms, legs, feet, or hands\n* upset stomach\n* vomiting\n* lightheadedness\n* irregular heartbeat\n* sudden weight gain\n* shortness of breath, especially during the night\n* dry, hacking cough\n* swelling or pain in the stomach\n* swelling of the eyes, face, lips, tongue, throat, arms, hands, feet, ankles, or lower legs\n* difficulty breathing or swallowing\n* rash\n* hives\n* itching\n\nPrednisone may slow growth and development in children. Your child's doctor will watch his or her growth carefully. Talk to your child's doctor about the risks of giving prednisone to your child.\n\nPrednisone may increase the risk that you will develop osteoporosis. Talk to your doctor about the risks of taking prednisone and about things that you can do to decrease the chance that you will develop osteoporosis.\n\nSome patients who took prednisone or similar medications developed a type of cancer called Kaposi's sarcoma. Talk to your doctor about the risks of taking prednisone.\n\nPrednisone may cause other side effects. Call your doctor if you have any unusual problems while you are taking this medication.\n\nIf you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (<https://www.fda.gov/Safety/MedWatch>) or by phone (1-800-332-1088).\n\n## What should I know about storage and disposal of this medication?\n\nKeep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).\n\nKeep all medication out of sight and reach of children as many containers are not child-resistant. Always lock safety caps. Place the medication in a safe location – one that is up and away and out of their sight and reach. <https://www.upandaway.org>\n\nDispose of unneeded medications in a way so that pets, children, and other people cannot take them. Do not flush this medication down the toilet. Use a medicine take-back program. Talk to your pharmacist about take-back programs in your community. Visit the FDA's Safe Disposal of Medicines website <https://goo.gl/c4Rm4p> for more information.\n\n## In case of emergency/overdose\n\nIn case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at <https://www.poisonhelp.org/help>. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.\n\n## What other information should I know?\n\nKeep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your body's response to prednisone.\n\nIf you are having any skin tests such as allergy tests or tuberculosis tests, tell the doctor or technician that you are taking prednisone.\n\nDo not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.\n\nKeep a written list of all of the prescription and nonprescription (over-the-counter) medicines, vitamins, minerals, and dietary supplements you are taking. Bring this list with you each time you visit a doctor or if you are admitted to the hospital. You should carry the list with you in case of emergencies.\n\n## Brand names\n\n* Rayos®\n* Cortan®[¶](#discontinued)\n* Deltasone®[¶](#discontinued)\n* Orasone®[¶](#discontinued)\n* Prednisone Intensol\n* Sterapred®\n* Sterapred® DS\n\n¶ This branded product is no longer on the market. Generic alternatives may be available.\n\nLast Revised - 06/20/2024\n\n[Browse Drugs and Medicines](https://medlineplus.gov/druginformation.html)"
      }
    ]
  },
  "firm_searches": {
    "[\"merck\"]": {
      "fetched_at": "2026-01-16T12:31:04.998023+00:00",
      "firms": [
        "Merck"
      ],
      "results": [
        {
          "title": "FDA Approves LYNPARZA® (olaparib) Plus Abiraterone ...",
          "url": "https://www.merck.com/news/fda-approves-lynparza-olaparibplus-abiraterone-and-prednisone-or-prednisolone-for-treatment-of-adult-patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer-mcrpc/",
          "content": "LYNPARZA combination showed a clinically meaningful reduction in risk of disease progression or death in these patients in the Phase 3 PROpel trial.",
          "raw_content": "[![Site logo](https://www.merck.com/wp-content/uploads/sites/124/2025/08/site-logo.svg)](https://www.merck.com/ \"Merck.com\")\n\n![Site logo](https://www.merck.com/wp-content/uploads/sites/124/2025/08/site-logo.svg)\n![](https://www.merck.com/wp-content/themes/cex-wpvip-mhh-mhh2-mcc-theme/images/search-white.svg)\n![]()\n![](https://www.merck.com/wp-content/themes/cex-wpvip-mhh-mhh2-mcc-theme/images/burger-white.svg)\n![]()\n![Scientist reviewing test tubes]()\n\n#### Who we are\n\n## What can we help you find?\n\n# FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)\n\nJune 1, 2023 6:45 am EDT\n\n**LYNPARZA combination showed a clinically meaningful reduction in risk of disease progression or death in these patients in the Phase 3 PROpel trial**\n\n**First approval of a PARP inhibitor in combination with a new hormonal agent in mCRPC**\n\nRAHWAY, N.J.--(BUSINESS WIRE)-- \nAstraZeneca and Merck (NYSE: MRK),known as MSD outside of the United States and Canada, today announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with deleterious or suspected deleterious *BRCA*-mutated (*BRCA*m) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n\nThis approval was based on an exploratory subgroup analysis of the Phase 3 PROpel trial which showed that LYNPARZAplus abi/pred demonstrated clinically meaningful improvements in both radiographic progression-free survival (rPFS) (HR=0.24 [95% CI, 0.12-0.45]) and overall survival (OS) (HR=0.30 [95% CI, 0.15-0.59]) versus abi/pred alone in patients with *BRCA*m mCRPC. In the *BRCA*m subgroup (n=85), the median rPFS and OS were not reached (NR) in those receiving LYNPARZA plus abi/pred (95% CI, NR-NR for both rPFS and OS), compared to a median of eight months rPFS (95% CI, 6-15) and 23 months OS (95% CI, 18-34) in those receiving placebo plus abi/pred. As previously reported, there was a statistically significant improvement in rPFS in the full intention-to-treat (ITT) population in the PROpel trial (n=796). Based on exploratory analyses of rPFS and OS in the *BRCA*m and non-*BRCA*m subgroups (non-*BRCA* subgroup rPFS HR=0.77 [95% CI, 0.63-0.96]; non-*BRCA* subgroup OS HR=0.92 [95% CI, 0.74-1.14]), the FDA concluded that the improvement in the ITT population was primarily attributed to the results seen in the subgroup of patients with *BRCA*m.\n\nIn the ITT population, the most common adverse reactions (ARs) in patients who received LYNPARZA plus abi/pred (≥10%) were anemia (48%), fatigue (38%), nausea (30%), diarrhea (19%), decreased appetite (16%), lymphopenia and dizziness (14% each) and abdominal pain (13%). Among patients who received LYNPARZA in combination with abi/pred, 16% permanently discontinued treatment with LYNPARZA due to an AR, 48% had a dosage interruption of LYNPARZA and 21% had their dose of LYNPARZA reduced.\n\nIn the U.S., prostate cancer is the second most common cancer in men, and despite an increase in the number of available therapies for patients with mCRPC, five-year survival remains low.Many patients with mCRPC are only able to receive one line of therapy, as the disease can progress quickly. Approximately 10% of patients with mCRPC will have *BRCA* mutations, which are associated with a poor prognosis and worse outcomes.\n\nAndrew Armstrong, MD, ScM, Duke Cancer Institute, Durham, N.C. and an investigator in the trial, said, “Preventing or delaying radiographic progression is an important clinical endpoint in assessing cancer treatment and is very important to patients, their caregivers and their families. The PROpel results showed the LYNPARZA combination demonstrated a notable clinically meaningful benefit that should rapidly be considered as the standard of care treatment for patients with *BRCA*m mCRPC.”\n\nDave Fredrickson, executive vice president, oncology business unit, AstraZeneca, said, “There is a critical unmet need for new first-line treatment options for patients with *BRCA*m mCRPC, and this approval underscores the importance of *BRCA* testing at metastatic diagnosis. We look forward to bringing the benefit of this LYNPARZA combination to patients earlier in their treatment.”\n\nEliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, said, “It is imperative that we create new ways to treat advanced cancers and help improve patient outcomes by building on the current standard of care. In PROpel, the LYNPARZA combination improved rPFS and OS for the subgroup of patients with *BRCA*m mCRPC. This approval reinforces the importance of routine testing for genetic mutations at metastatic diagnosis to help guide clinical decisions.”\n\nThe rPFS results from the ITT population of the Phase 3 PROpel trial were published in *NEJM Evidence* in June 2022.\n\nLYNPARZA plus abi/pred is approved in several other countries for the treatment of appropriate adult patients with mCRPC based on the PROpel trial. In the European Union (EU), LYNPARZA plus abi/pred is approved for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated, regardless of biomarker status.\n\nIn the U.S., LYNPARZA was previously approved for patients with homologous recombination repair gene-mutated mCRPC who have progressed following prior treatment with enzalutamide or abiraterone, and in the EU, Japan and China for patients with *BRCA*m mCRPC who have progressed following prior therapy that included a new hormonal agent (NHA). These approvals were based on the data from the Phase 3 PROfound trial. For the U.S. indication, patients are selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n\n**About PROpel**\n\nPROpel (ClinicalTrials.gov, NCT03732820) is a randomized, double-blind Phase 3 trial testing the efficacy, safety and tolerability of LYNPARZAversus placebo when given in addition to abi/pred in 796 patients with mCRPC who had not received prior chemotherapy or NHAs in the mCRPC setting. The major efficacy outcome was rPFS as assessed by investigator per RECIST v1.1 and Prostate Cancer Working Group (bone) criteria. Overall survival was an additional efficacy outcome measure. Exploratory subgroup analyses were subsequently conducted to assess efficacy in patients with *BRCA*m (n=85) and patients without identified *BRCA*m (n=711). *BRCA*-mutated status was assessed after randomization and before primary analysis by both next generation sequencing-based tumor tissue and circulating tumor DNA tests. *BRCA*-mutated classification criteria in line with the FDA-approved assays were used to determine the deleterious and suspected deleterious somatic or germline mutation status of patients. *BRCA* was not a stratification factor in PROpel, and the *BRCA*m and non-*BRCA*m subgroup analyses were not controlled for Type 1 error.\n\n**IMPORTANT SAFETY INFORMATION**\n\n**CONTRAINDICATIONS**\n\nThere are no contraindications for LYNPARZA.\n\n**WARNINGS AND PRECAUTIONS**\n\n**Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML):** Occurred in approximately 1.5% of patients exposed to LYNPARZA monotherapy, and the majority of events had a fatal outcome. The median duration of therapy in patients who developed MDS/AML was 2 years (range: <6 months to >10 years). All of these patients had previous chemotherapy with platinum agents and/or other DNA-damaging agents, including radiotherapy.\n\nDo not start LYNPARZA until patients have recovered from hematological toxicity caused by previous chemotherapy (≤Grade 1). Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities, interrupt LYNPARZA and monitor blood count weekly until recovery.\n\nIf the levels have not recovered to Grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA if MDS/AML is confirmed.\n\n**Pneumonitis:** Occurred in 0.8% of patients exposed to LYNPARZA monotherapy, and some cases were fatal. If patients present with new or worsening respiratory symptoms such as dyspnea, cough, and fever, or a radiological abnormality occurs, interrupt LYNPARZA treatment and initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is confirmed and treat patient appropriately.\n\n**Venous Thromboembolism (VTE):** Including severe or fatal pulmonary embolism (PE) occurred in patients treated with LYNPARZA. In the combined data of two randomized, placebo-controlled clinical studies (PROfound and PROpel) in patients with metastatic castration-resistant prostate cancer (N=1180), VTE occurred in 8% of patients who received LYNPARZA, including pulmonary embolism in 6%. In the control arms, VTE occurred in 2.5%, including pulmonary embolism in 1.5%. Monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism, and treat as medically appropriate, which may include long-term anticoagulation as clinically indicated.\n\n**Embryo-Fetal Toxicity:** Based on its mechanism of action and findings in animals, LYNPARZA can cause fetal harm. Verify pregnancy status in females of reproductive potential prior to initiating treatment.\n\n*Females*\n\nAdvise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for 6 months following the last dose.\n\n*Males*\n\nAdvise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months following the last dose of LYNPARZA and to not donate sperm during this time.\n\n**ADVERSE REACTIONS—First-Line Maintenance *BRCA*m Advanced Ovarian Cancer**\n\nMost common adverse reactions (Grades 1-4) in ≥10% of patients who received LYNPARZA in the **first-line maintenance setting** for **SOLO-1** were: nausea (77%), fatigue (67%), abdominal pain (45%), vomiting (40%), anemia (38%), diarrhea (37%), constipation (28%), upper respiratory tract infection/influenza/nasopharyngitis/bronchitis (28%), dysgeusia (26%), decreased appetite (20%), dizziness (20%), neutropenia (17%), dyspepsia (17%), dyspnea (15%), leukopenia (13%), urinary tract infection (13%), thrombocytopenia (11%), and stomatitis (11%).\n\nMost common laboratory abnormalities (Grades 1-4) in ≥25% of patients who received LYNPARZA in the **first-line maintenance setting** for **SOLO-1** were: decrease in hemoglobin (87%), increase in mean corpuscular volume (87%), decrease in leukocytes (70%), decrease in lymphocytes (67%), decrease in absolute neutrophil count (51%), decrease in platelets (35%), and increase in serum creatinine (34%).\n\n**ADVERSE REACTIONS—First-Line Maintenance Advanced Ovarian Cancer in Combination with Bevacizumab**\n\nMost common adverse reactions (Grades 1-4) in ≥10% of patients treated with LYNPARZA/bevacizumab and at a ≥5% frequency compared to placebo/bevacizumab in the **first-line maintenance setting** for **PAOLA-1** were: nausea (53%), fatigue (including asthenia) (53%), anemia (41%), lymphopenia (24%), vomiting (22%), and leukopenia (18%). In addition, the most common adverse reactions (≥10%) for patients receiving LYNPARZA/bevacizumab irrespective of the frequency compared with the placebo/bevacizumab arm were: diarrhea (18%), neutropenia (18%), urinary tract infection (15%), and headache (14%).\n\nIn addition, venous thromboembolic events occurred more commonly in patients receiving LYNPARZA/bevacizumab (5%) than in those receiving placebo/bevacizumab (1.9%).\n\nMost common laboratory abnormalities (Grades 1-4) in ≥25% of patients for LYNPARZA in combination with bevacizumab in the **first-line maintenance setting** for **PAOLA-1** were: decrease in hemoglobin (79%), decrease in lymphocytes (63%), increase in serum creatinine (61%), decrease in leukocytes (59%), decrease in absolute neutrophil count (35%), and decrease in platelets (35%).\n\n**ADVERSE REACTIONS—Maintenance Recurrent Ovarian Cancer**\n\nMost common adverse reactions (Grades 1-4) in ≥20% of patients who received LYNPARZA in the **maintenance setting** for **SOLO-2** were: nausea (76%), fatigue (including asthenia) (66%), anemia (44%), vomiting (37%), nasopharyngitis/upper respiratory tract infection (URI)/influenza (36%), diarrhea (33%), arthralgia/myalgia (30%), dysgeusia (27%), headache (26%), decreased appetite (22%), and stomatitis (20%).\n\n**Study 19:** nausea (71%), fatigue (including asthenia) (63%), vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract infection (22%), constipation (22%), headache (21%), decreased appetite (21%), and dyspepsia (20%).\n\nMost common laboratory abnormalities (Grades 1-4) in ≥25% of patients who received LYNPARZA in the **maintenance setting (SOLO-2/Study 19**) were: increase in mean corpuscular volume (89%/82%), decrease in hemoglobin (83%/82%), decrease in leukocytes (69%/58%), decrease in lymphocytes (67%/52%), decrease in absolute neutrophil count (51%/47%), increase in serum creatinine (44%/45%), and decrease in platelets (42%/36%).\n\n**ADVERSE REACTIONS—Adjuvant Treatment of g*BRCA*m, HER2-Negative, High-Risk Early Breast Cancer**\n\nMost common adverse reactions (Grades 1-4) in ≥10% of patients who received LYNPARZA in the **adjuvant setting** for **OlympiA** were: nausea (57%), fatigue (including asthenia) (42%), anemia (24%), vomiting (23%), headache (20%), diarrhea (18%), leukopenia (17%), neutropenia (16%), decreased appetite (13%), dysgeusia (12%), dizziness (11%), and stomatitis (10%).\n\nMost common laboratory abnormalities (Grades 1-4) in ≥25% of patients who received LYNPARZA in the **adjuvant setting** for **OlympiA** were: decrease in lymphocytes (77%), increase in mean corpuscular volume (67%), decrease in hemoglobin (65%), decrease in leukocytes (64%), and decrease in absolute neutrophil count (39%).\n\n**ADVERSE REACTIONS—g*BRCA*m, HER2-Negative Metastatic Breast Cancer**\n\nMost common adverse reactions (Grades 1-4) in ≥20% of patients who received LYNPARZA in the **metastatic setting** for **OlympiAD** were: nausea (58%), anemia (40%), fatigue (including asthenia) (37%), vomiting (30%), neutropenia (27%), respiratory tract infection (27%), leukopenia (25%), diarrhea (21%), and headache (20%).\n\nMost common laboratory abnormalities (Grades 1-4) in >25% of patients who received LYNPARZA in the **metastatic setting** for **OlympiAD** were: decrease in hemoglobin (82%), decrease in lymphocytes (73%), decrease in leukocytes (71%), increase in mean corpuscular volume (71%), decrease in absolute neutrophil count (46%), and decrease in platelets (33%).\n\n**ADVERSE REACTIONS—First-Line Maintenance g*BRCA*m Metastatic Pancreatic Adenocarcinoma**\n\nMost common adverse reactions (Grades 1-4) in ≥10% of patients who received LYNPARZA in the **first-line maintenance setting** for **POLO** were: fatigue (60%), nausea (45%), abdominal pain (34%), diarrhea (29%), anemia (27%), decreased appetite (25%), constipation (23%), vomiting (20%), back pain (19%), arthralgia (15%), rash (15%), thrombocytopenia (14%), dyspnea (13%), neutropenia (12%), nasopharyngitis (12%), dysgeusia (11%), and stomatitis (10%).\n\nMost common laboratory abnormalities (Grades 1-4) in ≥25% of patients who received LYNPARZA in the **first-line maintenance setting** for **POLO** were: increase in serum creatinine (99%), decrease in hemoglobin (86%), increase in mean corpuscular volume (71%), decrease in lymphocytes (61%), decrease in platelets (56%), decrease in leukocytes (50%), and decrease in absolute neutrophil count (25%).\n\n**ADVERSE REACTIONS—HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer**\n\nMost common adverse reactions (Grades 1-4) in ≥10% of patients who received LYNPARZA for **PROfound** were: anemia (46%), fatigue (including asthenia) (41%), nausea (41%), decreased appetite (30%), diarrhea (21%), vomiting (18%), thrombocytopenia (12%), cough (11%), and dyspnea (10%).\n\nMost common laboratory abnormalities (Grades 1-4) in ≥25% of patients who received LYNPARZA for **PROfound** were: decrease in hemoglobin (98%), decrease in lymphocytes (62%), decrease in leukocytes (53%), and decrease in absolute neutrophil count (34%).\n\n**ADVERSE REACTIONS—Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone**\n\nMost common adverse reactions (Grades 1-4) in ≥10% of patients who received LYNPARZA/abiraterone with a difference of ≥5% compared to placebo for **PROpel** were: anemia (48%), fatigue (including asthenia) (38%), nausea (30%), diarrhea (19%), decreased appetite (16%), lymphopenia (14%), dizziness (14%), and abdominal pain (13%). Most common laboratory abnormalities (Grades 1-4) in ≥20% of patients who received LYNPARZA/abiraterone for **PROpel** were: decrease in hemoglobin (97%), decrease in lymphocytes (70%), decrease in platelets (23%), and decrease in absolute neutrophil count (23%).\n\n**DRUG INTERACTIONS**\n\n**Anticancer Agents:** Clinical studies of LYNPARZA with other myelosuppressive anticancer agents, including DNA-damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity.\n\n**CYP3A Inhibitors:** Avoid coadministration of strong or moderate CYP3A inhibitors when using LYNPARZA. If a strong or moderate CYP3A inhibitor must be coadministered, reduce the dose of LYNPARZA. Advise patients to avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during LYNPARZA treatment.\n\n**CYP3A Inducers:** Avoid coadministration of strong or moderate CYP3A inducers when using LYNPARZA.\n\n**USE IN SPECIFIC POPULATIONS**\n\n**Lactation:** No data are available regarding the presence of olaparib in human milk, its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in the breastfed infant, advise a lactating woman not to breastfeed during treatment with LYNPARZA and for 1 month after receiving the final dose.\n\n**Pediatric Use:** The safety and efficacy of LYNPARZA have not been established in pediatric patients.\n\n**Hepatic Impairment:** No adjustment to the starting dose is required in patients with mild or moderate hepatic impairment (Child-Pugh classification A and B). There are no data in patients with severe hepatic impairment (Child-Pugh classification C).\n\n**Renal Impairment:** No dosage modification is recommended in patients with mild renal impairment (CLcr 51-80 mL/min estimated by Cockcroft-Gault). In patients with moderate renal impairment (CLcr 31-50 mL/min), reduce the dose of LYNPARZA to 200 mg twice daily. There are no data in patients with severe renal impairment or end-stage renal disease (CLcr ≤30 mL/min).\n\n**INDICATIONS**\n\nLYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n\n**First-Line Maintenance *BRCA*m Advanced Ovarian Cancer**\n\nFor the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic *BRCA*-mutated (g*BRCA*m or s*BRCA*m) advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n\n**First-Line Maintenance HRD-Positive Advanced Ovarian Cancer in Combination with Bevacizumab**\n\nIn combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either:\n\nSelect patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n\n**Maintenance Recurrent Ovarian Cancer**\n\nFor the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.\n\n**Adjuvant Treatment of g*BRCA*m, HER2-Negative, High-Risk Early Breast Cancer**\n\nFor the adjuvant treatment of adult patients with deleterious or suspected deleterious g*BRCA*m, human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n\n**g*BRCA*m, HER2-Negative Metastatic Breast Cancer**\n\nFor the treatment of adult patients with deleterious or suspected deleterious g*BRCA*m*,* human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n\n**First-Line Maintenance g*BRCA*m Metastatic Pancreatic Cancer**\n\nFor the maintenance treatment of adult patients with deleterious or suspected deleterious g*BRCA*m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n\n**HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer**\n\nFor the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n\n***BRCA*m Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone**\n\nIn combination with abiraterone and prednisone or prednisolone (abi/pred) for the treatment of adult patients with deleterious or suspected deleterious *BRCA*-mutated (*BRCA*m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n\n**Please see complete** \n[**Prescribing Information**](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fden8dhaj6zs0e.cloudfront.net%2F50fd68b9-106b-4550-b5d0-12b045f8b184%2F00997c3f-5912-486f-a7db-930b4639cd51%2F00997c3f-5912-486f-a7db-930b4639cd51_viewable_rendition__v.pdf&esheet=53411534&newsitemid=20230601005433&lan=en-US&anchor=Prescribing+Information&index=1&md5=bb16acf7734dd6b6afbe1e2f1f4b5f20)\n**, including** \n[**Medication Guide**](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fden8dhaj6zs0e.cloudfront.net%2F50fd68b9-106b-4550-b5d0-12b045f8b184%2F00997c3f-5912-486f-a7db-930b4639cd51%2F00997c3f-5912-486f-a7db-930b4639cd51_viewable_rendition__v.pdf%23page%3D16&esheet=53411534&newsitemid=20230601005433&lan=en-US&anchor=Medication+Guide&index=2&md5=eab5184852c99fe18f85cfeb8d4fafc9)\n**.**\n\n**Financial considerations**\n\nUnder the oncology collaboration with AstraZeneca and following this new approval for LYNPARZA, AstraZeneca will receive a regulatory milestone payment from Merck.\n\n**AboutLYNPARZA® (olaparib)**\n\nLYNPARZA is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as *BRCA* mutations, to preferentially kill cancer cells. Inhibition of PARP with LYNPARZA leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death. LYNPARZA is being tested in a range of tumor types with defects and dependencies in the DDR.\n\nLYNPARZA*,* which is being jointly developed and commercialized by AstraZeneca and Merck, has a broad clinical trial development program, and AstraZeneca and Merck are working together to understand how it may affect multiple PARP-dependent tumors as a monotherapy and in combination across multiple cancer types.\n\n**About metastatic castration-resistant prostate cancer**\n\nProstate cancer is the second most common cancer in male patients globally and is associated with a significant mortality rate. Development of prostate cancer is often driven by male sex hormones called androgens, including testosterone. In patients with mCRPC, their prostate cancer grows and spreads to other parts of the body, despite the use of androgen-deprivation therapy to block the action of male sex hormones.Approximately 10-20% of patients with prostate cancer are estimated to develop castration-resistant prostate cancer (CRPC) within five years, with at least 84% of these patients presenting with metastases at the time of CRPC diagnosis.Of patients with no metastases at CRPC diagnosis, 33% are likely to develop metastases within two years.\n\n**About *BRCA* mutations**\n\n*BRCA*1 and *BRCA*2 (breast cancer susceptibility genes 1/2) are human genes that produce proteins responsible for repairing damaged DNA and play an important role maintaining the genetic stability of cells. When either of these genes is mutated or altered such that its protein product either is not made or does not function correctly, DNA damage may not be repaired properly, and cells become unstable. As a result, cells are more likely to develop additional genetic alterations that can lead to cancer.\n\nApproximately 10% of patients with mCRPC will have *BRCA* mutations, which are associated with a poor prognosis and worse outcomes.\n\n**About the AstraZeneca and Merck strategic oncology collaboration**\n\nIn July 2017, AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced a global strategic oncology collaboration to co-develop and co-commercialize certain oncology products including LYNPARZA, the world’s first PARP inhibitor, for multiple cancer types. Working together, the companies will develop these products in combination with other potential new medicines and as monotherapies. Independently, the companies will develop these oncology products in combination with their respective PD-L1 and PD-1 medicines.\n\n**Merck’s focus on cancer**\n\nOur goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers. For more information about our oncology clinical trials, visit [www.merck.com/clinicaltrials](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.merck.com%2Fclinicaltrials&esheet=53411534&newsitemid=20230601005433&lan=en-US&anchor=www.merck.com%2Fclinicaltrials&index=3&md5=e569d74df802c3ebd34a3b87497caa6f).\n\n**About Merck**\n\nAt Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit [www.merck.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.merck.com%2F&esheet=53411534&newsitemid=20230601005433&lan=en-US&anchor=www.merck.com&index=4&md5=1aa6dbcf701d1d2a0fd3fb8be083c800) and connect with us on [Twitter](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FMerck&esheet=53411534&newsitemid=20230601005433&lan=en-US&anchor=Twitter&index=5&md5=7e38da5b4ec5c69f3a766e9fe672ee97), [Facebook](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&esheet=53411534&newsitemid=20230601005433&lan=en-US&anchor=Facebook&index=6&md5=a568710d23e865ef885135c87040bd49), [Instagram](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&esheet=53411534&newsitemid=20230601005433&lan=en-US&anchor=Instagram&index=7&md5=46ab7e7875a7f5c4123fec7f04340b1c), [YouTube](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.youtube.com%2FMerck&esheet=53411534&newsitemid=20230601005433&lan=en-US&anchor=YouTube&index=8&md5=3c218c72ac946b9f9c5236aa0e07d2f6) and [LinkedIn](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&esheet=53411534&newsitemid=20230601005433&lan=en-US&anchor=LinkedIn&index=9&md5=9ad84e203f4fa9ea00a7b1f863dd814b).\n\n**Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA**\n\nThis news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.\n\nRisks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.\n\nThe company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ([www.sec.gov](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=53411534&newsitemid=20230601005433&lan=en-US&anchor=www.sec.gov&index=10&md5=8b1e2c58b1337a9c648e91f58db977dc)).\n\n![](https://cts.businesswire.com/ct/CT?id=bwnews&sty=20230601005433r1&sid=q4-prod&distro=nx&lang=en)\n\n![](https://cts.businesswire.com/ct/CT?id=bwnews&sty=20230601005433r1&sid=q4-prod&distro=nx&lang=en)\n\nMedia:\n  \nJulie Cunningham, (617) 519-6264\n  \nChrissy Trank, (640) 650-0694\n\nInvestor:\n  \nPeter Dannenbaum, (732) 594-1579\n  \nDamini Chokshi, (732) 594-1577\n\n## Multimedia\n\n[Merck Logo Horizontal Teal Grey RGB](https://s2.q4cdn.com/584635680/files/doc_multimedia/Merck_Logo_Horizontal_Teal-Grey_RGB.jpg) (206.4 KB)\n\n#### Related links\n\n![related content image #1]()\n\n**Company Statements**\n\nRead our latest company statements.\n\n![related content image #2]()\n\n**Media library**\n\nAccess videos, logos, photos, and infographics.\n\n![related content image #3]()\n\n**About Merck**\n\nWe are committed to providing leading innovations for today and the future that save and improve lives around the world.\n\n### Connect with us on social\n\n![Twitter icon ]()\n![Facebook icon ]()\n![Linkedin icon ]()\n![Instagram icon ]()\n![YouTube icon ]()\n![]()\n\n### Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA\n\nThis website of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.\n\nRisks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.\n\nThe company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).\n\n**No Duty to Update**\n\nThe information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.\n\n### \n\n### "
        },
        {
          "title": "Prednisone Side Effects: Common, Severe, Long Term",
          "url": "https://www.drugs.com/sfx/prednisone-side-effects.html",
          "content": "# Prednisone Side Effects. If you will be taking this medicine for a long time, *it is very important that your doctor check you at regular visits* for any unwanted effects that may be caused by this medicine. ## Serious side effects of prednisone. ## Other side effects of prednisone. * **Frequency not reported**: Amnesia, anxiety, delirium, depression, emotional instability and irritability, euphoria, hallucinations, severe psychiatric symptoms, insomnia, long-term memory loss, mania, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychiatric disorders including steroid psychoses or aggravation of preexisting psychiatric conditions, restlessness, schizophrenia, verbal memory loss, withdrawn behavior[Ref]. * **Frequency not reported**: Acne, acneiform eruptions, allergic dermatitis, alopecia, angioedema, angioneurotic edema, atrophy and thinning of skin, dry scaly skin, ecchymosis and petechiae (bruising), erythema, facial edema, hirsutism, impaired wound healing, increased sweating, lupus erythematosus-like lesions, perineal irritation, purpura, rash, striae, subcutaneous fat atrophy, suppression of reactions to skin tests, telangiectasis, thin fragile skin, thinning scalp hair, urticaria, hypertrichosis[Ref].",
          "raw_content": "[Skip to main content](#content)\n\n\n# Prednisone Side Effects\n\n[Medically reviewed](/support/editorial_policy.html#editorial-staff) by Drugs.com. Last updated on Feb 17, 2025.\n\nApplies to prednisone: **oral solution, oral tablet, oral tablet delayed release**.\n\n## Precautions\n\nIf you will be taking this medicine for a long time, *it is very important that your doctor check you at regular visits* for any unwanted effects that may be caused by this medicine. Blood or urine tests may be needed to check for unwanted effects.\n\nUsing this medicine while you are pregnant can harm your unborn baby. Use an effective form of birth control to keep from getting pregnant. If you think you have become pregnant while using this medicine, tell your doctor right away.\n\nIf you are using this medicine for a long time, tell your doctor about any extra stress or anxiety in your life, including other health concerns and emotional stress. Your dose of this medicine might need to be changed for a short time while you have extra stress.\n\nUsing too much of this medicine or using it for a long time may increase your risk of having adrenal gland problems. Talk to your doctor right away if you have more than one of these symptoms while you are using this medicine: blurred vision, dizziness or fainting, a fast, irregular, or pounding heartbeat, increased thirst or urination, irritability, or unusual tiredness or weakness.\n\nThis medicine may cause you to get more infections than usual. Avoid people who are sick or have infections and wash your hands often. If you are exposed to chickenpox or measles, tell your doctor right away. If you start to have a fever, chills, sore throat, or any other sign of an infection, call your doctor right away.\n\nCheck with your doctor right away if blurred vision, difficulty in reading, eye pain, or any other change in vision occurs during or after treatment. Your doctor may want you to have your eyes checked by an ophthalmologist (eye doctor).\n\nWhile you are being treated with prednisone, do not have any immunizations (vaccines) without your doctor's approval. Prednisone may lower your body's resistance and the vaccine may not work as well or you might get the infection the vaccine is meant to prevent. In addition, you should not be around other persons living in your household who receive live virus vaccines because there is a chance they could pass the virus on to you. Some examples of live vaccines include measles, mumps, influenza (nasal flu vaccine), poliovirus (oral form), rotavirus, and rubella. Do not get close to them and do not stay in the same room with them for very long. If you have questions about this, talk to your doctor.\n\nThis medicine may cause changes in mood or behavior for some patients. Tell your doctor right away if you have depression, mood swings, a false or unusual sense of well-being, trouble with sleeping, or personality changes while taking this medicine.\n\nThis medicine might cause thinning of the bones ([osteoporosis](/cg/osteoporosis.html)) or slow growth in children if used for a long time. Tell your doctor if you have any bone pain or if you have an increased risk for osteoporosis. If your child is using this medicine, tell the doctor if you think your child is not growing properly.\n\nMake sure any doctor or dentist who treats you knows that you are using this medicine. This medicine may affect the results of certain skin tests.\n\nDo not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.\n\n## Serious side effects of prednisone\n\nAlong with its needed effects, prednisone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.\n\n**Check with your doctor immediately** if any of the following side effects occur while taking prednisone:\n\n### More common side effects\n\n* aggression\n* agitation\n* blurred vision\n* decrease in the amount of urine\n* dizziness\n* fast, slow, pounding, or irregular heartbeat or pulse\n* headache\n* irritability\n* mood changes\n* noisy, rattling breathing\n* numbness or tingling in the arms or legs\n* pounding in the ears\n* [shortness of breath](/cg/dyspnea.html)\n* swelling of the fingers, hands, feet, or lower legs\n* trouble thinking, speaking, or walking\n* troubled breathing at rest\n* weight gain\n\n\n\n\n### Incidence not known\n\n* abdominal or stomach cramping or burning (severe)\n* abdominal or stomach pain\n* backache\n* bloody, black, or tarry stools\n* cough or hoarseness\n* darkening of the skin\n* decrease in height\n* decreased vision\n* diarrhea\n* dry mouth\n* eye pain\n* eye tearing\n* facial hair growth in females\n* fainting\n* fever or chills\n* flushed, dry skin\n* fractures\n* fruit-like breath odor\n* full or round face, neck, or trunk\n* heartburn or indigestion (severe and continuous)\n* increased hunger\n* increased thirst\n* increased urination\n* loss of appetite\n* loss of sexual desire or ability\n* lower back or side pain\n* menstrual irregularities\n* muscle pain or tenderness\n* muscle wasting or weakness\n* nausea\n* pain in the back, ribs, arms, or legs\n* painful or difficult urination\n* skin rash\n* sweating\n* trouble healing\n* trouble sleeping\n* unexplained weight loss\n* unusual tiredness or weakness\n* vision changes\n* vomiting\n* vomiting of material that looks like coffee grounds\n\n## Other side effects of prednisone\n\nSome side effects of prednisone may occur that usually **do not need medical attention**. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.\n\nCheck with your health care professional if any of the following side effects **continue or are bothersome** or if you have any questions about them:\n\n### More common side effects\n\n* increased appetite\n\n\n\n\n### Incidence not known\n\n* abnormal fat deposits on the face, neck, and trunk\n* acne\n* dry scalp\n* lightening of normal skin color\n* red face\n* reddish purple lines on the arms, face, legs, trunk, or groin\n* swelling of the stomach area\n* thinning of the scalp hair\n\n## See also:\n\n### [Saphnelo](/saphnelo.html)\n\nSaphnelo is used for moderate to severe SLE (lupus) for adults who are also receiving other lupus ...\n\n**Reviews & ratings**\n\n7.8 / 10\n\n[13 Reviews](/comments/anifrolumab/saphnelo.html)\n\n[View more](/saphnelo.html)\n\n### [Skyrizi](/skyrizi.html)\n\nSkyrizi (risankizumab) is an injection used to treat plaque psoriasis, psoriatic arthritis ...\n\n**Reviews & ratings**\n\n8.1 / 10\n\n[74 Reviews](/comments/risankizumab/skyrizi.html)\n\n[View more](/skyrizi.html)\n\nFeatured\n\n### [Benlysta](/benlysta.html)\n\nBenlysta is used to treat active systemic lupus erythematosus (SLE) or lupus nephritis in adults ...\n\n**Reviews & ratings**\n\n7.8 / 10\n\n[66 Reviews](/comments/belimumab/benlysta.html)\n\n[View more](/benlysta.html)\n\n### [neffy](/neffy.html)\n\nneffy (epinephrine nasal spray) is used to treat life-threatening, allergic reactions, including ...\n\n**Reviews & ratings**\n\n[Add a review](/members_comments_add/?ddc_id=989&brand_name_id=20813&condition_id=0)\n\n[View more](/neffy.html)\n\n### [Humira](/humira.html)\n\nHumira is a tumor necrosis factor blocker used to treat many inflammatory conditions in adults ...\n\n**Reviews & ratings**\n\n6.4 / 10\n\n[706 Reviews](/comments/adalimumab/humira.html)\n\n[View more](/humira.html)\n\n### [Plaquenil](/plaquenil.html)\n\nPlaquenil is used to treat or prevent malaria and to treat the symptoms of rheumatoid arthritis ...\n\n**Reviews & ratings**\n\n6.4 / 10\n\n[158 Reviews](/comments/hydroxychloroquine/plaquenil.html)\n\n[View more](/plaquenil.html)\n\n### [Enbrel](/enbrel.html)\n\nEnbrel is used to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Learn about ...\n\n**Reviews & ratings**\n\n7.7 / 10\n\n[307 Reviews](/comments/etanercept/enbrel.html)\n\n[View more](/enbrel.html)\n\n### [Remicade](/remicade.html)\n\nRemicade is used to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn's ...\n\n**Reviews & ratings**\n\n7.0 / 10\n\n[214 Reviews](/comments/infliximab/remicade.html)\n\n[View more](/remicade.html)\n\n### [Orencia](/orencia.html)\n\nOrencia is a type of biologic that is given by intravenous infusion or subcutaneous injection which ...\n\n**Reviews & ratings**\n\n6.2 / 10\n\n[73 Reviews](/comments/abatacept/orencia.html)\n\n[View more](/orencia.html)\n\n### [Rituxan](/rituxan.html)\n\nRituxan is used to treat certain leukemias and lymphomas and some non-cancer conditions, such as ...\n\n**Reviews & ratings**\n\n8.2 / 10\n\n[64 Reviews](/comments/rituximab/rituxan.html)\n\n[View more](/rituxan.html)\n\n[Managing side effects](/article/drug-side-effects.html) (general information)\n\n## For healthcare professionals\n\nApplies to prednisone: **compounding powder, oral delayed release tablet, oral solution, oral tablet**.\n\n### General adverse events\n\nThe most commonly reported adverse effects associated with corticosteroid use include fluid retention, alteration in glucose tolerance, [high blood pressure](/cg/hypertension.html), behavior and mood changes, increased appetite and weight gain. Occurrence is often associated with dose and duration of therapy; long-term effects include HPA suppression, Cushingoid appearance, cataracts and increased intraocular pressure/glaucoma, osteoporosis and vertebral compression fractures.[[Ref](#refs)]\n\n### Metabolic\n\n* **Frequency not reported**: Decreased carbohydrate and glucose tolerance, increased requirements for insulin or oral hypoglycemic agents in diabetics, lipid abnormal, negative nitrogen balance caused by protein catabolism, hypokalemia, hypokalemic alkalosis, [metabolic alkalosis](/cg/metabolic-alkalosis.html), potassium loss, sodium retention with resulting edema, increased appetite and weight gain, anorexia and weight loss, hypertriglyceridemia, [hypercholesterolemia](/cg/hyperlipidemia.html)[[Ref](#refs)]\n\n### Cardiovascular\n\n* **Frequency not reported**: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive [heart failure](/cg/heart-failure.html), ECG changes caused by potassium deficiency, edema, fat embolism, hypotension, hypertension or aggravation of hypertension, [hypertrophic cardiomyopathy](/cg/hypertrophic-cardiomyopathy.html) in premature infants, myocardial rupture following recent myocardial infarction, necrotizing angiitis, syncope, tachycardia, [thromboembolism](/cg/deep-vein-thrombosis.html), thrombophlebitis, vasculitis[[Ref](#refs)]\n\n### Endocrine\n\n* **Frequency not reported**: Adrenal insufficiency associated symptoms including arthralgias, buffalo hump, amenorrhea, postmenopausal bleeding or menstrual irregularities, development of cushingoid state, [hyperthyroidism](/cg/hyperthyroidism.html), hypothyroidism, moon face, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress as in trauma, surgery, or illness), increased or decreased motility and number of spermatozoa[[Ref](#refs)]\n\n### Ocular\n\n* **Frequency not reported**: Blurred vision, cataracts (including posterior subcapsular cataracts) central serous chorioretinopathy, secondary bacterial, fungal, and viral infections, exophthalmos, glaucoma, increased intraocular pressure[[Ref](#refs)]\n\n### Gastrointestinal\n\n* **Frequency not reported**: Abdominal distention, abdominal pain, [constipation](/cg/constipation.html), diarrhea, gastric irritation, nausea, oropharyngeal candidiasis, [pancreatitis](/cg/pancreatitis.html), [peptic ulcer](/cg/peptic-ulcer.html) with possible perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis, vomiting[[Ref](#refs)]\n\n### Immunologic\n\n* **Frequency not reported**: Immunosuppression, aggravation/masking of infections, decreased resistance to infection[[Ref](#refs)]\n\n### Musculoskeletal\n\n* **Frequency not reported**: Arthralgia, aseptic necrosis of femoral and humeral heads, increased risk of fracture, loss of muscle mass, muscle weakness, myalgias, osteopenia, osteoporosis, pathologic fracture of long bones, steroid myopathy, tendon rupture (particularly of the Achilles tendon), vertebral compression fractures, suppression of growth in pediatric patients[[Ref](#refs)]\n\n### Hypersensitivity\n\n* **Frequency not reported**: Anaphylaxis, angioedema, allergic reactions[[Ref](#refs)]\n\n### Nervous system\n\n* **Frequency not reported**: Arachnoiditis, benign [intracranial hypertension](/cg/idiopathic-intracranial-hypertension.html), convulsions, dementia, dizziness, EEG abnormalities, impaired cognition, increased intracranial pressure with papilledema, increased motor activity, ischemic neuropathy, severe tiredness or weakness, meningitis, neuritis, neuropathy, paraparesis/paraplegia, sensory disturbances[[Ref](#refs)]\n\n### Psychiatric\n\n* **Frequency not reported**: Amnesia, anxiety, delirium, depression, emotional instability and irritability, euphoria, hallucinations, severe psychiatric symptoms, insomnia, long-term memory loss, mania, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychiatric disorders including steroid psychoses or aggravation of preexisting psychiatric conditions, restlessness, [schizophrenia](/cg/schizophrenia.html), verbal memory loss, withdrawn behavior[[Ref](#refs)]\n\n### Hematologic\n\n* **Frequency not reported**: Anemia, neutropenia, febrile neutropenia, moderate [leukocytosis](/cg/leukocytosis.html), lymphopenia, eosinopenia, polycythemia[[Ref](#refs)]\n\n### Dermatologic\n\n* **Frequency not reported**: Acne, acneiform eruptions, [allergic dermatitis](/cg/contact-dermatitis.html), alopecia, angioedema, [angioneurotic edema](/cg/angioedema.html), atrophy and thinning of skin, dry scaly skin, ecchymosis and petechiae (bruising), erythema, facial edema, hirsutism, impaired wound healing, increased sweating, [lupus erythematosus](/cg/lupus-erythematosus.html)-like lesions, perineal irritation, purpura, rash, striae, subcutaneous fat atrophy, suppression of reactions to skin tests, telangiectasis, thin fragile skin, thinning scalp hair, urticaria, hypertrichosis[[Ref](#refs)]\n\n### Hepatic\n\n* **Frequency not reported**: ALT, AST and alkaline phosphatase elevations (usually reversible upon discontinuation), hepatomegaly[[Ref](#refs)]\n\n### Respiratory\n\n* **Frequency not reported**: Hiccups, [pulmonary edema](/cg/pulmonary-edema.html)[[Ref](#refs)]\n\n### Oncologic\n\n* **Frequency not reported**: [Kaposi's sarcoma](/cg/kaposi-s-sarcoma.html)[[Ref](#refs)]\n\n### Other\n\n* **Frequency not reported**: Vertigo, pyrexia, abnormal fat deposits, malaise[[Ref](#refs)]\n\n#### References\n\n1. Cerner Multum, Inc. \"UK Summary of Product Characteristics.\"\n\n2. Cerner Multum, Inc. \"Australian Product Information.\"\n\n3. (2016) \"Product Information. Rayos (prednisone).\" *Horizon Therapeutics USA Inc*\n\n4. (2016) \"Product Information. PredniSONE (prednisone).\" *Watson Pharmaceuticals*\n\n5. (2001) \"Product Information. Deltasone (prednisone).\" *Pharmacia and Upjohn*\n\n### Does Prednisone interact with my other drugs?\n\nEnter medications to view a detailed interaction report using our [Drug Interaction Checker](/drug_interactions.html).\n\n## Frequently asked questions\n\n* [What is considered a high dose of prednisone?](/medical-answers/considered-high-dose-prednisone-3561211/)\n* [What's a good prednisone taper schedule?](/medical-answers/good-prednisone-taper-schedule-3570111/)\n* [Is it OK to drink alcohol with Prednisone?](/medical-answers/you-drink-alcohol-prednisone-3561294/)\n* [How long can you take prednisone safely?](/medical-answers/long-you-prednisone-safely-3561220/)\n* [Prednisone: What are 12 Things You Should Know?](/medical-answers/prednisone-12-things-you-3573757/)\n* [How long does it take for prednisone to work?](/medical-answers/long-prednisone-work-3562260/)\n* [Do I take all 6 prednisone pills at once on the first day?](/medical-answers/prednisone-prescription-6-pills-first-day-6-547595/)\n* [How long does prednisone stay in your system?](/medical-answers/long-prednisone-stay-patients-system-after-course-3069825/)\n* [Why does prednisone cause weight gain?](/medical-answers/prednisone-weight-gain-3562498/)\n\n## More about prednisone\n\n* [Check interactions](/drug-interactions/prednisone.html)\n* [Compare alternatives](/compare/prednisone)\n* [Pricing & coupons](/price-guide/prednisone)\n* [Reviews (876)](/comments/prednisone/)\n* [Drug images](/image/prednisone-images.html)\n* [Dosage information](/dosage/prednisone.html)\n* [Patient tips](/tips/prednisone-patient-tips)\n* [During pregnancy](/pregnancy/prednisone.html)\n* [Support group](/answers/support-group/prednisone/)\n* [Drug class: glucocorticoids](/drug-class/glucocorticoids.html)\n* [Breastfeeding](/breastfeeding/prednisone.html)\n* [En español](/mtm_esp/prednisone.html)\n\n### Patient resources\n\n* [Prednisone drug information](/prednisone.html)\n\n#### Other brands\n\n[Deltasone](/cons/deltasone.html), [Sterapred](/cons/sterapred.html), [Rayos](/rayos.html), [Prednicot](/cons/prednicot.html), [Sterapred DS](/cons/sterapred-ds.html)\n\n### Professional resources\n\n* [Prednisone monograph](/monograph/prednisone.html)\n* [Prednisone (FDA)](/pro/prednisone.html)\n* [Prednisone Delayed Release Tablets (FDA)](/pro/prednisone-delayed-release-tablets.html)\n* [Prednisone Tablets (FDA)](/pro/prednisone-tablets.html)\n\n#### Other brands\n\n[Deltasone](/pro/deltasone.html), [Rayos](/pro/rayos.html)\n\n### Related treatment guides\n\n* [Allergic Reactions](/condition/allergic-reaction.html)\n* [Adrenocortical Insufficiency](/condition/adrenocortical-insufficiency.html)\n* [Adrenogenital Syndrome](/condition/adrenogenital-syndrome.html)\n* [Acute Lymphocytic Leukemia](/cg/acute-lymphocytic-leukemia.html)\n\n## Further information\n\n**Prednisone** side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.\n\n**Note:** Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following [this guide](/fda-consumer/your-guide-to-reporting-problems-to-fda-71.html).\n\n[Medical Disclaimer](/support/disclaimer.html)\n\n**Drug Status**\n\n**Availability**\nPrescription only\nRx\n\n[**Pregnancy & Lactation**](/pregnancy/prednisone.html)\nRisk data available\n\n**CSA Schedule\\***\nNot a controlled drug\nN/A\n\n**Approval History**\nDrug history at FDA\n\nLoading...\n\n**WADA Class**\nAnti-Doping Classification\n\nLoading...\n\nUser Reviews & Ratings\n\n7.5 / 10\n\n[876 Reviews](/comments/prednisone/)"
        },
        {
          "title": "Prednisone Patient Tips: 7 things you should know - Drugs.com",
          "url": "https://www.drugs.com/tips/prednisone-patient-tips",
          "content": "* All corticosteroids, including prednisone, can cause salt and fluid retention, which may lead to blood pressure elevation and increased potassium excretion. Corticosteroids, such as prednisone can cause fetal harm when administered to a pregnant woman; an increased risk of orofacial clefts is associated with use during the first trimester. * Prednisone controls inflammation and suppresses overactive immune responses, treating diverse conditions including endocrine disorders, rheumatic diseases, severe allergies, eye inflammation, respiratory conditions, blood disorders, and certain cancers. * Limit or avoid alcohol use while taking prednisone to help reduce the risk of indigestion and the development of stomach ulcers. Medicines that interact with prednisone may either decrease its effect, affect how long it works, increase side effects, or have less of an effect when taken with prednisone. Common medications that may interact with prednisone include:. Note that this list is not all-inclusive and includes only common medications that may interact with prednisone. ## More about prednisone.",
          "raw_content": "[Skip to main content](#content)\n\n\n# Prednisone Patient Tips\n\nMedically reviewed by [Carmen Pope, BPharm](/support/editorial_policy.html#carmen-pope-bpharm). Last updated on Oct 28, 2025.\n\n## 1. How it works\n\n* Prednisone is used to reduce inflammation and calm down an overactive immune system. It has predominantly glucocorticoid activity and low mineralocorticoid activity, which means it affects the immune response and inflammation rather than affecting the body's balance of electrolytes and water.\n* Prednisone works by mimicking the effect of glucocorticoid hormones that are secreted naturally by our adrenal glands in response to stress and which are essential for life. Prednisone is a man-made (synthetic) version of these hormones.\n* Prednisone belongs to the drug class called glucocorticoids, which are a type of corticosteroid.\n\n## 2. Upsides\n\n* Prednisone helps dampen down an over-reactive immune system and reduces inflammation.\n* Used to treat endocrine & metabolic disorders, such as adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis.\n* Treats various rheumatic & musculoskeletal conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, acute gout, bursitis, tenosynovitis, and post-traumatic osteoarthritis (typically short-term adjunctive therapy).\n* Also used to treat dermatologic & allergic conditions, such as severe skin diseases (pemphigus, Stevens-Johnson syndrome, severe psoriasis), and incapacitating allergic states (bronchial asthma, allergic rhinitis, contact dermatitis, serum sickness).\n* FDA approved for various ophthalmic, respiratory & hematologic disorders, including severe eye inflammation (uveitis, optic neuritis, keratitis), symptomatic sarcoidosis, pulmonary tuberculosis with appropriate chemotherapy, and blood disorders (thrombocytopenic purpura, hemolytic anemia).\n* Also has oncologic, renal & gastrointestinal uses, including the palliative management of leukemias and lymphomas, nephrotic syndrome to induce diuresis, ulcerative colitis, and regional enteritis during critical periods.\n* Approved for various neurologic & infectious conditions, such as acute multiple sclerosis exacerbations, tuberculous meningitis with subarachnoid block (with antituberculous therapy), and trichinosis with neurologic or cardiac involvement.\n* Generic prednisone is available.\n\n## 3. Downsides\n\nIf you are between the ages of 18 and 60, take no other medication or have no other medical conditions, side effects you are more likely to experience include:\n\n* Agitation or irritability, dizziness, indigestion, headache, an irregular heartbeat, swelling, and mood changes are common side effects reported with short-term use. Facial hair growth (especially in women); high blood pressure and other cardiovascular effects; an increased appetite which may result in weight gain; slow skin healing and skin thinning; osteoporosis (brittle bones); the onset of diabetes; and stomach ulcers are associated with moderate-to-long term use.\n* Prednisone increases a person's susceptibility to infection. The risk is greater with higher dosages. Some signs of an infection may be masked by prednisone. Some infections associated with prednisone use have been fatal, especially those associated with viral illnesses such as chickenpox or measles.\n* Prednisone exacerbates systemic fungal infections and should not be used in people with systemic fungal disease (such as candidiasis or aspergillosis). Latent diseases (caused by pathogens such as amoeba, tuberculosis, or Toxoplasma) may also be activated.\n* Side effects are more likely to be experienced at dosages greater than 7.5 mg/day and with long-term therapy. Long-term prednisone administration has been associated with the suppression of the hypothalamic-pituitary-adrenal (HPA) axis (a complex interactive signaling and feedback system involving the hypothalamus, the pituitary gland, and the adrenal glands). Suppression of this axis can result in corticosteroid insufficiency - where natural corticosteroid levels are no longer adequate to maintain vital bodily processes - after withdrawal of treatment. For this reason, moderate-to-long-term prednisone therapy should be withdrawn gradually.\n* The dosage of prednisone requires adjusting during times of stress.\n* All corticosteroids, including prednisone, can cause salt and fluid retention, which may lead to blood pressure elevation and increased potassium excretion. Calcium excretion is also increased.\n* Prolonged prednisone use may affect growth and development in children.\n* Cataracts, glaucoma, eye infections, an increase in new episodes of optic neuritis, and corneal perforation associated with herpes simplex of the eye, have all been reported with prednisone use.\n* Alcohol should be limited or avoided to help reduce the risk of gastrointestinal side effects.\n* With high doses of corticosteroids, live or live-attenuated vaccines should be delayed until several months after corticosteroid treatment has stopped.\n* May not be suitable for some people including those with cardiovascular disease, low thyroid levels, gastrointestinal disease, pre-existing bone disease, or psychiatric disorders.\n* May interact with several other drugs including some anti-infectives, antidiabetic agents, bupropion, NSAIDs, and drugs metabolized by CYP 3A4 liver enzymes.\n* Should not be used during pregnancy unless the benefits outweigh the risks. Corticosteroids, such as prednisone can cause fetal harm when administered to a pregnant woman; an increased risk of orofacial clefts is associated with use during the first trimester. Intrauterine growth restriction and decreased birth weight have also been reported. Animal studies have found prednisone to be teratogenic. Prednisone is present in human milk at doses less than 1% of the maternal daily dose. Use the lowest possible dose during breastfeeding because high doses could potentially produce problems in the breastfed infant such as growth and developmental delays and interfere with endogenous corticosteroid production.\n\n**Note:** In general, seniors or children, people with certain medical conditions (such as liver or kidney problems, heart disease, diabetes, seizures) or people who take other medications are more at risk of developing a wider range of side effects. [View complete list of side effects](/sfx/prednisone-side-effects.html)\n\n## 4. Bottom Line\n\n* Prednisone controls inflammation and suppresses overactive immune responses, treating diverse conditions including endocrine disorders, rheumatic diseases, severe allergies, eye inflammation, respiratory conditions, blood disorders, and certain cancers. Common short-term side effects include agitation, dizziness, indigestion, and mood changes. Long-term use risks adrenal suppression, increased infection susceptibility, osteoporosis, diabetes, weight gain, and cardiovascular effects. Dosages above 7.5mg/day increase side effect risk. Prednisone must be used at the lowest effective dose for the shortest duration and withdrawn gradually to prevent adrenal insufficiency.\n\n## 5. Tips\n\n* Take with food and a full glass of water to reduce the risk of prednisone adversely affecting your stomach.\n* Single doses are preferred over split doses; however, larger dosages may be split. Some people may be instructed to only take prednisone every other day (alternate-day therapy).\n* Take prednisone in the morning, before 9 AM (unless instructed otherwise) to more closely mimic your body's natural secretion of cortisol. Take your prednisone exactly as directed by your doctor. Never increase the dosage unless under your doctor's advice.\n* Stopping prednisone suddenly can be dangerous. Your doctor will advise you on how to taper down your prednisone dose if you have been taking it for more than a few weeks.\n* If you are taking higher dosages of prednisone, you should not receive any live or live-attenuated vaccines. Your response to killed or inactivated vaccines may also be diminished.\n* Avoid contact with anybody known to have, or recently exposed to, viral illnesses such as chickenpox or measles. If you inadvertently come into contact with somebody, contact your doctor immediately as immune globulin or antiviral treatment may be required.\n* Limit or avoid alcohol use while taking prednisone to help reduce the risk of indigestion and the development of stomach ulcers.\n* Talk with your doctor as soon as possible if you are taking prednisone and you become unwell, for any reason.\n* Tell your doctor if you are breastfeeding, pregnant, or intending to become pregnant because prednisone may not be suitable for you.\n\n## 6. Response and effectiveness\n\n* Prednisone takes approximately 60 minutes to be metabolized in the liver to its active form, prednisolone. Liver disease does not appear to affect metabolism. Effects can last from 18-36 hours, meaning that alternate-day dosing is possible.\n* Temporary dosage increases may be necessary during disease flare-ups or during times of stress or infection.\n* Prednisone is five times more potent at relieving inflammation than naturally occurring cortisol.\n\n## 7. Interactions\n\nMedicines that interact with prednisone may either decrease its effect, affect how long it works, increase side effects, or have less of an effect when taken with prednisone. An interaction between two medications does not always mean that you must stop taking one of the medications; however, sometimes it does. Speak to your doctor about how drug interactions should be managed.\n\nCommon medications that may interact with prednisone include:\n\n* antibiotics, such as clarithromycin, erythromycin, rifabutin, rifampin, or troleandomycin\n* anticholinesterases, such as neostigmine, or pyridostigmine\n* anticoagulants (blood thinners) such as apixaban, dabigatran, fondaparinux, heparin, or warfarin\n* antidepressants, such as desipramine, fluoxetine, sertraline, or St. John's Wort\n* antifungal medications, such as itraconazole, ketoconazole, or voriconazole\n* antinausea medications, such as aprepitant\n* aspirin\n* epilepsy medications, such as carbamazepine, oxcarbazepine, phenobarbital, phenytoin, or primidone\n* estrogen-containing hormonal contraceptives (includes birth control pills, patches, rings, implants, and injections)\n* heart medications, such as amiodarone, diltiazem, or verapamil\n* HIV medications (eg, atazanavir, delavirdine, efavirenz, indinavir, etravirine, ritonavir, nevirapine, saquinavir, or tipranavir)\n* immunosuppressants, such as cyclosporine\n* nonsteroidal anti-inflammatories (NSAIDs), such as celecoxib, diclofenac, etodolac, ibuprofen, ketorolac, meloxicam, nabumetone, or naproxen\n* other corticosteroids, such as dexamethasone\n* potassium-depleting agents, such as amphotericin B Injection and diuretics (eg, furosemide, hydrochlorothiazide)\n* some asthma medications, such as zafirlukast\n* vaccines (may inhibit the immune response)\n* others, such as aminoglutethimide, bupropion, cholestyramine, cyclosporine, digoxin, isoniazid, quetiapine, or thalidomide.\n\nPrednisone may increase blood glucose concentrations in people with diabetes and dosage adjustments of antidiabetic agents (eg, insulin, glyburide) may be required. Administration with fluoroquinolone antibiotics (such as ciprofloxacin or levofloxacin) may increase the risk of tendon rupture with fluoroquinolones.\n\nIn addition, alcohol can increase the likelihood of gastrointestinal side effects with prednisone, and possibly liver and kidney damage. Prednisone may suppress the inflammatory response to skin tests.\n\nNote that this list is not all-inclusive and includes only common medications that may interact with prednisone. You should refer to the prescribing information for prednisone for a complete list of interactions.\n\n## Related/similar drugs\n\n### [Saphnelo](/saphnelo.html)\n\nSaphnelo is used for moderate to severe SLE (lupus) for adults who are also receiving other lupus ...\n\n**Reviews & ratings**\n\n7.8 / 10\n\n[13 Reviews](/comments/anifrolumab/saphnelo.html)\n\n[View more](/saphnelo.html)\n\n### [Skyrizi](/skyrizi.html)\n\nSkyrizi (risankizumab) is an injection used to treat plaque psoriasis, psoriatic arthritis ...\n\n**Reviews & ratings**\n\n8.1 / 10\n\n[74 Reviews](/comments/risankizumab/skyrizi.html)\n\n[View more](/skyrizi.html)\n\nFeatured\n\n### [Benlysta](/benlysta.html)\n\nBenlysta is used to treat active systemic lupus erythematosus (SLE) or lupus nephritis in adults ...\n\n**Reviews & ratings**\n\n7.8 / 10\n\n[66 Reviews](/comments/belimumab/benlysta.html)\n\n[View more](/benlysta.html)\n\n### [neffy](/neffy.html)\n\nneffy (epinephrine nasal spray) is used to treat life-threatening, allergic reactions, including ...\n\n**Reviews & ratings**\n\n[Add a review](/members_comments_add/?ddc_id=989&brand_name_id=20813&condition_id=0)\n\n[View more](/neffy.html)\n\n### [Humira](/humira.html)\n\nHumira is a tumor necrosis factor blocker used to treat many inflammatory conditions in adults ...\n\n**Reviews & ratings**\n\n6.4 / 10\n\n[706 Reviews](/comments/adalimumab/humira.html)\n\n[View more](/humira.html)\n\n### [Plaquenil](/plaquenil.html)\n\nPlaquenil is used to treat or prevent malaria and to treat the symptoms of rheumatoid arthritis ...\n\n**Reviews & ratings**\n\n6.4 / 10\n\n[158 Reviews](/comments/hydroxychloroquine/plaquenil.html)\n\n[View more](/plaquenil.html)\n\n### [Enbrel](/enbrel.html)\n\nEnbrel is used to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Learn about ...\n\n**Reviews & ratings**\n\n7.7 / 10\n\n[307 Reviews](/comments/etanercept/enbrel.html)\n\n[View more](/enbrel.html)\n\n### [Remicade](/remicade.html)\n\nRemicade is used to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn's ...\n\n**Reviews & ratings**\n\n7.0 / 10\n\n[214 Reviews](/comments/infliximab/remicade.html)\n\n[View more](/remicade.html)\n\n### [Orencia](/orencia.html)\n\nOrencia is a type of biologic that is given by intravenous infusion or subcutaneous injection which ...\n\n**Reviews & ratings**\n\n6.2 / 10\n\n[73 Reviews](/comments/abatacept/orencia.html)\n\n[View more](/orencia.html)\n\n### [Rituxan](/rituxan.html)\n\nRituxan is used to treat certain leukemias and lymphomas and some non-cancer conditions, such as ...\n\n**Reviews & ratings**\n\n8.2 / 10\n\n[64 Reviews](/comments/rituximab/rituxan.html)\n\n[View more](/rituxan.html)\n\n## Frequently asked questions\n\n* [What is considered a high dose of prednisone?](/medical-answers/considered-high-dose-prednisone-3561211/)\n* [What's a good prednisone taper schedule?](/medical-answers/good-prednisone-taper-schedule-3570111/)\n* [Is it OK to drink alcohol with Prednisone?](/medical-answers/you-drink-alcohol-prednisone-3561294/)\n* [How long can you take prednisone safely?](/medical-answers/long-you-prednisone-safely-3561220/)\n* [Prednisone: What are 12 Things You Should Know?](/medical-answers/prednisone-12-things-you-3573757/)\n* [How long does it take for prednisone to work?](/medical-answers/long-prednisone-work-3562260/)\n* [Do I take all 6 prednisone pills at once on the first day?](/medical-answers/prednisone-prescription-6-pills-first-day-6-547595/)\n* [How long does prednisone stay in your system?](/medical-answers/long-prednisone-stay-patients-system-after-course-3069825/)\n* [Why does prednisone cause weight gain?](/medical-answers/prednisone-weight-gain-3562498/)\n\n## More about prednisone\n\n* [Check interactions](/drug-interactions/prednisone.html)\n* [Compare alternatives](/compare/prednisone)\n* [Pricing & coupons](/price-guide/prednisone)\n* [Reviews (876)](/comments/prednisone/)\n* [Drug images](/image/prednisone-images.html)\n* [Side effects](/sfx/prednisone-side-effects.html)\n* [Dosage information](/dosage/prednisone.html)\n* [During pregnancy](/pregnancy/prednisone.html)\n* [Support group](/answers/support-group/prednisone/)\n* [Drug class: glucocorticoids](/drug-class/glucocorticoids.html)\n* [Breastfeeding](/breastfeeding/prednisone.html)\n* [En español](/mtm_esp/prednisone.html)\n\n### Patient resources\n\n* [Prednisone drug information](/prednisone.html)\n\n#### Other brands\n\n[Deltasone](/cons/deltasone.html), [Sterapred](/cons/sterapred.html), [Rayos](/rayos.html), [Prednicot](/cons/prednicot.html), [Sterapred DS](/cons/sterapred-ds.html)\n\n### Professional resources\n\n* [Prednisone monograph](/monograph/prednisone.html)\n* [Prednisone (FDA)](/pro/prednisone.html)\n* [Prednisone Delayed Release Tablets (FDA)](/pro/prednisone-delayed-release-tablets.html)\n* [Prednisone Tablets (FDA)](/pro/prednisone-tablets.html)\n\n#### Other brands\n\n[Deltasone](/pro/deltasone.html), [Rayos](/pro/rayos.html)\n\n### Related treatment guides\n\n* [Allergic Reactions](/condition/allergic-reaction.html)\n* [Adrenocortical Insufficiency](/condition/adrenocortical-insufficiency.html)\n* [Adrenogenital Syndrome](/condition/adrenogenital-syndrome.html)\n* [Acute Lymphocytic Leukemia](/cg/acute-lymphocytic-leukemia.html)\n\n## References\n\n* Prednisone Package Insert / Prescribing Information. <https://www.drugs.com/pro/prednisone.html>\n\n## Further information\n\nRemember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Prednisone only for the indication prescribed.\n\nAlways consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.\n\nCopyright 1996-2026 Drugs.com. Revision date: October 28, 2025.\n\n[Medical Disclaimer](/support/disclaimer.html)\n\n**Drug Status**\n\n**Availability**\nPrescription only\nRx\n\n[**Pregnancy & Lactation**](/pregnancy/prednisone.html)\nRisk data available\n\n**CSA Schedule\\***\nNot a controlled drug\nN/A\n\nLoading...\n\n**Approval History**\nDrug history at FDA\n\nLoading...\n\n**WADA Class**\nAnti-Doping Classification\n\nLoading...\n\nUser Reviews & Ratings\n\n7.5 / 10\n\n[876 Reviews](/comments/prednisone/)"
        }
      ]
    }
  }
}